PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22999261-0 2013 Does pioglitazone improve depression through insulin-sensitization? Pioglitazone 5-17 insulin Homo sapiens 45-52 23349486-4 2013 The effect of 10 and 21 days of pioglitazone treatment on insulin sensitivity in 26 diabetic subjects was assessed by hyperinsulinemic-euglycemic clamp studies. Pioglitazone 32-44 insulin Homo sapiens 58-65 23349486-6 2013 Improved hepatic and peripheral insulin sensitivity was seen after 21 days of pioglitazone. Pioglitazone 78-90 insulin Homo sapiens 32-39 22802358-1 2013 BACKGROUND: Pioglitazone ameliorates insulin resistance, but has an adverse effect of oedema that may result in subsequent heart failure, especially in diabetic patients with coronary artery disease. Pioglitazone 12-24 insulin Homo sapiens 37-44 23680744-3 2013 In addition to their beneficial effects on glucose homeostasis, TZDs-especially pioglitazone-exert a number of other pleiotropic effects that make them ideal agents as monotherapy or in combination with other oral agents, glucagon-like peptide-1 analogs, or insulin. Pioglitazone 80-92 insulin Homo sapiens 258-265 24124423-13 2013 The reduced insulin resistance might be the reason that CTx values decreased and osteocalcin increased significantly after short-term pioglitazone treatment. Pioglitazone 134-146 insulin Homo sapiens 12-19 22344583-5 2013 In parallel with these advances, there are already randomized trials evaluating several established treatments for insulin resistance (pioglitazone and exenatide) as possible disease modifying drugs in Parkinson"s disease, with only preliminary insights regarding their mechanisms of action in neurodegeneration, which may be effective in both disease processes through an action on mitochondrial function. Pioglitazone 135-147 insulin Homo sapiens 115-122 23631252-2 2013 Insulin sensitizers such as metformin and pioglitazone reduce peripheral insulin resistance, whereas dipeptidyl peptidase-4(DPP-4) inhibitors augment postprandial insulin secretion and inhibit glucagon secretion. Pioglitazone 42-54 insulin Homo sapiens 0-7 23631252-2 2013 Insulin sensitizers such as metformin and pioglitazone reduce peripheral insulin resistance, whereas dipeptidyl peptidase-4(DPP-4) inhibitors augment postprandial insulin secretion and inhibit glucagon secretion. Pioglitazone 42-54 insulin Homo sapiens 73-80 23367497-10 2013 This report highlights the clinical features of SEIR and the role of insulin sensitizers like pioglitazone in the management of such patients. Pioglitazone 94-106 insulin Homo sapiens 69-76 23197113-6 2013 Incubation with pioglitazone, an insulin sensitizer, increased peroxisome proliferator-activated receptor-gamma (PPARgamma) expression after 48 h. A 48-h pre-incubation with insulin reduced the phosphorylation and concentration of the insulin receptors, which were increased by insulin treatment. Pioglitazone 16-28 insulin Homo sapiens 33-40 23197113-6 2013 Incubation with pioglitazone, an insulin sensitizer, increased peroxisome proliferator-activated receptor-gamma (PPARgamma) expression after 48 h. A 48-h pre-incubation with insulin reduced the phosphorylation and concentration of the insulin receptors, which were increased by insulin treatment. Pioglitazone 16-28 insulin Homo sapiens 174-181 23197113-6 2013 Incubation with pioglitazone, an insulin sensitizer, increased peroxisome proliferator-activated receptor-gamma (PPARgamma) expression after 48 h. A 48-h pre-incubation with insulin reduced the phosphorylation and concentration of the insulin receptors, which were increased by insulin treatment. Pioglitazone 16-28 insulin Homo sapiens 174-181 23197113-6 2013 Incubation with pioglitazone, an insulin sensitizer, increased peroxisome proliferator-activated receptor-gamma (PPARgamma) expression after 48 h. A 48-h pre-incubation with insulin reduced the phosphorylation and concentration of the insulin receptors, which were increased by insulin treatment. Pioglitazone 16-28 insulin Homo sapiens 174-181 24379032-5 2013 The purpose of this study was to examine whether pioglitazone, given with insulin, preserved beta cell function in patients with new-onset T1DM. Pioglitazone 49-61 insulin Homo sapiens 74-81 24379032-16 2013 The interaction of HbA1c and insulin dose (HbA1c* insulin/kg/day), which combines degree of diabetic control and dose of insulin required to achieve this control, showed transient improvement in the pioglitazone group at 12 weeks but was not sustained at 24 weeks. Pioglitazone 199-211 insulin Homo sapiens 29-36 24379032-16 2013 The interaction of HbA1c and insulin dose (HbA1c* insulin/kg/day), which combines degree of diabetic control and dose of insulin required to achieve this control, showed transient improvement in the pioglitazone group at 12 weeks but was not sustained at 24 weeks. Pioglitazone 199-211 insulin Homo sapiens 50-57 24379032-16 2013 The interaction of HbA1c and insulin dose (HbA1c* insulin/kg/day), which combines degree of diabetic control and dose of insulin required to achieve this control, showed transient improvement in the pioglitazone group at 12 weeks but was not sustained at 24 weeks. Pioglitazone 199-211 insulin Homo sapiens 50-57 24020899-3 2013 Therefore, we examined the hypothesis that pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, would decrease inflammation and disease activity and improve insulin resistance in patients with RA. Pioglitazone 43-55 insulin Homo sapiens 196-203 24020899-12 2013 CONCLUSION: Addition of pioglitazone to RA therapy improves insulin resistance and modestly reduces RA disease activity measured by DAS28-CRP and two of its components, including patient-reported global health and CRP, but not DAS28-ESR or ESR. Pioglitazone 24-36 insulin Homo sapiens 60-67 24029780-1 2013 BACKGROUND: Thiazolidinediones (TZDs) - rosiglitazone and pioglitazone - a class of insulin sensitizer for treating type 2 diabetes, have been reported to exhibit neuroprotective effects in preclinical studies and have good effects in the control of blood sugar for diabetic patients with insulin resistance. Pioglitazone 58-70 insulin Homo sapiens 84-91 24029780-1 2013 BACKGROUND: Thiazolidinediones (TZDs) - rosiglitazone and pioglitazone - a class of insulin sensitizer for treating type 2 diabetes, have been reported to exhibit neuroprotective effects in preclinical studies and have good effects in the control of blood sugar for diabetic patients with insulin resistance. Pioglitazone 58-70 insulin Homo sapiens 289-296 23200554-10 2013 In the U.S. sample, patients treated with pioglitazone, when compared to placebo treated patents, had significantly lower fasting glucose (F=3.99, P=0.02), improved insulin sensitivity (lower H0MA-IR, F=6.24, P=.002), lower triglycerides (F=2.68, P=.06) and increased HDL (F=6.50, P=.001). Pioglitazone 42-54 insulin Homo sapiens 165-172 23401789-0 2013 Improved Insulin Sensitivity during Pioglitazone Treatment Is Associated with Changes in IGF-I and Cortisol Secretion in Type 2 Diabetes and Impaired Glucose Tolerance. Pioglitazone 36-48 insulin Homo sapiens 9-16 23401789-18 2013 Pioglitazone affected cortisol levels in both groups but differently, suggesting different mechanisms for improving insulin sensitivity between T2D and IGT. Pioglitazone 0-12 insulin Homo sapiens 116-123 22964975-11 2013 CONCLUSION: Pioglitazone decreased blood glucose and TG, increased insulin sensitivity, and ameliorated endothelial dysfunction of IGR subjects among the first-degree relatives of T2DM patients. Pioglitazone 12-24 insulin Homo sapiens 67-74 24448252-5 2013 Drugs that directly reduce insulin resistance (pioglitazone and metformin) are also associated with lesser but still significant decreases in MACE. Pioglitazone 47-59 insulin Homo sapiens 27-34 22612529-1 2012 Pioglitazone is a thiazolidinedione insulin sensitizer that has shown efficacy in Type 2 diabetes and nonalcoholic fatty liver disease in humans. Pioglitazone 0-12 insulin Homo sapiens 36-43 23148347-9 2012 The average time in days to initiation on insulin in the sulphonylurea, rosiglitazone and pioglitazone group was 343, 252 and 339, respectively. Pioglitazone 90-102 insulin Homo sapiens 42-49 24082557-1 2012 OBJECTIVES: To evaluate the effect of metformin and pioglitazone on insulin resistance, ovulation and hyperandrogenism in women with PCOS. Pioglitazone 52-64 insulin Homo sapiens 68-75 25755455-6 2012 RESULTS: Both pentoxifylline and pioglitazone were effective in improving transaminases, insulin resistance (HOMA-IR) and adiponectin levels significantly. Pioglitazone 33-45 insulin Homo sapiens 89-96 23087748-9 2012 The most reduction in average FBS, TG, serum insulin level, and HOMA index was observed in pioglitazone group, the most reduction in average amount of cholesterol was seen in metformin group, and the most decrease in average amount of AST and ALT occurred in silymarin group. Pioglitazone 91-103 insulin Homo sapiens 45-52 22334369-0 2012 Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Pioglitazone 77-89 insulin Homo sapiens 45-52 22361751-9 2012 Thus, pioglitazone decreased the sympathetic nerve traffic through the improvement of insulin resistance in DM patients with recent MI, which indicate that the sympathoinhibitory effects of pioglitazone may, at least in part, have contributed to the beneficial effects of pioglitazone. Pioglitazone 6-18 insulin Homo sapiens 86-93 22334369-2 2012 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. Pioglitazone 20-32 insulin Homo sapiens 71-78 22334369-2 2012 Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin-resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients. Pioglitazone 20-32 insulin Homo sapiens 133-140 22334369-5 2012 Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels, and homeostasis model assessment of insulin resistance score and increased serum adiponectin levels during the 16-week run-in phase and maintained these improvements during the standard-care phase. Pioglitazone 0-12 insulin Homo sapiens 72-79 22334369-5 2012 Pioglitazone treatment improved hemoglobin A1c (HbA1c), plasma glucose, insulin levels, and homeostasis model assessment of insulin resistance score and increased serum adiponectin levels during the 16-week run-in phase and maintained these improvements during the standard-care phase. Pioglitazone 0-12 insulin Homo sapiens 124-131 22334369-7 2012 CONCLUSION: Treatment with pioglitazone before and during treatment with peginterferon alpha-2a plus ribavirin improved several indices of glycemic control in patients with chronic hepatitis C and insulin resistance, but did not improve virologic response rates compared with peginterferon alpha-2a plus ribavirin alone. Pioglitazone 27-39 insulin Homo sapiens 197-204 22437669-4 2012 To establish the functional role of single nucleotide polymorphisms (SNPs) in genes modulated by pioglitazone alone or in combination with fenofibrate, we examined genome-wide association data of continuous glycemic phenotypes from the Meta-Analyses of Glucose and Insulin-Related Traits Consortium study and adipose eQTL data from the Multi Tissue Human Expression Resource study. Pioglitazone 97-109 insulin Homo sapiens 265-272 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Pioglitazone 200-212 insulin Homo sapiens 35-45 22462531-1 2012 OBJECTIVE: Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS). Pioglitazone 49-61 insulin Homo sapiens 75-82 22462531-6 2012 Pioglitazone was found to be significantly more effective than metformin at reducing fasting insulin level (P = 0.002, standardized mean differences [SMD] = -0.37, 95% confidence interval [CI] [-0.61, -0.13]). Pioglitazone 0-12 insulin Homo sapiens 93-100 22462531-10 2012 CONCLUSION: This systematic review and meta-analysis suggests that pioglitazone was more suitable for treating hyperinsulinemia and insulin resistance among PCOS patients, while metformin was more effective in reducing body weight. Pioglitazone 67-79 insulin Homo sapiens 116-123 22592687-0 2012 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Pioglitazone 53-65 insulin Homo sapiens 0-7 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Pioglitazone 200-212 insulin Homo sapiens 38-45 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Pioglitazone 200-212 insulin Homo sapiens 46-53 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Pioglitazone 200-212 insulin Homo sapiens 46-53 22059736-9 2012 A greater reduction in the fasting proinsulin/insulin ratio and a greater increase in homeostasis model assessment of beta-cell function (HOMA-beta) were observed with sitagliptin/metformin than with pioglitazone, while greater decreases in fasting insulin and HOMA of insulin resistance (HOMA-IR), and a greater increase in quantitative insulin sensitivity check index (QUICKI) were observed with pioglitazone than with sitagliptin/metformin. Pioglitazone 200-212 insulin Homo sapiens 46-53 22068250-6 2012 In the pioglitazone + metformin group (24 hours off medication), fasting plasma glucose fell from 109 to 102 mg/dL; plasma glucose area under the curve decreased by 12.0%; insulin sensitivity and beta-cell function improved by 42% and 50%, respectively (all P<.001); 14.3% converted to normal glucose tolerance; and no patient developed diabetes. Pioglitazone 7-19 insulin Homo sapiens 172-179 22068250-7 2012 In the pioglitazone + metformin + exenatide group (24 hours off medication), fasting plasma glucose fell from 109 to 98 mg/dL; plasma glucose area under the curve decreased by 21.2%; insulin sensitivity and beta-cell function improved by 52% and 109%, respectively (all P<.001); 59.1% of patients with IGT reverted to normal glucose tolerance; and no patient developed diabetes. Pioglitazone 7-19 insulin Homo sapiens 183-190 21782251-14 2012 CONCLUSION: Although preliminary, pioglitazone appears to reduce depression severity and improve several markers of cardiometabolic risk, including insulin resistance and inflammation. Pioglitazone 34-46 insulin Homo sapiens 148-155 22094332-6 2012 With addition of pioglitazone, the phosphorylation of Akt by insulin remained unchanged, whereas insulin-stimulated Erk phosphorylation was reduced by pioglitazone. Pioglitazone 17-29 insulin Homo sapiens 61-68 22094332-6 2012 With addition of pioglitazone, the phosphorylation of Akt by insulin remained unchanged, whereas insulin-stimulated Erk phosphorylation was reduced by pioglitazone. Pioglitazone 151-163 insulin Homo sapiens 97-104 22036866-4 2012 Insulin sensitizers (such as rosiglitazone and pioglitazone) inhibit inflammation while improving insulin sensitivity. Pioglitazone 47-59 insulin Homo sapiens 0-7 22036866-4 2012 Insulin sensitizers (such as rosiglitazone and pioglitazone) inhibit inflammation while improving insulin sensitivity. Pioglitazone 47-59 insulin Homo sapiens 98-105 21782251-0 2012 Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. Pioglitazone 92-104 insulin Homo sapiens 7-14 21782251-1 2012 OBJECTIVE: This study was conducted to examine the safety and efficacy of pioglitazone, a thiazolidinedione insulin sensitizer, in adult outpatients with major depressive disorder. Pioglitazone 74-86 insulin Homo sapiens 108-115 22715547-8 2012 Only insulin sensitizing drugs like metformin and pioglitazone have been consistently shown to reduce cardiovascular risk. Pioglitazone 50-62 insulin Homo sapiens 5-12 22049096-1 2012 Pioglitazone and metformin are insulin sensitisers used for the treatment of T2DM. Pioglitazone 0-12 insulin Homo sapiens 31-38 22049096-4 2012 Pioglitazone significantly decreased fasting insulin, HbA(1C) and HOMA-IR (p < 0.05 for all) and increased FMD (p = 0.002). Pioglitazone 0-12 insulin Homo sapiens 45-52 22451180-1 2012 AIM: to compare the effectiveness of metformin and pioglitazone in ameliorating insulin resistance and cardiovascular risk factors in women with polycystic ovary syndrome (PCOS). Pioglitazone 51-63 insulin Homo sapiens 80-87 22451180-9 2012 CONCLUSION: these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight. Pioglitazone 34-46 insulin Homo sapiens 89-96 21968139-2 2011 Pioglitazone improves insulin sensitivity by activating PPARgamma. Pioglitazone 0-12 insulin Homo sapiens 22-29 22739963-4 2012 The aim of this study was to investigate the effect of pioglitazone versus placebo on total daily insulin requirements and several pleiotropic factors in type 2 diabetes patients requiring hemodialysis. Pioglitazone 55-67 insulin Homo sapiens 98-105 22739963-12 2012 CONCLUSIONS: Addition of pioglitazone to insulin in patients with late-stage kidney failure requiring hemodialysis is a well-tolerated treatment option that improves glycemic control with simultaneous insulin-sparing potential. Pioglitazone 25-37 insulin Homo sapiens 201-208 22971482-0 2012 The adipose tissue endocrine mechanism of the prophylactic protective effect of pioglitazone in high-fat diet-induced insulin resistance. Pioglitazone 80-92 insulin Homo sapiens 118-125 22971482-1 2012 OBJECTIVE: To explore the adipose tissue endocrine mechanism of pioglitazone and its possible prophylactic role in insulin resistance. Pioglitazone 64-76 insulin Homo sapiens 115-122 22971482-10 2012 CONCLUSIONS: Pioglitazone prevented insulin resistance in rats fed a high-fat diet. Pioglitazone 13-25 insulin Homo sapiens 36-43 22971482-11 2012 Liver AdipoR2-mediated glucose uptake is important in the prophylactic effect of pioglitazone on insulin resistance. Pioglitazone 81-93 insulin Homo sapiens 97-104 21993383-4 2012 RESULTS: Compared with placebo, pioglitazone significantly increased HDL-cholesterol plasma levels (14.2%), reduced fasting insulin plasma levels (23.6%) and the homeostasis model assessment-insulin resistance (31.7%). Pioglitazone 32-44 insulin Homo sapiens 124-131 21993383-4 2012 RESULTS: Compared with placebo, pioglitazone significantly increased HDL-cholesterol plasma levels (14.2%), reduced fasting insulin plasma levels (23.6%) and the homeostasis model assessment-insulin resistance (31.7%). Pioglitazone 32-44 insulin Homo sapiens 191-198 21993383-7 2012 CONCLUSION: Pioglitazone significantly enhanced insulin sensitivity, reduced inflammation, and modified HDL characteristics, suggesting a potential beneficial effect of this drug in patients with SLE with a risk to develop cardiovascular disease. Pioglitazone 12-24 insulin Homo sapiens 48-55 21968139-10 2011 There were significant changes in some laboratory values and biochemical markers of insulin sensitivity after pioglitazone therapy. Pioglitazone 110-122 insulin Homo sapiens 84-91 22028424-6 2011 Because of this, rosiglitazone and pioglitazone have been evaluated as potential treatments for AD because of their insulin-sensitizing and antiinflammatory effects. Pioglitazone 35-47 insulin Homo sapiens 116-123 22029000-1 2011 Pioglitazone was approved in 1999 as an adjunct to exercise and diet to improve glycemic control in adults with type 2 diabetes mellitus, primarily by reducing insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 160-167 19923038-6 2011 In addition, pioglitazone treatment resulted in a decrease in fasting plasma insulin levels, indicating enhanced insulin sensitivity. Pioglitazone 13-25 insulin Homo sapiens 77-84 21554488-12 2011 Pioglitazone had no effect on waveform structure, despite significantly reducing insulin resistance, fasting glucose, and triglycerides (p < 0.05). Pioglitazone 0-12 insulin Homo sapiens 81-88 21554488-14 2011 Pioglitazone improved glucose, insulin sensitivity, and triglycerides without influencing the contour of the waveforms. Pioglitazone 0-12 insulin Homo sapiens 31-38 21893273-2 2011 Several pharmacologic therapies have shown some promise; currently, vitamin E and insulin-sensitizing agents such as pioglitazone can be considered in appropriate cases. Pioglitazone 117-129 insulin Homo sapiens 82-89 19923038-6 2011 In addition, pioglitazone treatment resulted in a decrease in fasting plasma insulin levels, indicating enhanced insulin sensitivity. Pioglitazone 13-25 insulin Homo sapiens 113-120 21492190-1 2011 Pioglitazone is a thiazolidinedione class of antidiabetic agent with proven efficacy in increasing insulin sensitivity in humans with noninsulin-dependent diabetes mellitus, a syndrome of insulin resistance sharing similarities with equine metabolic syndrome. Pioglitazone 0-12 insulin Homo sapiens 99-106 21756323-1 2011 BACKGROUND: We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk. Pioglitazone 67-79 insulin Homo sapiens 147-154 21756323-14 2011 CONCLUSIONS: Addition of pioglitazone but not of metformin reduces MMP-9, hs-CRP and increased insulin sensitivity and adiponectin in this study. Pioglitazone 25-37 insulin Homo sapiens 95-102 21756323-16 2011 Pioglitazone is suggested to be a rational add-on therapy to basal insulin in patients with high CV risk. Pioglitazone 0-12 insulin Homo sapiens 67-74 21816321-0 2011 Lowering the triglyceride/high-density lipoprotein cholesterol and its association with the beneficial impact of pioglitazone on coronary atherosclerosis in the PERISCOPE study is likely due to lowering insulin resistance. Pioglitazone 113-125 insulin Homo sapiens 203-210 21639813-5 2011 EXPERT OPINION: Treatment with pioglitazone in T2DM was shown to improve insulin resistance and blood glucose levels without increasing the risk of hypoglycemia. Pioglitazone 31-43 insulin Homo sapiens 73-80 21651446-2 2011 Pioglitazone is now the only thiazolidinedione approved for the treatment of T2DM and can be administered in combination with metformin, sulfonylureas, exenatide, dipeptidyl peptidase 4 (DPP-4) inhibitors or insulin. Pioglitazone 0-12 insulin Homo sapiens 208-215 21081243-7 2011 Metreleptin administration in HIV-positive, leptin-deficient patients with lipoatrophy treated with pioglitazone improves postprandial glycemia and insulin sensitivity. Pioglitazone 100-112 insulin Homo sapiens 148-155 21492190-1 2011 Pioglitazone is a thiazolidinedione class of antidiabetic agent with proven efficacy in increasing insulin sensitivity in humans with noninsulin-dependent diabetes mellitus, a syndrome of insulin resistance sharing similarities with equine metabolic syndrome. Pioglitazone 0-12 insulin Homo sapiens 137-144 21106874-5 2011 High-fat + pioglitazone mice were shorter, their tibial growth and the growth plate height reduced, and their insulin lower than those of high-fat mice. Pioglitazone 11-23 insulin Homo sapiens 110-117 21595275-3 2011 Pioglitazone, a thiazolidinedione class agent, is an insulin sensitizer and alogliptin belongs to DPP-4 (dipeptidyl peptidase-4) inhibitor class agents, which promote postprandial insulin secretion and suppress glucagon secretion in a blood glucose dependent fashion. Pioglitazone 0-12 insulin Homo sapiens 53-60 21595275-3 2011 Pioglitazone, a thiazolidinedione class agent, is an insulin sensitizer and alogliptin belongs to DPP-4 (dipeptidyl peptidase-4) inhibitor class agents, which promote postprandial insulin secretion and suppress glucagon secretion in a blood glucose dependent fashion. Pioglitazone 0-12 insulin Homo sapiens 180-187 21314724-2 2011 Pioglitazone (PG) is an insulin-sensitizing drug used in humans that is absorbed after oral administration to horses. Pioglitazone 0-12 insulin Homo sapiens 24-31 21314724-2 2011 Pioglitazone (PG) is an insulin-sensitizing drug used in humans that is absorbed after oral administration to horses. Pioglitazone 14-16 insulin Homo sapiens 24-31 21875310-13 2011 Insulin sensitizing agents such as pioglitazone and anti-oxidant agents such as vitamin E show some promise in improving liver histology in patients with NASH, however, the long-term benefit of these medications has not been demonstrated. Pioglitazone 35-47 insulin Homo sapiens 0-7 21722594-5 2011 One focus was on the impact of insulin-sensitizing therapy with pioglitazone on the pancreatic beta-cell load. Pioglitazone 64-76 insulin Homo sapiens 31-38 21722594-6 2011 RESULTS: Treatment with pioglitazone resulted in significant decreases in elevated proinsulin levels in type 2 diabetes patients. Pioglitazone 24-36 insulin Homo sapiens 83-93 22416367-3 2011 Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. Pioglitazone 10-22 insulin Homo sapiens 86-93 22416367-3 2011 Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. Pioglitazone 10-22 insulin Homo sapiens 264-271 21225393-8 2011 Modification of insulin resistance with pioglitazone and metformin, lipid-lowering therapy with a statin, lowering blood pressure to <130/80 mmHg, and antiplatelet therapy should be considered in individuals with DM. Pioglitazone 40-52 insulin Homo sapiens 16-23 24843462-1 2011 UNLABELLED: Aims/Introduction: The present study was designed to determine the effects of pioglitazone on glycemic control and atherosclerosis in patients with poorly controlled type 2 diabetes on insulin therapy. Pioglitazone 91-103 insulin Homo sapiens 198-205 24843462-7 2011 The insulin dose lowered by 0.04 +- 0.10 units/kg/day in the pioglitazone group and increased by 0.03 +- 0.10 units/kg/day in the control group (P < 0.05). Pioglitazone 61-73 insulin Homo sapiens 4-11 24843462-8 2011 The number of insulin injections decreased by 0.1 +- 0.6 times/day in the pioglitazone group and increased by 0.2 +- 0.4 times/day in the control group (P < 0.05). Pioglitazone 74-86 insulin Homo sapiens 14-21 24843462-10 2011 CONCLUSIONS: These findings show that pioglitazone is useful in improving glycemic control and preventing the progression of atherosclerosis in poorly-controlled type 2 diabetics on insulin therapy. Pioglitazone 40-52 insulin Homo sapiens 184-191 20959530-0 2011 Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 73-85 insulin Homo sapiens 114-121 20959530-3 2011 We evaluated whether the peroxisome proliferator-activated receptor-gamma agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 82-94 insulin Homo sapiens 150-157 20959530-3 2011 We evaluated whether the peroxisome proliferator-activated receptor-gamma agonist pioglitazone with exercise training improves central and peripheral insulin sensitivity more than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 82-94 insulin Homo sapiens 227-234 20959530-8 2011 Exercise training augmented the beneficial effects of pioglitazone on peripheral insulin sensitivity. Pioglitazone 54-66 insulin Homo sapiens 81-88 20959530-10 2011 We conclude that supplementing pioglitazone with increased physical activity improved insulin sensitivity more effectively than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 31-43 insulin Homo sapiens 86-93 20959530-10 2011 We conclude that supplementing pioglitazone with increased physical activity improved insulin sensitivity more effectively than pioglitazone alone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 31-43 insulin Homo sapiens 175-182 20959530-0 2011 Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. Pioglitazone 73-85 insulin Homo sapiens 42-49 20684955-14 2011 CONCLUSION(S): In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance. Pioglitazone 69-81 insulin Homo sapiens 210-217 20547473-2 2010 Pioglitazone, an anti-diabetic drug, improves insulin resistance, but its influence on sympathetic nerve activity is not clear. Pioglitazone 0-12 insulin Homo sapiens 46-53 21209881-8 2010 Myotubes established from PCOS patients with or without pioglitazone treatment also showed no significant differences between groups, neither at baseline nor during acute insulin stimulation, although in vivo pioglitazone treatment significantly improved insulin sensitivity. Pioglitazone 209-221 insulin Homo sapiens 255-262 20547473-11 2010 These results suggest that improved insulin resistance with pioglitazone provides an additional effect on inhibition of sympathetic nerve activity. Pioglitazone 60-72 insulin Homo sapiens 36-43 22166651-0 2010 Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone. Pioglitazone 154-166 insulin Homo sapiens 12-19 21036144-7 2010 Furthermore, pioglitazone enhanced insulin secretion in pSilencer-control transfected cells exposed to FFAs for 48h, but not in cells transfected with GPR40shRNA. Pioglitazone 13-25 insulin Homo sapiens 35-42 20662773-6 2010 Pioglitazone increased 2.3-fold plasma adiponectin and improved insulin resistance, glucose tolerance and glucose clearance, steatosis and necroinflammation (all P < 0.01-0.001 vs. placebo). Pioglitazone 0-12 insulin Homo sapiens 64-71 20945270-0 2010 Pioglitazone has direct effects on insulin sensitivity and intracellular lipid content in L6 skeletal muscle cells. Pioglitazone 0-12 insulin Homo sapiens 35-42 20945270-6 2010 We conclude that pioglitazone has direct insulin-sensitizing effects on the L6 skeletal muscle cell line, which are paralleled by a reduction in intramyocellular triglyceride accumulation. Pioglitazone 17-29 insulin Homo sapiens 41-48 20528570-5 2010 The thiazolidinediones rosiglitazone and pioglitazone were recently applied as insulin sensitising treatment in patients with PCOS. Pioglitazone 41-53 insulin Homo sapiens 79-86 20883052-7 2010 Glycosylated haemoglobin, fasting glucose, insulin parameters and beta-cell function are all improved with pioglitazone treatment, with efficacy similar to third-generation sulfonylureas, metformin and dipeptidyl peptidase-4 inhibitors. Pioglitazone 107-119 insulin Homo sapiens 43-50 20859539-2 2010 Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atherosclerotic and cardiovascular events. Pioglitazone 0-12 insulin Homo sapiens 25-32 20877770-6 2010 Pioglitazone could be used with insulin therapy but not as triple therapy. Pioglitazone 0-12 insulin Homo sapiens 32-39 20739883-7 2010 Given these new findings, it can be anticipated that FCHL patients could also benefit from insulin-sensitizing therapy such as pioglitazone and metformin. Pioglitazone 127-139 insulin Homo sapiens 91-98 20599791-6 2010 This was reversed by restoration of normal growth medium, while the insulin resistance was prevented by pioglitazone or metformin. Pioglitazone 104-116 insulin Homo sapiens 68-75 20816593-2 2010 METHODS: The electronic databases PubMed, Embase and The Cochrane Library were searched systematically to identify randomized controlled trials (RCTs) of pioglitazone therapy in patients with type 2 diabetes mellitus (DM) inadequately controlled after treatment with insulin. Pioglitazone 154-166 insulin Homo sapiens 267-274 20816593-9 2010 CONCLUSIONS: Our study implied that in patients with type 2 DM whose control is inadequate on insulin therapy, the additional pioglitazone could significantly improve glucose metabolism and might have a positive effect on important components of the lipid profile, which may have important implications in reducing the risk of cardiovascular disease, a major long-term complication in type 2 diabetes mellitus. Pioglitazone 126-138 insulin Homo sapiens 94-101 20831680-13 2010 Fasting plasma insulin decreased in the pioglitazone group after both the titration period and the full treatment period compared to both the baseline value and the acarbose group. Pioglitazone 40-52 insulin Homo sapiens 15-22 20455891-5 2010 RESULTS: Pioglitazone decreased fasting plasma glucose concentration (10.5 +/- 0.7 to 7.8 +/- 0.6 mM, P < 0.0003) and HbA1c (9.7 +/- 0.7 to 7.5 +/- 0.5%, P < 0.003) despite increased body weight and no change in plasma insulin concentrations. Pioglitazone 9-21 insulin Homo sapiens 225-232 20662773-9 2010 CONCLUSIONS: Adiponectin exerts an important metabolic role at the level of the liver, and its increase during pioglitazone treatment is critical to reverse insulin resistance and improve liver histology in NASH patients. Pioglitazone 111-123 insulin Homo sapiens 157-164 20821932-10 2010 Insulin resistance improved and the HOMA-IR index decreased after pioglitazone treatment. Pioglitazone 66-78 insulin Homo sapiens 0-7 20923486-0 2010 Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Pioglitazone 0-12 insulin Homo sapiens 169-176 21437092-0 2010 Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin. Pioglitazone 0-12 insulin Homo sapiens 89-96 20560108-7 2010 Pioglitazone plus vildagliptin were found to be more effective in preserving beta-cell function, and in reducing insulin resistance, and inflammatory state parameters. Pioglitazone 0-12 insulin Homo sapiens 113-120 20831543-4 2010 RESULTS AND DISCUSSION: Three-month treatment with pioglitazone improved glycaemic control, homeostasis model assessment for insulin resistance (HOMA), dyslipidaemia and liver function tests in association with a marked increase in serum HMW adiponectin level. Pioglitazone 51-63 insulin Homo sapiens 125-132 20540652-4 2010 RESULTS: Pioglitazone effectively reduced erythropoietin dose and maintained the target hemoglobin levels by improving insulin resistance up to the end of the study. Pioglitazone 9-21 insulin Homo sapiens 119-126 20540652-8 2010 CONCLUSION: Pioglitazone treatment resulted in better glycemic control, improved lipid levels, an increase in insulin sensitivity and adiponectin levels, and a decrease in inflammatory markers, thus improving the risk factors of cardiovascular disease. Pioglitazone 12-24 insulin Homo sapiens 110-117 20540652-9 2010 Erythropoietin responsiveness improved with a reduction in erythropoietin dose and may be associated with the improvement in insulin resistance due to long-term pioglitazone treatment. Pioglitazone 161-173 insulin Homo sapiens 125-132 20392866-8 2010 The improvement in insulin sensitivity from pioglitazone resulted in a 52 +/- 0.2% reduction in MMP-9 mRNA. Pioglitazone 44-56 insulin Homo sapiens 19-26 20530928-6 2010 To improve her insulin resistance, we administered pioglitazone therapy for 1 week; however, subsequent laboratory findings did not indicate any improvement in her liver damage. Pioglitazone 51-63 insulin Homo sapiens 15-22 20197197-1 2010 Pioglitazone is prescribed to improve insulin sensitivity in type 2 diabetes mellitus patients and has been discussed as a therapy for metabolic syndrome. Pioglitazone 0-12 insulin Homo sapiens 38-45 20407626-13 2010 The addition of pioglitazone tends to reduce daily insulin dosages, but study findings have not been consistent. Pioglitazone 16-28 insulin Homo sapiens 51-58 20237169-4 2010 RESULTS: A rapid and sustained decrease in insulin dose was observed with pioglitazone vs. a progressive increase with placebo. Pioglitazone 74-86 insulin Homo sapiens 43-50 20237169-5 2010 By study end, the mean insulin dose was lower with pioglitazone (42 vs. 55 U/d with placebo; P < 0.0001). Pioglitazone 51-63 insulin Homo sapiens 23-30 20237169-6 2010 The insulin regimen (number on insulin, need for multiple injections, and reduction in oral agents) had been simplified vs. placebo; nevertheless, a greater glycosylated hemoglobin reduction was observed with pioglitazone (-0.93%) vs. placebo (-0.45%; P < 0.0001). Pioglitazone 209-221 insulin Homo sapiens 4-11 20237169-7 2010 At the final visit, insulin had been discontinued in 9% of pioglitazone vs. 2% of placebo patients (P < 0.0001). Pioglitazone 59-71 insulin Homo sapiens 20-27 20237169-8 2010 More insulin-resistant patients (defined as poorly controlled type 2 diabetes despite high doses of insulin) in the pioglitazone plus insulin group showed the greatest glycosylated hemoglobin decline. Pioglitazone 116-128 insulin Homo sapiens 5-12 20237169-8 2010 More insulin-resistant patients (defined as poorly controlled type 2 diabetes despite high doses of insulin) in the pioglitazone plus insulin group showed the greatest glycosylated hemoglobin decline. Pioglitazone 116-128 insulin Homo sapiens 100-107 20237169-8 2010 More insulin-resistant patients (defined as poorly controlled type 2 diabetes despite high doses of insulin) in the pioglitazone plus insulin group showed the greatest glycosylated hemoglobin decline. Pioglitazone 116-128 insulin Homo sapiens 100-107 20237169-9 2010 There were nonsignificant reductions with pioglitazone relative to placebo in the cardiovascular primary (hazard ratio 0.86; 95% confidence interval 0.71, 1.04; P = 0.1198) and main secondary (hazard ratio 0.85; 95% confidence interval 0.67, 1.08; P = 0.1831) end points in insulin-treated patients. Pioglitazone 42-54 insulin Homo sapiens 274-281 20237169-11 2010 CONCLUSIONS: Pioglitazone use in combination with insulin resulted in a sustained improved glycemic control and allowed the treatment regimens to be simplified and the insulin doses reduced. Pioglitazone 13-25 insulin Homo sapiens 168-175 19910937-7 2010 Insulin resistance (steady-state plasma insulin and glucose (SSPG)) decreased following pioglitazone (P < 0.001). Pioglitazone 88-100 insulin Homo sapiens 0-7 20415685-10 2010 Insulin sensitizers, including pioglitazone and rosiglitazone, and lipid-lowering agents, including statins and fibrates, also upregulate adiponectin and ameliorate liver histology. Pioglitazone 31-43 insulin Homo sapiens 0-7 20513338-0 2010 High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. Pioglitazone 149-161 insulin Homo sapiens 114-121 20407626-16 2010 Combination therapy of even small doses of pioglitazone with insulin should be primarily used for patients who achieve insufficient reduction in glycemia with insulin monotherapy. Pioglitazone 43-55 insulin Homo sapiens 159-166 20229808-6 2010 Several studies have shown that insulin sensitizers (pioglitazone and rosiglitazone) improve cognition and memory in patients with mild Alzheimer disease as well as animal model of Alzheimer disease. Pioglitazone 53-65 insulin Homo sapiens 32-39 19919569-0 2010 Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 139-146 19919569-3 2010 The safety and efficacy of pioglitazone on insulin sensitivity and SVR in treatment-naive patients with chronic hepatitis C (CHC) genotype 4 with IR receiving standard antiviral therapy were evaluated in a randomized-controlled study. Pioglitazone 27-39 insulin Homo sapiens 43-50 19875376-7 2010 Pioglitazone treatment increased the insulin sensitivity index compared with the control group (-0.8 +/- 3.1x10(-)(2) vs +1.1 +/- 3.7x10(-)(2), P = 0.036). Pioglitazone 0-12 insulin Homo sapiens 37-44 19875376-8 2010 CONCLUSIONS: These results suggest that pioglitazone treatment reduces the progression of carotid IMT and improves insulin resistance in renal allograft recipients without a history of diabetes. Pioglitazone 40-52 insulin Homo sapiens 115-122 20146161-8 2010 Nevertheless, the positive findings did not result from better glycemic control, but from the complexity of effects of PPARgamma agonist pioglitazone on insulin resistance, lipoprotein spectrum, blood pressure, endothelial function and biomarkers of subclinical inflammation. Pioglitazone 137-149 insulin Homo sapiens 153-160 20105179-1 2010 BACKGROUND AND PURPOSE: Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists, such as rosiglitazone and pioglitazone, sensitize cells to insulin, and are therefore used to treat type 2 diabetes. Pioglitazone 121-133 insulin Homo sapiens 154-161 19889003-8 2010 At steady-state, FeLi (marker of proximal-tubular sodium delivery to the distal nephron) increased significantly with added pioglitazone (12.4 +/- 1.3 to 18.0 +/- 3.2%) vs. no significant change with insulin alone (15.4 +/- 1.2 to 14.5 +/- 2.3%). Pioglitazone 124-136 insulin Homo sapiens 200-207 19889003-10 2010 CONCLUSION: In intensively insulin-treated obese type 2 diabetic patients, at equivalent glycaemic control, the addition of pioglitazone causes greater weight gain, but a similar increase in body water that is mainly extracellular and interstitial compared with intracellular increase with insulin therapy alone. Pioglitazone 124-136 insulin Homo sapiens 27-34 20158097-1 2010 Peroxisome proliferator-activated receptor gamma (PPARgamma) plays critical roles on insulin sensitivity and adipocyte differentiation, and therefore, several agonists such as pioglitazone and rosiglitazone are used as anti-diabetic drugs. Pioglitazone 176-188 insulin Homo sapiens 85-92 19834871-1 2010 Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 32-39 20158101-4 2010 Indeed, pioglitazone and rosiglitazone, ligands for PPARgamma, improve insulin resistance in diabetic patients, and now become one of the most popular anti-diabetic drugs in the developed countries. Pioglitazone 8-20 insulin Homo sapiens 71-78 20158105-3 2010 Pharmacologic treatment with thiazolidinedions, such as rosiglitazone and pioglitazone, agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), may offer some therapeutic relief of AD by lowering peripheral insulin and enhancing insulin sensitivity. Pioglitazone 74-86 insulin Homo sapiens 246-253 20158105-3 2010 Pharmacologic treatment with thiazolidinedions, such as rosiglitazone and pioglitazone, agonists of the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma), may offer some therapeutic relief of AD by lowering peripheral insulin and enhancing insulin sensitivity. Pioglitazone 74-86 insulin Homo sapiens 268-275 20814432-1 2010 Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARgamma), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Pioglitazone 103-115 insulin Homo sapiens 195-202 20091537-0 2010 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Pioglitazone 53-65 insulin Homo sapiens 0-7 20160397-0 2010 Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. Pioglitazone 10-22 insulin Homo sapiens 48-55 20160397-1 2010 Pioglitazone is an insulin-sensitizing agent that has been reported to have anti-arteriosclerotic effects. Pioglitazone 0-12 insulin Homo sapiens 19-26 20160397-2 2010 The aim of this study was to obtain a better understanding of the mechanism involved in the insulin sensitizing effect of pioglitazone. Pioglitazone 122-134 insulin Homo sapiens 92-99 19820024-0 2009 Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients. Pioglitazone 0-12 insulin Homo sapiens 59-66 19755409-0 2009 Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. Pioglitazone 0-12 insulin Homo sapiens 22-29 19755409-3 2009 OBJECTIVES: To assess insulin sensitivity in CAH patients and the effect of pioglitazone treatment on insulin sensitivity in CAH patients. Pioglitazone 76-88 insulin Homo sapiens 102-109 19755409-11 2009 Treatment with pioglitazone significantly improved insulin sensitivity in CAH patients (glucose infusion rate (GIR) from 28.5+/-11.6 to 38.9+/-11.0 micromol/kg per min, P=0.000, GIR in controls 46.2+/-23.4 micromol/kg per min, P<0.05 versus CAH). Pioglitazone 15-27 insulin Homo sapiens 51-58 19755409-15 2009 Treatment with pioglitazone improves insulin sensitivity and decreases blood pressure in CAH patients. Pioglitazone 15-27 insulin Homo sapiens 37-44 19170716-10 2009 Pioglitazone treatment significantly improved insulin sensitivity without affecting testosterone, body composition, MCP-1, MIP-1alpha and MIF levels. Pioglitazone 0-12 insulin Homo sapiens 46-53 19835463-9 2009 Reductions in HbA(1c), fasting blood glucose and fasting blood insulin levels, and an increase in HDL-C were significantly greater with pioglitazone throughout most of the study (p < 0.05). Pioglitazone 136-148 insulin Homo sapiens 63-70 19835463-10 2009 Fewer patients in the pioglitazone group commenced permanent treatment with insulin (3.3% vs. 13.7% in the control group). Pioglitazone 22-34 insulin Homo sapiens 76-83 19820024-4 2009 OBJECTIVE: The objective of the study was to study the effects of treatment with the TZD pioglitazone on sc adipose tissue morphology and function in insulin-resistant subjects. Pioglitazone 89-101 insulin Homo sapiens 150-157 19820024-10 2009 RESULTS: Pioglitazone treatment significantly improved the insulin sensitivity index (placebo: 0.35 +/- 0.16 micromol/kg . Pioglitazone 9-21 insulin Homo sapiens 59-66 19820024-13 2009 The increase in insulin sensitivity was accompanied by a significant enlargement of the sc adipocyte cell surface (placebo: 2323 +/- 725 microm(2); pioglitazone 2821 +/- 885 microm(2), P = 0.03). Pioglitazone 148-160 insulin Homo sapiens 16-23 19820024-14 2009 CONCLUSIONS: In the human situation, treatment of insulin-resistant subjects with pioglitazone improves insulin sensitivity, whereas at the same time, sc adipocyte cell surface increases. Pioglitazone 82-94 insulin Homo sapiens 50-57 19820024-14 2009 CONCLUSIONS: In the human situation, treatment of insulin-resistant subjects with pioglitazone improves insulin sensitivity, whereas at the same time, sc adipocyte cell surface increases. Pioglitazone 82-94 insulin Homo sapiens 104-111 19683825-6 2009 There was no change in IAF content after both treatments whereas significant increase in SCF content was only seen after pioglitazone treatment (p<0.05 versus insulin). Pioglitazone 121-133 insulin Homo sapiens 162-169 20144400-1 2009 BACKGROUND: The aim of our study was to examine the efficacy of short-term intravenous insulin intervention followed by oral pioglitazone/metformin therapy to prevent patients from continuous insulin application. Pioglitazone 125-137 insulin Homo sapiens 192-199 20144400-13 2009 CONCLUSIONS: Our pilot study demonstrated that a beneficial effect of a short-term intravenous insulin application on glycemic control was effectively maintained by pioglitazone/metformin treatment for at least 4 months. Pioglitazone 165-177 insulin Homo sapiens 95-102 19821299-0 2009 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Pioglitazone 53-65 insulin Homo sapiens 0-7 20144400-0 2009 Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study. Pioglitazone 9-21 insulin Homo sapiens 92-99 19614944-11 2009 HOMA-IR, insulin, proinsulin and C-peptide decreased and HOMA-B increased in the pioglitazone group relative to the placebo group. Pioglitazone 81-93 insulin Homo sapiens 9-16 19670459-1 2009 UNLABELLED: Pioglitazone treatment improves insulin resistance (IR), glucose metabolism, hepatic steatosis, and necroinflammation in patients with nonalcoholic steatohepatitis (NASH). Pioglitazone 12-24 insulin Homo sapiens 44-51 19670459-2 2009 Because abnormal lipid metabolism/elevated plasma free fatty acids (FFAs) are important to the pathophysiology of NASH, we examined the impact of pioglitazone therapy on adipose tissue insulin resistance (Adipo-IR) during the treatment of patients with NASH. Pioglitazone 146-158 insulin Homo sapiens 185-192 19999145-6 2009 Oral administration of pioglitazone improved the excessive insulin secretion as assessed by OGTT. Pioglitazone 23-35 insulin Homo sapiens 59-66 19667111-9 2009 Pioglitazone and adiponectin regulate gene expression of SRA and LOX-1, and this may have clinical implications in arresting the untoward sequalae of insulin resistance and diabetes, including accelerated atherosclerosis. Pioglitazone 0-12 insulin Homo sapiens 150-157 19614944-11 2009 HOMA-IR, insulin, proinsulin and C-peptide decreased and HOMA-B increased in the pioglitazone group relative to the placebo group. Pioglitazone 81-93 insulin Homo sapiens 33-42 19476476-0 2009 Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers. Pioglitazone 0-12 insulin Homo sapiens 76-83 19417125-7 2009 Following pioglitazone, triglycerides and FFA were reduced (P = 0.05 and P < 0.04, respectively), and glycerol R(a) was more suppressed [-40 (137) vs. +7 (202) mumol/min of placebo, P < 0.05] despite a greater fall in insulin [-85 (176) vs. -20 (58) pmol/l, P = 0.05]. Pioglitazone 10-22 insulin Homo sapiens 224-231 19394976-10 2009 Pioglitazone-metformin-based therapeutic control is associated with the most quantitatively relevant improvement in insulin resistance-related parameters, whereas the sulfonylurea-metformin-including protocol has less relevant effects. Pioglitazone 0-12 insulin Homo sapiens 116-123 19520186-7 2009 There was 40% decrease in proliferation with pioglitazone in VEGF stimulated cells, which was reversed by insulin. Pioglitazone 45-57 insulin Homo sapiens 106-113 19417125-8 2009 We conclude that, in well-controlled T2DM patients, whole body lipolysis is insulin resistant, and pioglitazone improves the insulin sensitivity of lipolysis. Pioglitazone 99-111 insulin Homo sapiens 125-132 19367381-0 2009 Insulin-dependent actions of pioglitazone in newly diagnosed, drug naive patients with type 2 diabetes. Pioglitazone 29-41 insulin Homo sapiens 0-7 19568428-2 2009 The oral agent pioglitazone is licensed for use with insulin when metformin is contraindicated or not tolerated. Pioglitazone 15-27 insulin Homo sapiens 53-60 19568428-17 2009 CONCLUSIONS/SIGNIFICANCE: When added to insulin regimens, pioglitazone confers a small advantage in terms of HbA1c in type 2 diabetes patients with previous inadequate glucose control, but at the cost of increased hypoglycaemia and weight gain. Pioglitazone 58-70 insulin Homo sapiens 40-47 19367381-10 2009 Multiple regression analysis revealed that the baseline insulin level is the predominant determinant of the changes of insulin levels with pioglitazone. Pioglitazone 139-151 insulin Homo sapiens 56-63 19367381-10 2009 Multiple regression analysis revealed that the baseline insulin level is the predominant determinant of the changes of insulin levels with pioglitazone. Pioglitazone 139-151 insulin Homo sapiens 119-126 19367381-11 2009 These results suggest that pioglitazone appears to have two effects: to reduce insulin resistance (and lower insulin) and to improve beta-cell function (and increase insulin). Pioglitazone 27-39 insulin Homo sapiens 79-86 19367381-11 2009 These results suggest that pioglitazone appears to have two effects: to reduce insulin resistance (and lower insulin) and to improve beta-cell function (and increase insulin). Pioglitazone 27-39 insulin Homo sapiens 109-116 19367381-1 2009 The aim of this study was to study the effects of pioglitazone on several diabetic parameters with subjects possessing distinct levels of insulin. Pioglitazone 50-62 insulin Homo sapiens 138-145 19367381-8 2009 Significant correlations between the changes of insulin/C-peptide levels with pioglitazone and the baseline insulin/C-peptide levels were observed. Pioglitazone 78-90 insulin Homo sapiens 48-55 19367381-8 2009 Significant correlations between the changes of insulin/C-peptide levels with pioglitazone and the baseline insulin/C-peptide levels were observed. Pioglitazone 78-90 insulin Homo sapiens 56-65 19367381-8 2009 Significant correlations between the changes of insulin/C-peptide levels with pioglitazone and the baseline insulin/C-peptide levels were observed. Pioglitazone 78-90 insulin Homo sapiens 108-115 19367381-8 2009 Significant correlations between the changes of insulin/C-peptide levels with pioglitazone and the baseline insulin/C-peptide levels were observed. Pioglitazone 78-90 insulin Homo sapiens 116-125 19267711-12 2009 Pioglitazone reduced insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR)) more than metformin. Pioglitazone 0-12 insulin Homo sapiens 21-28 19402055-0 2009 Pioglitazone: more than just an insulin sensitizer. Pioglitazone 0-12 insulin Homo sapiens 32-39 19473593-0 2009 Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. Pioglitazone 45-57 insulin Homo sapiens 10-17 19473593-1 2009 OBJECTIVE: The thiazolidindione (TDZ) pioglitazone reduces insulin resistance and blood pressure in non-diabetic patients with arterial hypertension as previously reported [Fullert et al. Pioglitazone 38-50 insulin Homo sapiens 59-66 19473593-5 2009 MATERIAL AND METHODS: Insulin sensitivity indices (SI indices) were obtained by analyzing fasting glucose and insulin concentration with homeostasis model assessment (HOMA), the glucose and insulin profiles after 75 g dextrose oral glucose tolerance tests (OGTT, Matsuda-Index) and euglycemic hyperinsulinemic clamp (m-value) in a double-blind placebo-controlled study in 60 patients with arterial hypertension before and after 4 months treatment with Pioglitazone 45 mg (PIO45). Pioglitazone 452-464 insulin Homo sapiens 22-29 19349323-13 2009 CONCLUSIONS: In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity. Pioglitazone 31-43 insulin Homo sapiens 175-182 19405411-10 2009 Rosiglitazone and pioglitazone are also effective for ameliorating hirsutism and insulin resistance. Pioglitazone 18-30 insulin Homo sapiens 81-88 19169664-8 2009 Following pioglitazone, insulin-stimulated glucose disposal increased by 30% (p < 0.01), and muscle AMPK and acetyl-CoA carboxylase (ACC) phosphorylation increased by 38% and 53%, respectively (p < 0.05). Pioglitazone 10-22 insulin Homo sapiens 24-31 19249234-6 2009 Pioglitazone was added to her treatment, and follow-up showed improvement of metabolic control 7 months after introducing pioglitazone, and improvement of insulin sensitivity 2 years later. Pioglitazone 0-12 insulin Homo sapiens 155-162 19267711-12 2009 Pioglitazone reduced insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR)) more than metformin. Pioglitazone 0-12 insulin Homo sapiens 73-80 19249234-8 2009 Nevertheless, therapy with pioglitazone resulted in marked and sustained improvements in metabolic control and insulin sensitivity. Pioglitazone 27-39 insulin Homo sapiens 111-118 19449763-2 2009 At the beginning of the therapy, metformin is used; later, insulin sensitizers (PPAR-gamma stimulators) such as rosiglitazone and pioglitazone are often applied. Pioglitazone 130-142 insulin Homo sapiens 59-66 19298459-2 2009 OBJECTIVES: To examine the effect of pioglitazone addition to existing therapy on FFA dynamics and insulin action. Pioglitazone 37-49 insulin Homo sapiens 99-106 19298459-8 2009 RESULTS: At Week 104, pioglitazone treatment decreased fasting FFAs by 0.08 mmol L(-1) when added to sulfonylurea and by 0.11 mmol L(-1) when added to metformin versus the respective sulfonylurea + metformin groups (0.03 mmol L(-1), P=0.05 and 0.04 mmol L(-1), P<0.05), and this was accompanied by significant improvements in fasting adipose tissue insulin sensitivity. Pioglitazone 22-34 insulin Homo sapiens 352-359 19298459-11 2009 Insulin sensitivity of FFA rose when pioglitazone was added to sulfonylurea (P<0.05), but decreased for gliclazide + metformin (P<0.05). Pioglitazone 37-49 insulin Homo sapiens 0-7 19283231-4 2009 DISCUSSION: Pioglitazone and rosiglitazone can be employed as oral therapy in patients with type 2 diabetes and preserved endogenous insulin secretion. Pioglitazone 12-24 insulin Homo sapiens 133-140 19224430-2 2009 With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. Pioglitazone 70-73 insulin Homo sapiens 102-109 19217454-0 2009 Relationship between changes in insulin sensitivity and associated cardiovascular disease risk factors in thiazolidinedione-treated, insulin-resistant, nondiabetic individuals: pioglitazone versus rosiglitazone. Pioglitazone 177-189 insulin Homo sapiens 32-39 18984667-2 2009 OBJECTIVE: The aim of the study was to evaluate effects of pioglitazone on whole body insulin action and ovarian androgen biosynthesis in PCOS. Pioglitazone 59-71 insulin Homo sapiens 86-93 18984667-9 2009 RESULTS: Compared with placebo, pioglitazone treatment significantly improved multiple measures of insulin action, including glucose disposal rate (P < 0.01), 2-h glucose during 75-g oral glucose tolerance test (P < 0.01), area under the curve glucose during oral glucose tolerance test (P < 0.01), serum adiponectin (P < 0.01), and fasting hyperinsulinemia (P < 0.01). Pioglitazone 32-44 insulin Homo sapiens 99-106 18984667-12 2009 CONCLUSIONS: Compared to placebo, pioglitazone treatment in PCOS was associated with improvements in insulin action and glucose homeostasis and ameliorated the hyperandrogenic ovarian response. Pioglitazone 34-46 insulin Homo sapiens 101-108 19224430-2 2009 With this study, we wanted to investigate the effect of pioglitazone (PIO) and simvastatin (SIMVA) on insulin resistance and RBP4 plasma concentrations in nondiabetic patients with metabolic syndrome and increased risk for cardiovascular complications. Pioglitazone 56-68 insulin Homo sapiens 102-109 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Pioglitazone 23-26 insulin Homo sapiens 74-81 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Pioglitazone 23-26 insulin Homo sapiens 121-128 19217454-7 2009 In conclusion, RSG and PIO appear to have comparable abilities to improve insulin sensitivity and lower daylong glucose, insulin, and FFA concentrations in nondiabetic, insulin-resistant individuals. Pioglitazone 23-26 insulin Homo sapiens 121-128 18547343-0 2009 Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Pioglitazone 34-46 insulin Homo sapiens 65-72 18547343-3 2009 OBJECTIVE: To compare the change in IR and its variability before and after treatment with insulin sensitization through metformin and pioglitazone, compared to that induced by weight loss with orlistat. Pioglitazone 135-147 insulin Homo sapiens 91-98 21299185-1 2009 BACKGROUND: Thiazolidinediones (rosiglitazone and pioglitazone) whether administered alone or in combination with metformin, sulfonylurea, or insulin, are often accompanied by an increase in weight and/or plasma volume. Pioglitazone 50-62 insulin Homo sapiens 142-149 19159848-8 2009 The insulin and homeostasis model assessment insulin resistance at follow-up were significantly lower in the pioglitazone group than in the SES group. Pioglitazone 109-121 insulin Homo sapiens 4-11 19159848-8 2009 The insulin and homeostasis model assessment insulin resistance at follow-up were significantly lower in the pioglitazone group than in the SES group. Pioglitazone 109-121 insulin Homo sapiens 45-52 19525594-2 2009 We report a slowly progressive type 1 diabetic patient whose insulin production was preserved for 4 years (SigmaC-peptide from 29.48 ng/mL to 24.58 ng/mL) using pioglitazone despite a high titer of anti-GAD antibody (GADA; 120.7 U/mL). Pioglitazone 161-173 insulin Homo sapiens 61-68 19738363-0 2009 A pilot study suggests that the G/G genotype of resistin single nucleotide polymorphism at -420 may be an independent predictor of a reduction in fasting plasma glucose and insulin resistance by pioglitazone in type 2 diabetes. Pioglitazone 195-207 insulin Homo sapiens 173-180 19338380-1 2009 BACKGROUND: Pioglitazone is an antidiabetic drug that belongs to the thiazolidinedione (TZD) class of insulin-sensitizing agents. Pioglitazone 12-24 insulin Homo sapiens 102-109 18476983-0 2008 Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Pioglitazone 18-30 insulin Homo sapiens 49-56 18549351-10 2008 Enhanced PC1 levels, leading to improved processing of proinsulin and proglucagon, may contribute to the benefits of pioglitazone therapy. Pioglitazone 117-129 insulin Homo sapiens 55-65 18476983-8 2008 CONCLUSIONS: Rosiglitazone and pioglitazone have similar beneficial effects on glycaemic control insulin sensitivity, insulin secretion and plasma adipocytokine levels. Pioglitazone 31-43 insulin Homo sapiens 97-104 19091199-10 2008 CONCLUSIONS: Treatment with pioglitazone was associated with significant improvements of lipid and glycemic parameters that are linked to insulin resistance and cardiovascular risk in patients with T2DM in their routine clinical care. Pioglitazone 28-40 insulin Homo sapiens 138-145 18926586-10 2008 CONCLUSIONS: The results demonstrate characteristic differences in the effects of insulin glargine vs. pioglitazone on measures of beta-cell function and insulin sensitivity as well as cardiac load. Pioglitazone 103-115 insulin Homo sapiens 154-161 20165603-0 2008 Correlation between changes in blood pressure with insulin resistance in type 2 diabetes mellitus with four weeks of pioglitazone therapy. Pioglitazone 117-129 insulin Homo sapiens 51-58 18769904-0 2008 Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes. Pioglitazone 11-23 insulin Homo sapiens 54-61 18769904-1 2008 AIMS/HYPOTHESIS: We sought to determine whether pioglitazone and metformin alter NEFA-induced insulin resistance in type 2 diabetes and, if so, the mechanism whereby this is effected. Pioglitazone 48-60 insulin Homo sapiens 94-101 18769904-8 2008 CONCLUSIONS/INTERPRETATION: We conclude that pioglitazone improves both the hepatic and the extrahepatic action of insulin but does not prevent NEFA-induced insulin resistance. Pioglitazone 45-57 insulin Homo sapiens 115-122 17825080-6 2008 The pharmacological tools available to improve insulin sensitivity include the biguanides (metformin) and thiazolidinediones (rosiglitazone and pioglitazone). Pioglitazone 144-156 insulin Homo sapiens 47-54 18331610-8 2008 Basal glucose oxidation rate (P = 0.004) and insulin sensitivity (P = 0.03) improved in the patients who received pioglitazone treatment. Pioglitazone 114-126 insulin Homo sapiens 45-52 18331610-9 2008 The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Pioglitazone 57-69 insulin Homo sapiens 14-21 18331610-9 2008 The change in insulin-stimulated adiponectin level after pioglitazone treatment was positively correlated to the change in insulin-stimulated total glucose disposal (R = 0.69, P = 0.04). Pioglitazone 57-69 insulin Homo sapiens 123-130 18793563-0 2008 Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. Pioglitazone 41-53 insulin Homo sapiens 76-83 18700562-2 2008 Pioglitazone is one of thiazolidinediones that acts as insulin sensitizer. Pioglitazone 0-12 insulin Homo sapiens 55-62 18544618-0 2008 Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Pioglitazone 145-157 insulin Homo sapiens 9-16 18544618-9 2008 Pioglitazone treatment improved insulin-stimulated glucose metabolism and GS activity in PCOS (all P < 0.05) and restored the ability of insulin to dephosphorylate GS at sites 2 and 2a. Pioglitazone 0-12 insulin Homo sapiens 32-39 18544618-11 2008 The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites. Pioglitazone 15-27 insulin Homo sapiens 39-46 18544618-11 2008 The ability of pioglitazone to enhance insulin sensitivity, in part, involves improved insulin action on GS activity and dephosphorylation at NH2-terminal sites. Pioglitazone 15-27 insulin Homo sapiens 87-94 18544642-6 2008 Pioglitazone significantly improved insulin sensitivity in human volunteers (P = 0.002) but did not alter markers of endoplasmic reticulum stress. Pioglitazone 0-12 insulin Homo sapiens 36-43 18544642-10 2008 Together, our data suggest that improved insulin sensitivity with pioglitazone is not mediated by a reduction in endoplasmic reticulum stress. Pioglitazone 66-78 insulin Homo sapiens 41-48 18640389-0 2008 Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Pioglitazone 0-12 insulin Homo sapiens 77-84 18728124-10 2008 Treatment with pioglitazone resulted in progressive amelioration of insulin resistance, hyperinsulinaemia and hyperandrogenaemia. Pioglitazone 15-27 insulin Homo sapiens 68-75 18702951-13 2008 We hypothesize that pioglitazone could partially ameliorate insulin resistance via modulating fetuin-A levels. Pioglitazone 20-32 insulin Homo sapiens 60-67 24692813-3 2008 Biguanides, such as metformin, and thiazolidinediones (TZDs), such as pioglitazone, improve insulin resistance. Pioglitazone 70-82 insulin Homo sapiens 92-99 18346811-15 2008 Pioglitazone might have the potential to reduce the number of type 2 diabetics on HD who ultimately require insulin injection therapy. Pioglitazone 0-12 insulin Homo sapiens 108-115 18753719-3 2008 Nilvadipine (a Ca-channel blocker), telmisartan (an angiotension II receptor blocker), and pioglitazone (an insulin sensitizer) were administered for the control of the hypertension and diabetes. Pioglitazone 91-103 insulin Homo sapiens 108-115 18560589-6 2008 Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0.05). Pioglitazone 15-27 insulin Homo sapiens 37-44 18560589-6 2008 Treatment with pioglitazone improved insulin-stimulated glucose metabolism and plasma adiponectin, and reduced fasting serum insulin (all P<0.05). Pioglitazone 15-27 insulin Homo sapiens 125-132 18560589-10 2008 These data indicate that pioglitazone therapy restores insulin sensitivity, in part, by a coordinated upregulation of genes involved in mitochondrial OXPHOS and ribosomal protein biosynthesis in muscle in PCOS. Pioglitazone 25-37 insulin Homo sapiens 55-62 18413496-4 2008 Pioglitazone treatment led to improvement in levels of multiple cardiovascular risk markers, including high-sensitivity C-reactive protein, apolipoprotein B, apolipoprotein A1, high-density lipoprotein (HDL) cholesterol, triglyceride, insulin, and free fatty acid. Pioglitazone 0-12 insulin Homo sapiens 235-242 18514142-7 2008 The addition of pioglitazone (TZD group) markedly decreased homeostasis model assessment of insulin resistance (HOMA-IR) (P = 0.021) compared with the SU group (P = 0.688). Pioglitazone 16-28 insulin Homo sapiens 92-99 17980009-10 2008 RESULTS: Pioglitazone treatment resulted in a significant reduction in fasting levels of PI and SPI compared to those of the controls. Pioglitazone 9-21 insulin Homo sapiens 89-91 17980009-11 2008 Postprandially, pioglitazone treatment had no effect on the insulin AUC response to the meal but significantly reduced the PI and SPI AUCs. Pioglitazone 16-28 insulin Homo sapiens 123-125 17980009-13 2008 CONCLUSIONS: Sensitization to insulin with pioglitazone reduces the amount of insulin precursor species present in fasting and postprandially and may reduce cardiovascular risk. Pioglitazone 43-55 insulin Homo sapiens 30-37 17980009-13 2008 CONCLUSIONS: Sensitization to insulin with pioglitazone reduces the amount of insulin precursor species present in fasting and postprandially and may reduce cardiovascular risk. Pioglitazone 43-55 insulin Homo sapiens 78-85 18346728-1 2008 The use of the thiazolidinedione insulin sensitizers rosiglitazone and pioglitazone for the treatment of type 2 diabetes mellitus in recent years has proven to be effective in helping patients resume normal glycemic control. Pioglitazone 71-83 insulin Homo sapiens 33-40 18324929-0 2008 High circulating levels of RBP4 and mRNA levels of aP2, PGC-1alpha and UCP-2 predict improvement in insulin sensitivity following pioglitazone treatment of drug-naive type 2 diabetic subjects. Pioglitazone 130-142 insulin Homo sapiens 100-107 18333889-6 2008 In addition, 24-h insulin profile was significantly elevated only in the liraglutide + pioglitazone group. Pioglitazone 87-99 insulin Homo sapiens 18-25 18333889-10 2008 CONCLUSIONS: Combination therapy with insulinotropic GLP-1 agonist liraglutide and insulin sensitizer, pioglitazone, improves glycaemic control above and beyond what would be expected from additive effects of the two antidiabetic agents. Pioglitazone 103-115 insulin Homo sapiens 38-45 18378631-12 2008 Median fasting insulin levels decreased with pioglitazone and increased with glimepiride (P < .001). Pioglitazone 45-57 insulin Homo sapiens 15-22 18324929-8 2008 RESULTS: Pioglitazone improved insulin sensitivity after 4 weeks combined with lower glucose and insulin levels without any change in BMI. Pioglitazone 9-21 insulin Homo sapiens 31-38 19885350-1 2008 AIM: Pioglitazone is an established peroxisome proliferator-activated receptor gamma agonist for the treatment of insulin resistance in patients with type 2 diabetes mellitus. Pioglitazone 5-17 insulin Homo sapiens 114-121 18160120-13 2008 These data suggest that pioglitazone reduces peripheral insulin resistance via mechanisms different from those of metformin. Pioglitazone 24-36 insulin Homo sapiens 56-63 17977950-0 2008 Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Pioglitazone 135-147 insulin Homo sapiens 9-16 17803698-2 2008 In the present study we evaluated total and HMW adiponectin in polycystic ovary syndrome (PCOS) patients and controls and examined possible mechanisms for increased insulin sensitivity during pioglitazone treatment. Pioglitazone 192-204 insulin Homo sapiens 165-172 17803698-10 2008 CONCLUSION: A close correlation between increased total adiponectin levels and increased insulin-stimulated glucose metabolism during pioglitzone treatment supports the hypothesis that the insulin-sensitizing effect of pioglitazone in PCOS is, at least in part, mediated by adiponectin. Pioglitazone 219-231 insulin Homo sapiens 89-96 17803698-10 2008 CONCLUSION: A close correlation between increased total adiponectin levels and increased insulin-stimulated glucose metabolism during pioglitzone treatment supports the hypothesis that the insulin-sensitizing effect of pioglitazone in PCOS is, at least in part, mediated by adiponectin. Pioglitazone 219-231 insulin Homo sapiens 189-196 18000176-0 2008 Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Pioglitazone 147-159 insulin Homo sapiens 33-40 21221185-3 2008 Metformin and the thiazolidinediones, pioglitazone and rosiglitazone, are insulin-sensitizing agents available for treatment of type 2 diabetes. Pioglitazone 38-50 insulin Homo sapiens 74-81 21221185-5 2008 The fixed-dose combination of metformin and pioglitazone appears to be a good option for treating diabetes in insulin-resistant patients. Pioglitazone 44-56 insulin Homo sapiens 110-117 18000176-9 2008 Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3.21 relative units [0.76-13.6] vs. 2.33 relative units [0.84-6.46]) and hsCRP decreased (P < 0.05). Pioglitazone 10-22 insulin Homo sapiens 34-41 18000176-12 2008 Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS. Pioglitazone 0-12 insulin Homo sapiens 53-60 18000176-12 2008 Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS. Pioglitazone 0-12 insulin Homo sapiens 145-152 17977950-3 2008 RESEARCH DESIGN AND METHODS: We determined molecular mediators of insulin signaling to glucose transport in skeletal muscle biopsies of 24 PCOS patients and 14 matched control subjects metabolically characterized by euglycemic-hyperinsulinemic clamps and indirect calorimetry, and we examined the effect of 16 weeks of treatment with pioglitazone in PCOS patients. Pioglitazone 334-346 insulin Homo sapiens 66-73 17977950-7 2008 Importantly, the pioglitazone-mediated improvement in insulin-stimulated glucose metabolism, which did not fully reach normal levels, was accompanied by normalization of insulin-mediated Akt phosphorylation at Ser473 and Thr308 and AS160 phosphorylation. Pioglitazone 17-29 insulin Homo sapiens 54-61 17977950-7 2008 Importantly, the pioglitazone-mediated improvement in insulin-stimulated glucose metabolism, which did not fully reach normal levels, was accompanied by normalization of insulin-mediated Akt phosphorylation at Ser473 and Thr308 and AS160 phosphorylation. Pioglitazone 17-29 insulin Homo sapiens 170-177 18220486-6 2008 Rosiglitazone and pioglitazone resulted in a similar improvement in HbA1c and insulin sensitivity. Pioglitazone 18-30 insulin Homo sapiens 78-85 17909084-0 2008 Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. Pioglitazone 12-24 insulin Homo sapiens 51-58 19075761-5 2008 With the clinical success of the PPARgamma agonists, pioglitazone (Actos) and rosiglitazone (Avandia), development of novel and potent insulin-sensitizing agents with diverse clinical profiles has been accelerated. Pioglitazone 53-65 insulin Homo sapiens 135-142 18270461-6 2008 RESULTS: Treatment with pioglitazone significantly decreased the levels of HbA1c, FPG, the homeostasis model assessment of insulin resistance (HOMA-IR) index, RLP-C, PAI-1, TNF- alpha , and hs-CRP, but not the level, IRI, lipids, or leptin. Pioglitazone 24-36 insulin Homo sapiens 123-130 17999918-5 2008 In line with this, pioglitazone inhibited Erk1/2-phosphorylation and subsequent insulin-dependent MMP-9 synthesis in THP-1 cells. Pioglitazone 19-31 insulin Homo sapiens 80-87 17909084-9 2008 CONCLUSIONS: Addition of pioglitazone or ramipril to intensive insulin therapy in type 2 diabetes further improves vascular dysfunction. Pioglitazone 25-37 insulin Homo sapiens 63-70 17145061-6 2007 Insulin sensitivity improved with pioglitazone treatment (p=0.001) and, in keeping with this, adiponectin increased by 85.2% (p<0.001). Pioglitazone 34-46 insulin Homo sapiens 0-7 18184212-0 2008 Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone. Pioglitazone 97-109 insulin Homo sapiens 22-29 18021872-7 2007 Furthermore, in the pioglitazone group HDL cholesterol (+28%; p = 0.003) and adiponectin (+156.2%; p = 0.0001) were increased and plasma insulin (-35%; p = 0.017) was reduced. Pioglitazone 20-32 insulin Homo sapiens 137-144 17914032-5 2008 In contrast, pioglitazone enhanced (P < 0.01) insulin-induced suppression of both glucose production (6.0 +/- 1.0 vs. 0.2 +/- 1.6 micromol x kg(-1) x min(-1)) and gluconeogenesis (n = 11; 4.5 +/- 0.9 vs. 0.8 +/- 1.2 micromol x kg(-1) x min(-1)). Pioglitazone 13-25 insulin Homo sapiens 49-56 17914032-7 2008 Insulin-induced suppression of free fatty acids was greater (P < 0.05) after treatment with pioglitazone (0.14 +/- 0.03 vs. 0.06 +/- 0.01 mmol/l) but unchanged with metformin (0.12 +/- 0.03 vs. 0.15 +/- 0.07 mmol/l). Pioglitazone 95-107 insulin Homo sapiens 0-7 17914032-8 2008 CONCLUSIONS: Thus, relative to metformin, pioglitazone improves hepatic insulin action in people with type 2 diabetes, partly by enhancing insulin-induced suppression of gluconeogenesis. Pioglitazone 42-54 insulin Homo sapiens 72-79 18759508-1 2008 BACKGROUND: Pioglitazone is an antidiabetic drug that targets insulin resistance in patients with type 2 diabetes mellitus by stimulating the peroxisome proliferator-activated receptor (PPAR)-gamma. Pioglitazone 12-24 insulin Homo sapiens 62-69 19902036-0 2008 Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. Pioglitazone 114-126 insulin Homo sapiens 51-58 17211855-14 2007 The additional beneficial effect of PGZ on lipid metabolism may be related to its effects on insulin-independent VLDL production and CETP activity. Pioglitazone 36-39 insulin Homo sapiens 93-100 17696960-10 2007 CONCLUSIONS: The present study demonstrated that pioglitazone can restore the nocturnal BP declines in parallel to reductions in the HOMA index, suggesting that insulin resistance may play an important role in the genesis of circadian BP rhythms. Pioglitazone 49-61 insulin Homo sapiens 161-168 17618953-7 2007 The pioglitazone treatment significantly increased high-density lipoprotein cholesterol and decreased triglyceride levels and insulin resistance. Pioglitazone 4-16 insulin Homo sapiens 126-133 17823625-8 2007 The patients with hyperinsulinemia receiving only pioglitazone showed a significant decrease in insulin levels compared with those with normal insulin levels. Pioglitazone 50-62 insulin Homo sapiens 23-30 17587394-4 2007 RESULTS: Pioglitazone significantly reduced (p < 0.05) insulin dose requirements 2 weeks after treatment initiation. Pioglitazone 9-21 insulin Homo sapiens 58-65 17587394-5 2007 At study end relative to baseline, pioglitazone reduced daily insulin dosages by 12.0 units (p < 0.001), a 21.5% (12.0/55.8 units at baseline) group mean average reduction. Pioglitazone 35-47 insulin Homo sapiens 62-69 17587394-6 2007 Relative to placebo, pioglitazone reduced daily insulin dosages by 12.7 units [95% confidence interval [CI]: -17.5, -8.0], while improving mean HbA(1c) levels [adjusted mean HbA(1c) change: pioglitazone, -1.6% vs. placebo, -1.4% (not statistically different)]. Pioglitazone 21-33 insulin Homo sapiens 48-55 17587394-9 2007 CONCLUSIONS: Pioglitazone in combination with insulin therapy improved glycaemic control, reduced insulin dose requirements and improved lipid profiles in patients with type 2 diabetes previously poorly controlled with combination therapy. Pioglitazone 13-25 insulin Homo sapiens 98-105 17587394-0 2007 Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. Pioglitazone 10-22 insulin Homo sapiens 81-88 17587394-1 2007 AIM: The aim of this randomized placebo-controlled study was to evaluate the safety and efficacy of pioglitazone administered alone or in combination with metformin in reducing insulin dosage requirements for improved glycaemic control in patients with type 2 diabetes previously poorly controlled with combination therapy. Pioglitazone 100-112 insulin Homo sapiens 177-184 17511791-4 2007 In a large randomised, controlled, long-term cardiovascular outcomes study pioglitazone showed durable glycaemic control, a powerful insulin-sparing effect and changes in the lipid profile associated with reduced cardiovascular risk. Pioglitazone 75-87 insulin Homo sapiens 133-140 17823625-8 2007 The patients with hyperinsulinemia receiving only pioglitazone showed a significant decrease in insulin levels compared with those with normal insulin levels. Pioglitazone 50-62 insulin Homo sapiens 96-103 30743802-2 2007 While glimepiride stimulates beta-cell secretion and leads to a reduction of blood glucose levels, pioglitazone activates peroxisome proliferator-activated receptor-gamma and improves insulin resistance. Pioglitazone 99-111 insulin Homo sapiens 184-191 17594391-5 2007 Pioglitazone is a potent and selective peroxisome proliferator-activated receptor-gamma agonist that improves whole-body insulin sensitivity and augments hepatic glucose uptake. Pioglitazone 0-12 insulin Homo sapiens 121-128 17213476-6 2007 This duration of pioglitazone improved insulin"s suppression of glucose production by 41% and enhanced stimulation of glucose uptake by 27% in concert with increased gene expression and plasma levels of adiponectin. Pioglitazone 17-29 insulin Homo sapiens 39-46 17452150-2 2007 Pioglitazone, a novel insulin-sensitizing thiazolidinedione, has been shown to reduce neointimal hyperplasia after coronary stenting in patients with type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 22-29 17452150-6 2007 Pioglitazone treatment improved insulin resistance and decreased visceral fat accumulation without significant changes in plasma glucose levels, glycosylated hemoglobin A1c levels, and lipid profiles. Pioglitazone 0-12 insulin Homo sapiens 32-39 18220657-1 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Pioglitazone 54-66 insulin Homo sapiens 77-84 17007957-15 2007 This result was supported by the effects of the insulin sensitizer, pioglitazone. Pioglitazone 68-80 insulin Homo sapiens 48-55 17485893-5 2007 Pioglitazone hydrochloride reduced fasting serum insulin levels, with low fasting plasma glucose (FPG) and glycohemoglobin levels, compared to the baseline, suggesting an improvement of insulin resistance. Pioglitazone 0-26 insulin Homo sapiens 49-56 17485893-5 2007 Pioglitazone hydrochloride reduced fasting serum insulin levels, with low fasting plasma glucose (FPG) and glycohemoglobin levels, compared to the baseline, suggesting an improvement of insulin resistance. Pioglitazone 0-26 insulin Homo sapiens 186-193 17485893-8 2007 Pioglitazone hydrochloride improved dyslipidemia related to insulin resistance, whereas glibenclamide enhanced insulin secretion, with only a minor effect on lipid control, in Japanese patients with type 2 diabetes. Pioglitazone 0-26 insulin Homo sapiens 60-67 17327450-0 2007 Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Pioglitazone 11-23 insulin Homo sapiens 114-121 17259945-6 2007 In mild-to-moderate T2D, pioglitazone monotherapy decreased fasting and post-prandial glycemia, principally via inhibition of gluconeogenesis, improved hepatic and peripheral insulin resistance. Pioglitazone 25-37 insulin Homo sapiens 175-182 17106061-8 2007 Pioglitazone and rosiglitazone similarly improved FPG, mean plasma glucose during OGTT, Hb A1c, and insulin-mediated total body glucose disposal (Rd) and decreased mean plasma FFA during OGTT (all P<0.01, ANOVA). Pioglitazone 0-12 insulin Homo sapiens 100-107 17327450-1 2007 Pioglitazone is widely used for the treatment of diabetic patients with insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 72-79 17327450-2 2007 The mechanism of pioglitazone to improve insulin sensitivity is not fully understood. Pioglitazone 17-29 insulin Homo sapiens 41-48 17327450-4 2007 Here, we examined whether the insulin-sensitizing effect of pioglitazone affects the SOCS induction. Pioglitazone 60-72 insulin Homo sapiens 30-37 17327450-6 2007 In 3T3-L1 adipocytes, mediators of insulin resistance such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6, growth hormone, and insulin increased SOCS3 expression, which was partially inhibited by pioglitazone. Pioglitazone 207-219 insulin Homo sapiens 35-42 17327450-6 2007 In 3T3-L1 adipocytes, mediators of insulin resistance such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6, growth hormone, and insulin increased SOCS3 expression, which was partially inhibited by pioglitazone. Pioglitazone 207-219 insulin Homo sapiens 138-145 17327450-10 2007 These results suggest that pioglitazone exerts its effect to improve whole-body insulin sensitivity in part through the suppression of SOCS3, which is associated with the increase in STAT3 phosphorylation and adiponectin production in fat tissue. Pioglitazone 27-39 insulin Homo sapiens 80-87 18220657-1 2007 The thiazolidinediones (TZDs) rosiglitazone (ROS) and pioglitazone (PIO) are insulin-sensitising agents widely used to treat patients with type 2 diabetes mellitus (T2DM). Pioglitazone 68-71 insulin Homo sapiens 77-84 16968813-6 2007 In contrast to metformin, pioglitazone improved S(I), glucose tolerance, and insulin-independent glucose disposal [glucose effectiveness (S(G))]. Pioglitazone 26-38 insulin Homo sapiens 77-84 17239709-15 2007 CONCLUSIONS: Pioglitazone, probably by reducing insulin resistance, has additive anti-inflammatory effects to simvastatin in non-diabetic subjects with CVD and high hs-CRP. Pioglitazone 13-25 insulin Homo sapiens 48-55 16968813-8 2007 Insulin secretion in response to arginine at maximally potentiating glucose levels (AIR(max)) tended to increase after metformin and to decrease after pioglitazone; however, when adjusted for S(I), the changes were not significant. Pioglitazone 151-163 insulin Homo sapiens 0-7 16781793-7 2007 CONCLUSION: Pioglitazone administration during a period of 4 weeks decreased late and total insulin secretion phases, fasting insulin and 2h postload glucose levels, and improved insulin sensitivity in patients with both impaired fasting glucose and impaired glucose tolerance. Pioglitazone 12-24 insulin Homo sapiens 92-99 16781793-7 2007 CONCLUSION: Pioglitazone administration during a period of 4 weeks decreased late and total insulin secretion phases, fasting insulin and 2h postload glucose levels, and improved insulin sensitivity in patients with both impaired fasting glucose and impaired glucose tolerance. Pioglitazone 12-24 insulin Homo sapiens 126-133 17969365-3 2007 The thiazolidinedione, pioglitazone, is known to offer multiple, potentially antiatherogenic, effects that may have a beneficial impact on macrovascular outcomes, including long-term improvements in insulin resistance (associated with an increased rate of atherosclerosis) and improvement in the atherogenic lipid triad (low HDL-cholesterol, raised triglycerides, and a preponderance of small, dense LDL particles) that is observed in patients with type 2 diabetes. Pioglitazone 23-35 insulin Homo sapiens 199-206 17460368-0 2007 Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Pioglitazone 29-41 insulin Homo sapiens 59-66 17460368-9 2007 Pioglitazone significantly reduced fasting glucose (p<0.05), and homeostasis model assessment of insulin resistance (HOMA-IR) (p<0.05) and metformin (p<0.01) reduced cholesterol. Pioglitazone 0-12 insulin Homo sapiens 100-107 17460368-13 2007 In conclusion, pioglitazone was superior to metformin for the improvement of insulin resistance and adiponectin, and both drugs were equally effective in reducing vWF and aldosterone in subjects with IGT and early diabetes. Pioglitazone 15-27 insulin Homo sapiens 77-84 17948362-6 2007 Agents such as the peroxisome proliferator-activated receptor-gamma agonist pioglitazone and the CB1 receptor antagonist rimonabant improve insulin resistance as well as atherogenic dyslipidemia. Pioglitazone 76-88 insulin Homo sapiens 140-147 17062758-3 2007 OBJECTIVE: We studied the protective effect of pioglitazone on FFA-induced insulin resistance and the effects on intramyocellular glycosphingolipids. Pioglitazone 47-59 insulin Homo sapiens 75-82 17062758-10 2007 MAIN OUTCOME MEASURE: The change in peripheral insulin sensitivity after treatment with pioglitazone and during the infusion of the lipid emulsion was the main outcome measure. Pioglitazone 88-100 insulin Homo sapiens 47-54 17062758-15 2007 CONCLUSIONS: Pioglitazone increases Rd and insulin-mediated suppression of plasma FFA, but does not protect patients with type 2 diabetes mellitus from FFA-induced insulin resistance. Pioglitazone 13-25 insulin Homo sapiens 43-50 18078023-4 2007 Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. Pioglitazone 0-16 insulin Homo sapiens 23-30 18200815-3 2007 Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. Pioglitazone 114-126 insulin Homo sapiens 284-291 16764964-16 2006 CONCLUSIONS: Short-term pioglitazone therapy improved beta-cell dysfunction, the mechanism might involve the attenuation of insulin resistance. Pioglitazone 24-36 insulin Homo sapiens 124-131 17121522-9 2006 PGZ therapy improved insulin sensitivity to a greater degree (P = 0.007 and P = 0.001 for fasting plasma insulin (FPI) and HOMA-IR, respectively) than MET (P = 0.75 and P = 0.02 for FPI and HOMA-IR, respectively) but this improvement was not significantly different from that of MET at the end of 12 weeks (P = 0.146 and P = 0.09 for FPI and HOMA-IR, respectively). Pioglitazone 0-3 insulin Homo sapiens 21-28 17121522-9 2006 PGZ therapy improved insulin sensitivity to a greater degree (P = 0.007 and P = 0.001 for fasting plasma insulin (FPI) and HOMA-IR, respectively) than MET (P = 0.75 and P = 0.02 for FPI and HOMA-IR, respectively) but this improvement was not significantly different from that of MET at the end of 12 weeks (P = 0.146 and P = 0.09 for FPI and HOMA-IR, respectively). Pioglitazone 0-3 insulin Homo sapiens 105-112 17121522-10 2006 However, improvement in insulin sensitivity with PGZ was not commensurate with the increase in adiponectin. Pioglitazone 49-52 insulin Homo sapiens 24-31 17121522-14 2006 CONCLUSIONS: Pioglitazone therapy appears to be better in achieving glycaemic control and increasing plasma adiponectin and insulin sensitivity in newly detected type 2 diabetics. Pioglitazone 13-25 insulin Homo sapiens 124-131 17084385-4 2006 In islets from non-diabetic subjects, both high glucose and tolbutamide-stimulated insulin secretion was inhibited by pioglitazone. Pioglitazone 118-130 insulin Homo sapiens 83-90 17084385-5 2006 When islets were continuously perifused with 5 mM glucose, short-term pretreatment with pioglitazone caused approximately 2-fold increase in insulin secretion after drug withdrawal. Pioglitazone 88-100 insulin Homo sapiens 141-148 17174194-11 2006 Consistently, improvement of insulin sensitivity achieved with pioglitazone significantly decreased urinary 11-dehydro-TXB2 excretion (-43%, p < 0.05) without changes in body weight. Pioglitazone 63-75 insulin Homo sapiens 29-36 17045610-0 2006 Pioglitazone increases gallbladder volume in insulin-resistant obese mice. Pioglitazone 0-12 insulin Homo sapiens 45-52 17137905-1 2006 OBJECTIVE: To determine whether the addition of the thiazoladinedione, pioglitazone, to standard therapy improves metabolic control in adolescents with type 1 diabetes (T1D) and clinical evidence of insulin resistance. Pioglitazone 71-83 insulin Homo sapiens 199-206 17137905-2 2006 STUDY DESIGN: Randomized, placebo-controlled 6-month 2-site trial of pioglitazone therapy in 35 adolescents with T1D, high insulin requirements (>0.9 U/kg/d), and suboptimal metabolic control (A1c 7.5%-11%), with the primary outcome of change in A1c. Pioglitazone 69-81 insulin Homo sapiens 123-130 17045610-12 2006 CONCLUSION: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Pioglitazone 68-80 insulin Homo sapiens 39-46 17045610-3 2006 Pioglitazone is a thiazolidinedione that has been shown to improve insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 67-74 17045610-12 2006 CONCLUSION: These data suggest that in insulin-resistant obese mice pioglitazone 1) lowers insulin-resistance, 2) increases resting gallbladder volume, and 3) does not alter gallbladder response to neurotransmitters. Pioglitazone 68-80 insulin Homo sapiens 91-98 17045610-13 2006 Therefore, we conclude that pioglitazone, while improving insulin resistance, paradoxically increases gallbladder volume and, thereby, may increase the propensity for gallstone formation by enhancing gallbladder stasis. Pioglitazone 28-40 insulin Homo sapiens 58-65 17045610-4 2006 Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25% carbohydrate diet. Pioglitazone 41-53 insulin Homo sapiens 68-75 17045610-4 2006 Therefore, we tested the hypothesis that pioglitazone would improve insulin resistance, decrease resting gallbladder volume and improve gallbladder response to neurotransmitters in insulin-resistant obese mice fed a 25% carbohydrate diet. Pioglitazone 41-53 insulin Homo sapiens 181-188 17135584-2 2006 Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. Pioglitazone 0-12 insulin Homo sapiens 53-60 18370736-9 2006 In insulin-treated patients with type 2 diabetes, the addition of pioglitazone improves endothelial function, as measured by FMD. Pioglitazone 66-78 insulin Homo sapiens 3-10 17145645-5 2006 The insulin-sensitizing agents available commercially include metformin, rosiglitazone and pioglitazone. Pioglitazone 91-103 insulin Homo sapiens 4-11 17003347-7 2006 After treatment of the impaired glucose-tolerant subjects with insulin sensitizers for 10 weeks, pioglitazone (but not metformin) resulted in a 60% increase in the insulin sensitivity index (Si) and a 32% decrease in IMCLs (both P < 0.01), along with an increase in lipin-beta (but not lipin-alpha) expression by 200% (P < 0.005). Pioglitazone 97-109 insulin Homo sapiens 63-70 17003347-7 2006 After treatment of the impaired glucose-tolerant subjects with insulin sensitizers for 10 weeks, pioglitazone (but not metformin) resulted in a 60% increase in the insulin sensitivity index (Si) and a 32% decrease in IMCLs (both P < 0.01), along with an increase in lipin-beta (but not lipin-alpha) expression by 200% (P < 0.005). Pioglitazone 97-109 insulin Homo sapiens 164-171 18370736-0 2006 Pioglitazone restores endothelial function in patients with type 2 diabetes treated with insulin. Pioglitazone 0-12 insulin Homo sapiens 89-96 17087306-4 2006 The agents that improve insulin resistance, such as metformin and pioglitazone, have multiple effects to improve glucose and lipid metabolism by increasing sensitivity for insulin without increasing insulin secretion and exert anti-atherogenic properties resulting in preventing development of atherosclerosis. Pioglitazone 66-78 insulin Homo sapiens 24-31 17087306-4 2006 The agents that improve insulin resistance, such as metformin and pioglitazone, have multiple effects to improve glucose and lipid metabolism by increasing sensitivity for insulin without increasing insulin secretion and exert anti-atherogenic properties resulting in preventing development of atherosclerosis. Pioglitazone 66-78 insulin Homo sapiens 172-179 16830140-4 2006 Results are relevant to diabetes because millions of diabetic patients take pioglitazone as an insulin-sensitising drug, and diabetes increases the risk of developing Alzheimer"s disease. Pioglitazone 76-88 insulin Homo sapiens 95-102 16804048-4 2006 RESULTS: Diet/exercise reduced body fat and visceral fat and improved insulin sensitivity parameters; pioglitazone improved insulin sensitivity to a similar degree but increased body fat. Pioglitazone 102-114 insulin Homo sapiens 124-131 16681563-6 2006 Insulin-mediated vasodilation improved after pioglitazone in Asian Indians, but not in Caucasians, and correlated with the change in insulin sensitivity (r = 0.52, P = 0.03). Pioglitazone 45-57 insulin Homo sapiens 0-7 17009067-7 2006 In the group receiving pioglitazone, the mean HbA1c three months after the insulin infusion was 16% lower and after six months 17% lower than baseline values (p < 0.02). Pioglitazone 23-35 insulin Homo sapiens 75-82 16782094-1 2006 OBJECTIVE: To thoroughly examine the mechanisms for insulin resistance in polycystic ovary syndrome (PCOS) and to evaluate the effects of pioglitazone treatment on insulin resistance, beta-cell function, LH secretion, and glucose metabolism. Pioglitazone 138-150 insulin Homo sapiens 164-171 16782094-8 2006 Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. Pioglitazone 0-12 insulin Homo sapiens 73-80 16782094-8 2006 Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. Pioglitazone 0-12 insulin Homo sapiens 106-113 16782094-8 2006 Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. Pioglitazone 0-12 insulin Homo sapiens 106-113 16782094-8 2006 Pioglitazone treatment resulted in significantly lower levels of fasting insulin and significantly higher insulin sensitivity, increased insulin-stimulated glucose oxidation, and increased insulin-stimulated inhibition of lipid oxidation. Pioglitazone 0-12 insulin Homo sapiens 106-113 16782094-11 2006 CONCLUSION(S): Insulin resistance in PCOS was characterized by hyperinsulinemia, impaired insulin-stimulated oxidative and nonoxidative glucose metabolism, which was partly reversed by pioglitazone treatment. Pioglitazone 185-197 insulin Homo sapiens 15-22 16782094-11 2006 CONCLUSION(S): Insulin resistance in PCOS was characterized by hyperinsulinemia, impaired insulin-stimulated oxidative and nonoxidative glucose metabolism, which was partly reversed by pioglitazone treatment. Pioglitazone 185-197 insulin Homo sapiens 68-75 16768125-0 2006 [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. Pioglitazone 56-68 insulin Homo sapiens 1-8 16768125-0 2006 [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. Pioglitazone 56-68 insulin Homo sapiens 86-93 16768125-5 2006 The insulin-sensitizing drugs, which were biguanides (metformin) and thiazolidinediones (pioglitazone) have been shown to correct not only insulin resistance but also steatosis and inflammation in the liver. Pioglitazone 89-101 insulin Homo sapiens 4-11 16768125-5 2006 The insulin-sensitizing drugs, which were biguanides (metformin) and thiazolidinediones (pioglitazone) have been shown to correct not only insulin resistance but also steatosis and inflammation in the liver. Pioglitazone 89-101 insulin Homo sapiens 139-146 16508777-0 2006 The insulin sensitiser pioglitazone does not influence skin microcirculatory function in patients with type 2 diabetes treated with insulin. Pioglitazone 23-35 insulin Homo sapiens 4-11 16508777-11 2006 CONCLUSIONS/INTERPRETATION: Pioglitazone improved glycaemic control and inflammatory markers over 9 weeks but had no effect on microcirculatory variables associated with oedema or insulin resistance in type 2 diabetic patients treated with insulin. Pioglitazone 28-40 insulin Homo sapiens 240-247 16822823-1 2006 CONTEXT: Activation of peroxisome proliferator-activated receptors (PPARs)-gamma by thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPARalpha/gamma agonists (pargluva, ragaglitazar) is a widely used pharmacological principle to treat insulin resistance and type 2 diabetes. Pioglitazone 104-116 insulin Homo sapiens 251-258 16682454-1 2006 Adipogenesis is an important process for the improvement of insulin resistance by peroxisome proliferator-activated receptor (PPAR) gamma agonists, such as rosiglitazone and pioglitazone. Pioglitazone 174-186 insulin Homo sapiens 60-67 16682454-7 2006 Furthermore, the long-term treatment of mature adipocytes with rosiglitazone and pioglitazone reduced the expression of phosphodiesterase 3B, the down-regulation of which has an important role in the development of insulin resistance; however, FK614 had no such effect in mature adipocytes. Pioglitazone 81-93 insulin Homo sapiens 215-222 16839832-7 2006 In conclusion, the present study is the first to demonstrate that increase in adiponectin level after treatment with the insulin sensitizers pioglitazone and metformin may improve arterial stiffness in patients with type 2 diabetes mellitus. Pioglitazone 141-153 insulin Homo sapiens 121-128 16681563-0 2006 Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. Pioglitazone 10-22 insulin Homo sapiens 26-33 16681563-6 2006 Insulin-mediated vasodilation improved after pioglitazone in Asian Indians, but not in Caucasians, and correlated with the change in insulin sensitivity (r = 0.52, P = 0.03). Pioglitazone 45-57 insulin Homo sapiens 133-140 16442489-4 2006 Using this assay system, the effects of insulin, cytochalasin B (hexose uptake inhibitor), LY294002 (inhibitor of glucose transporter translocation), and pioglitazone hydrochloride (insulin-sensitizing agent) on 2DG uptake into L6 myotubes could be assessed clearly. Pioglitazone 154-180 insulin Homo sapiens 182-189 16610015-5 2006 The second generation insulin sensitizer pioglitazone and rosiglitazone show the most promising improvements in NAFLD, but weight gain and potential hepatotoxicity calls for attention. Pioglitazone 41-53 insulin Homo sapiens 22-29 16448520-11 2006 CONCLUSIONS: In patients with poorly controlled type 2 diabetes, addition of pioglitazone to insulin significantly improved glycaemic control, had a positive effect on important components of the lipid profile in a dose-dependent manner and was generally well tolerated. Pioglitazone 77-89 insulin Homo sapiens 93-100 16429317-3 2006 To this aim we studied fasting and postprandial lipaemia in type 2 diabetic patients before and after sensitisation to insulin with pioglitazone, compared with that observed in patients on an insulin-providing regime. Pioglitazone 132-144 insulin Homo sapiens 119-126 16429317-7 2006 RESULTS: Compared with glibenclamide treatment, pioglitazone treatment decreased fasting triglyceride, glucose and insulin levels and the homeostasis model assessment score of insulin resistance. Pioglitazone 48-60 insulin Homo sapiens 115-122 16429317-7 2006 RESULTS: Compared with glibenclamide treatment, pioglitazone treatment decreased fasting triglyceride, glucose and insulin levels and the homeostasis model assessment score of insulin resistance. Pioglitazone 48-60 insulin Homo sapiens 176-183 16429317-12 2006 CONCLUSIONS/INTERPRETATION: Insulin sensitisation with pioglitazone has major effects in restoring postprandial lipaemia to normal, while also correcting fasting hypertriglyceridaemia; both factors may have consequences for atherogenic risk in diabetes. Pioglitazone 55-67 insulin Homo sapiens 28-35 16492206-7 2006 Insulin levels as well as insulin resistance assessed using HOMA-S decreased significantly only after pioglitazone treatment (-11.94 pmol/l and -1.03, respectively, both P = 0.002 vs. baseline). Pioglitazone 102-114 insulin Homo sapiens 0-7 16492206-7 2006 Insulin levels as well as insulin resistance assessed using HOMA-S decreased significantly only after pioglitazone treatment (-11.94 pmol/l and -1.03, respectively, both P = 0.002 vs. baseline). Pioglitazone 102-114 insulin Homo sapiens 26-33 16503818-2 2006 In clinical trials, pioglitazone as monotherapy or in combination with other oral antidiabetic drugs or insulin has demonstrated to effectively improve blood glucose levels, long-term glucose control and the lipid profile. Pioglitazone 20-32 insulin Homo sapiens 104-111 16492206-12 2006 This favourable effect of pioglitazone was due to its insulin-sensitizing effect and ability to decrease systemic glucose production. Pioglitazone 26-38 insulin Homo sapiens 54-61 16461819-9 2006 Treatment with pioglitazone significantly lowered plasma insulin (-22.9%; P<0.001), improved QUICKI insulin sensitivity index (3.7%; P<0.001), increased HDL cholesterol (8.2%; P<0.001), and reduced triglycerides (-15.1%; P=0.003), free fatty acids (-14%; P=0.005), and C-reactive protein (-28.6%; P=0.001). Pioglitazone 15-27 insulin Homo sapiens 57-64 16461819-9 2006 Treatment with pioglitazone significantly lowered plasma insulin (-22.9%; P<0.001), improved QUICKI insulin sensitivity index (3.7%; P<0.001), increased HDL cholesterol (8.2%; P<0.001), and reduced triglycerides (-15.1%; P=0.003), free fatty acids (-14%; P=0.005), and C-reactive protein (-28.6%; P=0.001). Pioglitazone 15-27 insulin Homo sapiens 103-110 16461819-12 2006 CONCLUSIONS: In nondiabetic patients with cardiovascular risk factors, pioglitazone treatment enhances insulin sensitivity, decreases C-reactive protein, and improves endothelial vasodilator function. Pioglitazone 71-83 insulin Homo sapiens 103-110 16367880-1 2006 AIM: Pioglitazone (PIO) has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations, lowered plasma insulin levels and lowered haemoglobin A1C (A1C) values. Pioglitazone 5-17 insulin Homo sapiens 51-58 16622303-10 2006 Our study results suggest that PG suppresses increases in postprandial glucose and TG levels, and improves insulin resistance; and, in addition, that PG may have a favorable impact on oxidative stress in type 2 diabetic patients. Pioglitazone 31-33 insulin Homo sapiens 107-114 16443789-6 2006 Comparison of changes in beta-cell compensation for insulin resistance across the TRIPOD and PIPOD studies revealed that pioglitazone stopped the decline in beta-cell function that occurred during placebo treatment in the TRIPOD study and maintained the stability of beta-cell function that had occurred during troglitazone treatment in the TRIPOD study. Pioglitazone 121-133 insulin Homo sapiens 52-59 16914073-0 2006 Metformin and pioglitazone: Effectively treating insulin resistance. Pioglitazone 14-26 insulin Homo sapiens 49-56 16914073-3 2006 Two key classes of insulin-sensitizing agents--the biguanides (principally metformin) and thiazolidinediones (pioglitazone and rosiglitazone)--have distinct molecular mechanisms of action and differing effects on metabolic dysfunction. Pioglitazone 110-122 insulin Homo sapiens 19-26 16914074-5 2006 FINDINGS: Pioglitazone increases insulin sensitivity, while metformin reduces hepatic gluconeogenesis and improves peripheral glucose uptake. Pioglitazone 10-22 insulin Homo sapiens 33-40 16373904-8 2006 Insulin, homeostasis model assessment of insulin resistance, eNOS, and leptin at follow-up were significantly reduced in the pioglitazone group compared with the control group. Pioglitazone 125-137 insulin Homo sapiens 0-7 16373904-8 2006 Insulin, homeostasis model assessment of insulin resistance, eNOS, and leptin at follow-up were significantly reduced in the pioglitazone group compared with the control group. Pioglitazone 125-137 insulin Homo sapiens 41-48 16367880-1 2006 AIM: Pioglitazone (PIO) has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations, lowered plasma insulin levels and lowered haemoglobin A1C (A1C) values. Pioglitazone 5-17 insulin Homo sapiens 170-177 16367880-1 2006 AIM: Pioglitazone (PIO) has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations, lowered plasma insulin levels and lowered haemoglobin A1C (A1C) values. Pioglitazone 19-22 insulin Homo sapiens 51-58 16367880-1 2006 AIM: Pioglitazone (PIO) has been shown to decrease insulin resistance in patients with type 2 diabetes, resulting in lowered blood glucose concentrations, lowered plasma insulin levels and lowered haemoglobin A1C (A1C) values. Pioglitazone 19-22 insulin Homo sapiens 170-177 16336518-2 2006 We hypothesized that pioglitazone treatment of FCH patients might increase insulin sensitivity, but may also improve serum lipid levels, body fat distribution, intramyocellular lipids (IMCL) and endothelial function. Pioglitazone 21-33 insulin Homo sapiens 75-82 16398569-1 2006 Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone 0-12 insulin Homo sapiens 69-76 16398569-1 2006 Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone 0-12 insulin Homo sapiens 122-129 16398569-3 2006 In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles. Pioglitazone 62-74 insulin Homo sapiens 138-145 16323003-10 2006 CONCLUSIONS/INTERPRETATION: In insulin-resistant, non-diabetic adults, pioglitazone increases NEFA clearance during physiological hyperinsulinaemia, whereas improved insulin sensitivity achieved by diet/exercise does not alter NEFA clearance but enhances insulin suppression of NEFA release. Pioglitazone 71-83 insulin Homo sapiens 31-38 16323003-10 2006 CONCLUSIONS/INTERPRETATION: In insulin-resistant, non-diabetic adults, pioglitazone increases NEFA clearance during physiological hyperinsulinaemia, whereas improved insulin sensitivity achieved by diet/exercise does not alter NEFA clearance but enhances insulin suppression of NEFA release. Pioglitazone 71-83 insulin Homo sapiens 135-142 16323003-10 2006 CONCLUSIONS/INTERPRETATION: In insulin-resistant, non-diabetic adults, pioglitazone increases NEFA clearance during physiological hyperinsulinaemia, whereas improved insulin sensitivity achieved by diet/exercise does not alter NEFA clearance but enhances insulin suppression of NEFA release. Pioglitazone 71-83 insulin Homo sapiens 135-142 16336518-7 2006 RESULTS: Pioglitazone improved insulin sensitivity (M value 37.7 +/- 3.6 micromol min(-1) kg(-1) vs. 33.0 +/- 3.3 micromol min(-1) kg(-1) during placebo, P < 0.05) and LDL composition by increasing the K value (-0.11 +/- 0.06 vs. -0.20 +/- 0.06 during placebo, P < 0.05). Pioglitazone 9-21 insulin Homo sapiens 31-38 16677060-1 2006 Pioglitazone (Actos(trade mark)) is an antihyperglycemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone 0-12 insulin Homo sapiens 88-95 16677060-1 2006 Pioglitazone (Actos(trade mark)) is an antihyperglycemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone 0-12 insulin Homo sapiens 141-148 16677060-3 2006 In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin, or a sulfonylurea, induced both long- and short-term improvements in glycemic control and serum lipid profiles. Pioglitazone 62-74 insulin Homo sapiens 138-145 16219007-2 2005 Thiazolidinediones such as rosiglitazone and pioglitazone enhance insulin-mediated glucose disposal, leading to reduced plasma insulin concentrations. Pioglitazone 45-57 insulin Homo sapiens 66-73 16364837-8 2005 Six months after treatment with the insulin-sensitizing agent pioglitazone (30 mg/day), these examinations were repeated in all subjects. Pioglitazone 62-74 insulin Homo sapiens 36-43 16364837-14 2005 CONCLUSIONS: The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia. Pioglitazone 51-63 insulin Homo sapiens 139-146 16364837-14 2005 CONCLUSIONS: The present findings demonstrate that pioglitazone improves endothelial function in nondiabetic hypertensive individuals with insulin resistance, and that the improvement is associated with the amelioration of insulin resistance itself rather than that of hyperglycemia or hyperinsulinemia. Pioglitazone 51-63 insulin Homo sapiens 223-230 16390779-6 2005 We found a significant decrease in insulin response to the OGTT and also in total and free testosterone levels, an increase in SHBG and a reduction in the LH response to GnRH stimulation after pioglitazone treatment. Pioglitazone 193-205 insulin Homo sapiens 35-42 16364837-0 2005 Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Pioglitazone 0-12 insulin Homo sapiens 21-28 16390779-5 2005 In the present study, we evaluated the effect of pioglitazone (30 mg/day for 2 months) on insulin response to an oral glucose tolerance test (OGTT), serum levels of androgens and sex hormone-binding globulin (SHBG), and pituitary gonadotropin response to GnRH stimulation in 15 obese PCOS women. Pioglitazone 49-61 insulin Homo sapiens 90-97 16306801-3 2005 Pioglitazone, a PPARgamma agonist, not only improves insulin resistance and glycemic control but may also have additional beneficial vascular effects in patients with type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 53-60 16306801-10 2005 Pioglitazone treatment reduced insulin, FFA, and C-reactive protein concentrations compared with placebo (18.3 +/- 2.4 versus 14.8 +/- 2.1 mU/L, P = 0.03; 641 +/- 46 versus 542 +/- 33 mumol/L, P = 0.04; and 3.5 +/- 0.6 mg/L versus 2.6 +/- 0.5 mg/L, P = 0.01; respectively). Pioglitazone 0-12 insulin Homo sapiens 31-38 16219007-2 2005 Thiazolidinediones such as rosiglitazone and pioglitazone enhance insulin-mediated glucose disposal, leading to reduced plasma insulin concentrations. Pioglitazone 45-57 insulin Homo sapiens 127-134 16219011-2 2005 Metformin and thiazolidinediones (pioglitazone and rosiglitazone) counter insulin resistance by different cellular mechanisms and with complementary effects, making them suited for use in combination. Pioglitazone 34-46 insulin Homo sapiens 74-81 16076946-11 2005 Pioglitazone treatment significantly decreased fasting insulin and homeostasis model assessment levels. Pioglitazone 0-12 insulin Homo sapiens 55-62 16131582-9 2005 Both rosiglitazone and pioglitazone abolished insulin-dependent stimulation of estradiol production in the presence of FSH. Pioglitazone 23-35 insulin Homo sapiens 46-53 16131582-10 2005 Rosiglitazone and pioglitazone inhibited testosterone production by 10% (P < 0.012) and 15% (P < 0.023), respectively, and abolished insulin-induced stimulation of testosterone production. Pioglitazone 18-30 insulin Homo sapiens 139-146 16131582-12 2005 Pioglitazone and rosiglitazone enhanced insulin-induced inhibition of IGFBP-1 production by 13% and 20%, respectively (P < 0.001). Pioglitazone 0-12 insulin Homo sapiens 40-47 16402538-5 2005 The requirement of insulin was reduced by almost 50% in the pioglitazone group as compared to the placebo group. Pioglitazone 60-72 insulin Homo sapiens 19-26 16402538-7 2005 In conclusion, in patients with type 2 diabetes who are at high cardiovascular risk, pioglitazone improves cardiovascular outcome, and reduces the need to add insulin to glucose-lowering regimens compared to placebo. Pioglitazone 85-97 insulin Homo sapiens 159-166 16076946-3 2005 Decreased abdominal fat mass and improved insulin sensitivity during pioglitazone treatment may affect GH secretion. Pioglitazone 69-81 insulin Homo sapiens 42-49 16076946-13 2005 CONCLUSION: Pioglitazone treatment significantly increased GHRH-stimulated GH levels and 24-h pulsatile GH secretion, probably directly or indirectly due to improved insulin sensitivity. Pioglitazone 12-24 insulin Homo sapiens 166-173 16194192-9 2005 CONCLUSIONS: We conclude that pioglitazone treatment provides protection against arterial thrombosis in an obese, insulin resistant, prothrombotic mouse model. Pioglitazone 30-42 insulin Homo sapiens 114-121 16194192-0 2005 Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 73-80 16231594-7 2005 Two classes of drugs have been shown to correct insulin resistance: biguanides (e.g., metformin) and thiazolidinediones (e.g., rosiglitazone and pioglitazone). Pioglitazone 145-157 insulin Homo sapiens 48-55 16207627-5 2005 Insulin-resistance decreased significantly in the pioglitazone group (6.15 +/- 4.05 to 3.85 +/- 1.92, p < .0001) and remained unchanged in the glimepiride group. Pioglitazone 50-62 insulin Homo sapiens 0-7 16098929-9 2005 Thus, we believe that pioglitazone is effective for reactive hypoglycemia and aggravated glycemic metabolism associated with insulin resistance. Pioglitazone 22-34 insulin Homo sapiens 125-132 16026380-0 2005 Long-term effects of pioglitazone and metformin on insulin sensitivity in patients with Type 2 diabetes mellitus. Pioglitazone 21-33 insulin Homo sapiens 51-58 16026380-1 2005 AIM: Despite their comparable glycaemic effects in patients with Type 2 diabetes mellitus (T2DM), pioglitazone and metformin may have different effects on insulin sensitivity because they have different mechanisms of action. Pioglitazone 98-110 insulin Homo sapiens 155-162 16026380-2 2005 We studied the changes in insulin sensitivity, as assessed by the Quantitative Insulin Sensitivity Check Index (QUICKI), in patients with T2DM who used metformin or pioglitazone as monotherapy or in combination therapy with sulphonylurea. Pioglitazone 165-177 insulin Homo sapiens 26-33 16026380-9 2005 Pioglitazone increased insulin sensitivity more than metformin from week 4 through week 52. Pioglitazone 0-12 insulin Homo sapiens 23-30 16026380-11 2005 Overall, pioglitazone + sulphonylurea significantly increased insulin sensitivity more than metformin + sulphonylurea. Pioglitazone 9-21 insulin Homo sapiens 62-69 16026380-12 2005 CONCLUSION: Pioglitazone differed from metformin in its effects on insulin sensitivity despite both drugs having comparable glycaemic effects. Pioglitazone 12-24 insulin Homo sapiens 67-74 16157982-0 2005 Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. Pioglitazone 150-162 insulin Homo sapiens 48-55 16053992-6 2005 Six months after treatment with pioglitazone (30 mg/day), an insulin sensitizer, these examinations were repeated. Pioglitazone 32-44 insulin Homo sapiens 61-68 16138265-7 2005 In conclusion, treatment with pioglitazone resulted in an improvement of markers for insulin resistance and beta-cell dysfunction, independent from blood glucose control. Pioglitazone 30-42 insulin Homo sapiens 85-92 16053992-11 2005 CONCLUSIONS: The present findings demonstrate that pioglitazone improves LV diastolic function without LV mass regression in hypertensive patients in proportion to the amelioration of insulin resistance. Pioglitazone 51-63 insulin Homo sapiens 184-191 16334613-0 2005 Insulin resistance index as a predictor for pioglitazone treatment in type 2 diabetes. Pioglitazone 44-56 insulin Homo sapiens 0-7 16334613-2 2005 The purpose of the present study was to investigate whether insulin resistance index, homeostasis model assessment index (HOMA-IR) is a useful predictor of hypoglycemic effect of pioglitazone in comparison with body mass index (BMI). Pioglitazone 179-191 insulin Homo sapiens 60-67 15883215-6 2005 Insulin resistance was also improved only in the pioglitazone group (homeostasis model assessment, -2.2+/-3.4 versus -0.3+/-3.3; P<0.0001 between groups). Pioglitazone 49-61 insulin Homo sapiens 0-7 15632102-0 2005 Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Pioglitazone 0-12 insulin Homo sapiens 22-29 15632102-2 2005 This study was designed to determine whether the insulin sensitizer drugs pioglitazone and metformin would improve glucose intolerance and insulin sensitivity by decreasing IMCL. Pioglitazone 74-86 insulin Homo sapiens 49-56 15632102-7 2005 With pioglitazone treatment, there was a 65% increase in insulin sensitivity along with a 34% decrease in IMCL (both P < or = 0.002). Pioglitazone 5-17 insulin Homo sapiens 57-64 15855580-2 2005 We sought to determine whether pioglitazone, an insulin-sensitizing peroxisome proliferator-activated receptor (PPAR)-gamma agonist, improves cardiac endothelial function in individuals with type 2 diabetes. Pioglitazone 31-43 insulin Homo sapiens 48-55 15978304-19 2005 CONCLUSION: Adding pioglitazone to insulin in these study patients with type 2 DM whose disease was inadequately controlled with insulin monotherapy further improved their glycemic control. Pioglitazone 19-31 insulin Homo sapiens 129-136 15855580-15 2005 CONCLUSIONS: Pioglitazone treatment for 12 weeks in subjects with insulin-requiring type 2 diabetes had no demonstrable effect on coronary flow reserve despite metabolic improvements. Pioglitazone 13-25 insulin Homo sapiens 66-73 15642799-9 2005 The present results suggests that either pioglitazone or metformin administration was associated with a clear improvement in the endogenous hypothalamic DA tone, simultaneously with an amelioration of the insulin resistance status in these obese women with PCOS. Pioglitazone 41-53 insulin Homo sapiens 205-212 15644405-0 2005 Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment. Pioglitazone 152-164 insulin Homo sapiens 125-132 15714423-2 2005 We found that the administration of pioglitazone, but not fenofibrate, improved insulin resistance, blood pressure, and lipid profile over a 12-month period. Pioglitazone 36-48 insulin Homo sapiens 80-87 15739120-0 2005 Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Pioglitazone 0-12 insulin Homo sapiens 47-54 15739120-1 2005 AIMS/HYPOTHESIS: Recent studies have demonstrated that pioglitazone (PIO) has beneficial effects on insulin sensitivity compared with placebo in patients with type 2 diabetes. Pioglitazone 55-67 insulin Homo sapiens 100-107 15739120-1 2005 AIMS/HYPOTHESIS: Recent studies have demonstrated that pioglitazone (PIO) has beneficial effects on insulin sensitivity compared with placebo in patients with type 2 diabetes. Pioglitazone 69-72 insulin Homo sapiens 100-107 15739120-2 2005 The effects of PIO and gliclazide (GLIC)-based therapy on insulin sensitivity have not previously been directly compared. Pioglitazone 15-18 insulin Homo sapiens 58-65 15704569-2 2005 The glitazones (pioglitazone, rosiglitazone) impact directly and selectively on the key problem of insulin resistance. Pioglitazone 16-28 insulin Homo sapiens 99-106 16473258-6 2005 Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Pioglitazone 0-12 insulin Homo sapiens 70-77 16473258-6 2005 Pioglitazone, an antidiabetic agent that acts primarily by decreasing insulin resistance, improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. Pioglitazone 0-12 insulin Homo sapiens 114-121 16473258-7 2005 Pioglitazone improves glycemic control while reducing circulating insulin levels. Pioglitazone 0-12 insulin Homo sapiens 66-73 15624096-0 2005 Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Pioglitazone 94-106 insulin Homo sapiens 9-16 15624096-0 2005 Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Pioglitazone 94-106 insulin Homo sapiens 124-131 15912796-1 2005 We report beneficial effects of pioglitazone on insulin resistance in diabetes mellitus accompanied with myotonic dystrophy (DM1). Pioglitazone 32-44 insulin Homo sapiens 48-55 15912796-10 2005 Pioglitazone treatment is useful to improve insulin resistance and glucose control in DM1 patients with diabetes mellitus, especially patients with reactive hyperinsulinemia to glucose loading. Pioglitazone 0-12 insulin Homo sapiens 44-51 15386821-7 2005 There was a decrease in fasting insulin in the pioglitazone group compared to an increase in the gliclazide group (p < 0.001). Pioglitazone 47-59 insulin Homo sapiens 32-39 15598674-0 2005 Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Pioglitazone 68-80 insulin Homo sapiens 32-39 15598674-0 2005 Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Pioglitazone 68-80 insulin Homo sapiens 91-98 15598674-5 2005 Fasting serum insulin concentration (P < 0.001 for both drugs) and the area under the insulin curve during a 2-h oral glucose tolerance test decreased after pioglitazone (P < 0.002) or metformin (P < 0.05) treatment. Pioglitazone 160-172 insulin Homo sapiens 14-21 15598674-5 2005 Fasting serum insulin concentration (P < 0.001 for both drugs) and the area under the insulin curve during a 2-h oral glucose tolerance test decreased after pioglitazone (P < 0.002) or metformin (P < 0.05) treatment. Pioglitazone 160-172 insulin Homo sapiens 89-96 15598674-9 2005 These results suggest that pioglitazone is as effective as metformin in improving insulin sensitivity and hyperandrogenism, despite an increase in body weight, body mass index, and the waist to hip ratio associated with pioglitazone. Pioglitazone 27-39 insulin Homo sapiens 82-89 15854187-5 2005 Fasting, 2- and 3-h plasma glucose, insulin and homeostasis model assessment for insulin resistance decreased significantly with pioglitazone compared with other monotherapies (p < 0.05) and decreased significantly with PIO + MET compared with SU + MET (p < 0.05). Pioglitazone 129-141 insulin Homo sapiens 36-43 15854187-5 2005 Fasting, 2- and 3-h plasma glucose, insulin and homeostasis model assessment for insulin resistance decreased significantly with pioglitazone compared with other monotherapies (p < 0.05) and decreased significantly with PIO + MET compared with SU + MET (p < 0.05). Pioglitazone 129-141 insulin Homo sapiens 81-88 15624096-2 2005 METHODS: Ten non-diabetic subjects, identified as having low IRS-1 and GLUT-4 protein in adipose cells as markers of insulin resistance, underwent 3 weeks of treatment with pioglitazone. Pioglitazone 173-185 insulin Homo sapiens 117-124 15624096-9 2005 CONCLUSIONS/INTERPRETATION: Short-term treatment with pioglitazone improved insulin sensitivity in the absence of any changes in circulating NEFA or lipid levels. Pioglitazone 54-66 insulin Homo sapiens 76-83 15575920-5 2004 The addition of pioglitazone caused no significant changes in serum creatinine or mean tacrolimus dose, and caused decreases in HBA1C (8.36%+/- 1.5% pre-pioglitazone, 7.08%+/- 1.5% post-pioglitazone, p = 0.018) and total daily insulin dose (125.1 +/- 28.1 units pre-pioglitazone, 80.6 +/- 22.8 units post-pioglitazone, p = 0.002). Pioglitazone 16-28 insulin Homo sapiens 227-234 15617852-11 2005 PPAR-gamma influences the gene expression involved in carbohydrate metabolism, and pioglitazone and rosiglitazone, ligands for PPAR-gamma, improve insulin resistance in diabetic patients. Pioglitazone 83-95 insulin Homo sapiens 147-154 15598336-18 2004 Several pharmacological agents have been used including ursodeoxycholic acid, vitamin E, betaine, n-acetyl cysteine, and insulin sensitizing agents like metformin, rosiglitazone, and pioglitazone. Pioglitazone 183-195 insulin Homo sapiens 121-128 15625656-2 2004 We conducted a pilot study for the following reasons: (1) to test the hypothesis that a combination of an antioxidant (vitamin E) and an insulin sensitizer (pioglitazone) would be superior to vitamin E alone for the treatment of NASH, and (2) to define the effects of these interventions on insulin-sensitive metabolic functions and correlate the effects with changes in liver histology. Pioglitazone 157-169 insulin Homo sapiens 137-144 15562234-0 2004 Pioglitazone treatment of insulin resistance in a patient with Werner"s syndrome. Pioglitazone 0-12 insulin Homo sapiens 26-33 15579760-1 2004 Pioglitazone increases the insulin sensitivity of peripheral tissues and may provide an alternative first-line treatment for type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 27-34 15270789-0 2004 Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Pioglitazone 21-33 insulin Homo sapiens 55-62 15270789-1 2004 AIMS: This study compared the effects of 52 weeks" treatment with pioglitazone, a thiazolidinedione that reduces insulin resistance, and glibenclamide, on insulin sensitivity, glycaemic control, and lipids in patients with Type 2 diabetes. Pioglitazone 66-78 insulin Homo sapiens 113-120 15270789-5 2004 RESULTS: Pioglitazone significantly increased insulin sensitivity compared with glibenclamide, as assessed by homeostasis model assessment (17.0% vs. -13.0%; P < 0.001), quantitative insulin sensitivity check index (0.011 vs. -0.007; P < 0.001) and fasting serum insulin (-1.3 pmol/l vs. 23.8 pmol/l; P = 0.007). Pioglitazone 9-21 insulin Homo sapiens 46-53 15270789-8 2004 CONCLUSIONS These data suggest that the effects of pioglitazone are more sustained than those of glibenclamide for improving insulin sensitivity in patients with Type 2 diabetes, and that 52 weeks" treatment with pioglitazone has favourable effects on glycaemic control and lipoprotein profile. Pioglitazone 51-63 insulin Homo sapiens 125-132 15292314-0 2004 Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Pioglitazone 33-45 insulin Homo sapiens 49-56 15292314-2 2004 The aim of this randomized, double-blind, controlled trial was to investigate whether the thiazolidinedione derivative pioglitazone diminishes insulin resistance and hyperandrogenism and enhances ovulation rates in women with PCOS. Pioglitazone 119-131 insulin Homo sapiens 143-150 15292314-4 2004 Administration of pioglitazone resulted in a remarkable decline in both fasting serum insulin levels (P < 0.02) and the area under the insulin response curve after an oral glucose load (P < 0.02). Pioglitazone 18-30 insulin Homo sapiens 86-93 15292314-4 2004 Administration of pioglitazone resulted in a remarkable decline in both fasting serum insulin levels (P < 0.02) and the area under the insulin response curve after an oral glucose load (P < 0.02). Pioglitazone 18-30 insulin Homo sapiens 138-145 15292314-8 2004 Thus, pioglitazone significantly improved insulin sensitivity, hyperandrogenism, and ovulation rates in women with PCOS, thereby providing both metabolic and reproductive benefits. Pioglitazone 6-18 insulin Homo sapiens 42-49 15161771-9 2004 Maximal insulin stimulation ( approximately 400 microU/ml) revealed pioglitazone-associated increases in glucose uptake (P+ = 10.5 +/- 0.9 vs. P- = 8.9 +/- 0.8 mg. kg(-1). Pioglitazone 68-80 insulin Homo sapiens 8-15 15117857-3 2004 We studied the effect of pioglitazone, a thiazolidinedione that reduces insulin resistance, on the AIP of patients with type 2 diabetes. Pioglitazone 25-37 insulin Homo sapiens 72-79 15117857-12 2004 CONCLUSIONS: Pioglitazone reduced AIP when used as monotherapy or in combination therapy with sulfonylurea, metformin, or insulin. Pioglitazone 13-25 insulin Homo sapiens 122-129 15220243-1 2004 OBJECTIVE: Pioglitazone is a member of the thiazolidinediones (TZDs), insulin-sensitizing agents used to treat type 2 diabetes. Pioglitazone 11-23 insulin Homo sapiens 70-77 15154941-0 2004 An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Pioglitazone 98-110 insulin Homo sapiens 15-22 15154941-5 2004 Pioglitazone increased basal insulin sensitivity by 24.7% (7.8) HOMA-%S vs. 2.1% (5.9) in the placebo group (P = 0.02). Pioglitazone 0-12 insulin Homo sapiens 29-36 15154941-6 2004 Stimulated insulin sensitivity, M/I, increased in the pioglitazone group compared with placebo: +15.1 (2.8) l kg(-1) min(-1) vs. +3.2 (2.9) l kg(-1) min(-1), respectively (P = 0.009). Pioglitazone 54-66 insulin Homo sapiens 11-18 15154941-9 2004 There was a significant reduction in the proinsulin/insulin ratio in the pioglitazone group, -0.057 (0.02) compared with placebo, +0.004 (0.02) (P = 0.03). Pioglitazone 73-85 insulin Homo sapiens 41-51 15154941-9 2004 There was a significant reduction in the proinsulin/insulin ratio in the pioglitazone group, -0.057 (0.02) compared with placebo, +0.004 (0.02) (P = 0.03). Pioglitazone 73-85 insulin Homo sapiens 44-51 15154941-12 2004 CONCLUSIONS: Basal beta-cell function and insulin sensitivity improved following pioglitazone therapy. Pioglitazone 81-93 insulin Homo sapiens 42-49 15161771-11 2004 Thus, only 21 days of pioglitazone therapy improved insulin action in humans with type 2 diabetes. Pioglitazone 22-34 insulin Homo sapiens 52-59 15220012-2 2004 Pioglitazone is a thiazolidinedione that reduces insulin resistance, and glimepiride is a sulfonylurea insulin secretagogue. Pioglitazone 0-12 insulin Homo sapiens 49-56 15024400-0 2004 Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Pioglitazone 101-113 insulin Homo sapiens 79-86 15285797-2 2004 One of these, PPARgamma, regulates responsiveness to insulin in adipose cells, and PPARgamma-activating drugs such as pioglitazone are used in the treatment of type 2 diabetes. Pioglitazone 118-130 insulin Homo sapiens 53-60 15140339-0 2004 Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 86-93 15645955-12 2004 Insulin resistance decreased significantly with metformin and pioglitazone, beta cell fuhction also showed improvement CONCLUSIONS: Glycaemic control was seen in all study groups, the improvement was better in drug treated groups than in the control group. Pioglitazone 62-74 insulin Homo sapiens 0-7 15645955-14 2004 Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also. Pioglitazone 14-26 insulin Homo sapiens 76-83 15645955-14 2004 Metformin and pioglitazone had beneficial effects on lipid levels, improved insulin sensitivity and improved insulin secretion also. Pioglitazone 14-26 insulin Homo sapiens 109-116 15319810-14 2004 The above findings suggest that pioglitazone has potent insulin-sensitizing and lipid-lowering properties in a HFD-fed rat model. Pioglitazone 32-44 insulin Homo sapiens 56-63 15319810-16 2004 Further treatment with pioglitazone once daily for 2 weeks significantly ameliorated changes in basal plasma insulin, TG and TC, and reversed oral glucose intolerance to normal in HFD-fed rats, suggesting its potential in the treatment of insulin resistance and glucose intolerance associated with abnormal lipid metabolism. Pioglitazone 23-35 insulin Homo sapiens 109-116 15319810-16 2004 Further treatment with pioglitazone once daily for 2 weeks significantly ameliorated changes in basal plasma insulin, TG and TC, and reversed oral glucose intolerance to normal in HFD-fed rats, suggesting its potential in the treatment of insulin resistance and glucose intolerance associated with abnormal lipid metabolism. Pioglitazone 23-35 insulin Homo sapiens 239-246 15140339-2 2004 demonstrated using the hyperinsulinemic, euglycemic clamp that pioglitazone (PIO) enhanced insulin sensitivity in patients (n = 23) with type 2 diabetes (T2D). Pioglitazone 63-75 insulin Homo sapiens 28-35 15140339-5 2004 STUDY AIM: To evaluate the effect of PIO monotherapy and in combination therapy with sulfonylurea (SU) or metformin (MET) on insulin sensitivity as assessed by HOMA-S and QUICKI in a large group of patients (approximately 1000). Pioglitazone 37-40 insulin Homo sapiens 125-132 15220012-3 2004 OBJECTIVE: The goals of this study were to compare changes in measures of glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes who received pioglitazone or glimepiride for 1 year. Pioglitazone 169-181 insulin Homo sapiens 95-102 15220012-14 2004 Pioglitazone therapy was associated with significant increases in insulin sensitivity (reduced insulin resistance), whereas glimepiride had no effect. Pioglitazone 0-12 insulin Homo sapiens 66-73 15220012-14 2004 Pioglitazone therapy was associated with significant increases in insulin sensitivity (reduced insulin resistance), whereas glimepiride had no effect. Pioglitazone 0-12 insulin Homo sapiens 95-102 15220012-18 2004 CONCLUSIONS: These data suggest that long-term treatment with pioglitazone enhances insulin sensitivity relative to glimepiride in Mexican patients with type 2 diabetes and that pioglitazone may have a more sustained antihyperglycemic effect. Pioglitazone 62-74 insulin Homo sapiens 84-91 14693980-6 2004 Fasting insulin levels were also reduced (pioglitazone arm -1.3 micro IU/ml; metformin arm -0.8 micro IU/ml). Pioglitazone 42-54 insulin Homo sapiens 8-15 14984448-11 2004 Subjects with greater insulin resistance or preserved beta-cell function displayed better response to pioglitazone, whereas subjects with reduced beta-cell function displayed better response to metformin. Pioglitazone 102-114 insulin Homo sapiens 22-29 15247874-0 2004 [Pioglitazone insulin sensitivity and type 2 diabetes mellitus: recent data]. Pioglitazone 1-13 insulin Homo sapiens 14-21 15055868-7 2004 As well as maintaining glycaemic control over the long term, pioglitazone also confers benefits in terms of improvements in fasting insulin, lipid parameters, C-peptide and 32,33-split proinsulin (independent predictors of cardiovascular risk) and hypoglycaemia compared with other monotherapies or combination therapies. Pioglitazone 61-73 insulin Homo sapiens 132-139 15055868-7 2004 As well as maintaining glycaemic control over the long term, pioglitazone also confers benefits in terms of improvements in fasting insulin, lipid parameters, C-peptide and 32,33-split proinsulin (independent predictors of cardiovascular risk) and hypoglycaemia compared with other monotherapies or combination therapies. Pioglitazone 61-73 insulin Homo sapiens 185-195 15061300-4 2004 Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 91-98 14671144-5 2003 Pioglitazone administration for 5 months improved insulin sensitivity as indicated by significantly (P < 0.05) increased glucose infusion rates during the clamp studies. Pioglitazone 0-12 insulin Homo sapiens 50-57 14715850-8 2004 EGP was almost completely suppressed after pioglitazone treatment; taken collectively, plasma adiponectin concentration, before and after pioglitazone treatment, still correlated negatively with EGP during the insulin clamp (r = -0.65, P < 0.001). Pioglitazone 43-55 insulin Homo sapiens 210-217 14671144-9 2003 The data indicate that granulosa cell responsiveness to FSH was enhanced by insulin after improved insulin sensitivity induced by pioglitazone. Pioglitazone 130-142 insulin Homo sapiens 99-106 15260389-0 2003 Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy. Pioglitazone 49-61 insulin Homo sapiens 135-142 14624133-5 2003 The peroxisome proliferator-activated receptor-gamma agonists, the thiazolidinediones, pioglitazone and rosiglitazone, are insulin sensitizing agents, that are licensed for the management of hyperglycaemia. Pioglitazone 87-99 insulin Homo sapiens 123-130 15260389-12 2003 CONCLUSIONS: With proper patient selection, pioglitazone with glibenclamide and metformin can be safely used in patients receiving insulin with good results. Pioglitazone 44-56 insulin Homo sapiens 131-138 14578253-7 2003 Both diet and exercise and pioglitazone improved insulin sensitivity, but only the former was associated with loss of intra-abdominal fat. Pioglitazone 27-39 insulin Homo sapiens 49-56 14578253-13 2003 Pioglitazone treatment also improves insulin sensitivity and lowers WHR, but this is due to a selective increase in lower body fat. Pioglitazone 0-12 insulin Homo sapiens 37-44 14578253-14 2003 This confirms a site-specific responsiveness of adipose tissue to TZD and suggests that improvements in insulin sensitivity by pioglitazone are achieved independent of changes in intra-abdominal fat. Pioglitazone 127-139 insulin Homo sapiens 104-111 15260389-3 2003 OBJECTIVE: To determine the effects of pioglitazone in combination with sulphonylurea and metformin on diabetes control in patients being treated with insulin due to secondary failure of oral hypoglycemic agents. Pioglitazone 39-51 insulin Homo sapiens 151-158 12941723-1 2003 OBJECTIVE: The oral antidiabetic agent pioglitazone improves insulin sensitivity and glycemic control and appears to lower atherogenic dense LDL in type 2 diabetes. Pioglitazone 39-51 insulin Homo sapiens 61-68 15017657-7 2003 Some parameters of insulin sensitivity improved when measured after 18 weeks of pioglitazone treatment. Pioglitazone 80-92 insulin Homo sapiens 19-26 12730556-0 2003 Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Pioglitazone 0-12 insulin Homo sapiens 22-29 12871871-11 2003 CONCLUSIONS: In women with PCOS who failed to respond optimally to metformin, when pioglitazone was added, insulin, glucose, IR, insulin secretion, and DHEAS fell, HDL cholesterol and sex hormone-binding globulin rose, and menstrual regularity improved, without adverse side-effects. Pioglitazone 83-95 insulin Homo sapiens 107-114 12730556-1 2003 BACKGROUND AND PURPOSE: The aim of this study was to determine the effectiveness of pioglitazone compared with placebo for improving insulin sensitivity among nondiabetic patients with a recent transient ischemic attack (TIA) or nondisabling ischemic stroke and impaired insulin sensitivity. Pioglitazone 84-96 insulin Homo sapiens 133-140 12730556-8 2003 The mean proportional increase in insulin sensitivity was 62% among patients assigned to pioglitazone compared with a -1% decline among patients assigned to placebo (P=0.0006). Pioglitazone 89-101 insulin Homo sapiens 34-41 12730556-10 2003 CONCLUSIONS: Pioglitazone is effective for improving insulin sensitivity among patients with recent TIA or stroke and impaired insulin sensitivity. Pioglitazone 13-25 insulin Homo sapiens 53-60 12825962-6 2003 When given as monotherapy or in combination with sulphonylureas, metformin or insulin in patients with type 2 diabetes, the currently available thiazolidinediones (rosiglitazone and pioglitazone) ameliorate glycaemic control, by lowering fasting and postprandial blood glucose levels, and improve insulin sensitivity in placebo-controlled trials. Pioglitazone 182-194 insulin Homo sapiens 78-85 12809958-1 2003 OBJECTIVE: The goal of this study was to compare the effects of 2 doses of pioglitazone hydrochloride (a thiazolidinedione insulin sensitizer) with placebo on glycated hemoglobin (HbA(1c)), insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus who had suboptimal glycemic control and mild dyslipidemia. Pioglitazone 75-101 insulin Homo sapiens 123-130 12809958-1 2003 OBJECTIVE: The goal of this study was to compare the effects of 2 doses of pioglitazone hydrochloride (a thiazolidinedione insulin sensitizer) with placebo on glycated hemoglobin (HbA(1c)), insulin sensitivity, and lipid profiles in patients with type 2 diabetes mellitus who had suboptimal glycemic control and mild dyslipidemia. Pioglitazone 75-101 insulin Homo sapiens 190-197 12809958-9 2003 Pioglitazone 30 and 45 mg significantly reduced fasting serum insulin versus placebo (P = 0.008 and P = 0.006, respectively) and increased insulin sensitivity by Homeostasis Model Assessment versus placebo (P = 0.039 and P = 0.001, respectively). Pioglitazone 0-12 insulin Homo sapiens 62-69 12809958-9 2003 Pioglitazone 30 and 45 mg significantly reduced fasting serum insulin versus placebo (P = 0.008 and P = 0.006, respectively) and increased insulin sensitivity by Homeostasis Model Assessment versus placebo (P = 0.039 and P = 0.001, respectively). Pioglitazone 0-12 insulin Homo sapiens 139-146 12809958-14 2003 CONCLUSIONS: In the present study, pioglitazone 30 and 45 mg produced significant improvements in HbA(1c), insulin sensitivity, and lipid profile in OAM-naive patients with type 2 diabetes mellitus with suboptimal glycemic control and mild dyslipidemia. Pioglitazone 35-47 insulin Homo sapiens 107-114 12679450-1 2003 Pioglitazone, a thiazolidinedione, improves glycemic control primarily by increasing peripheral insulin sensitivity in patients with type 2 diabetes, whereas metformin, a biguanide, exerts its effect primarily by decreasing hepatic glucose output. Pioglitazone 0-12 insulin Homo sapiens 96-103 12679450-5 2003 At endpoint, pioglitazone was significantly more effective than metformin in improving indicators of insulin sensitivity, as determined by reduction of fasting serum insulin (P = 0.003) and by analysis of homeostasis model assessment for insulin sensitivity (HOMA-S; P = 0.002). Pioglitazone 13-25 insulin Homo sapiens 101-108 12679450-5 2003 At endpoint, pioglitazone was significantly more effective than metformin in improving indicators of insulin sensitivity, as determined by reduction of fasting serum insulin (P = 0.003) and by analysis of homeostasis model assessment for insulin sensitivity (HOMA-S; P = 0.002). Pioglitazone 13-25 insulin Homo sapiens 166-173 12679450-5 2003 At endpoint, pioglitazone was significantly more effective than metformin in improving indicators of insulin sensitivity, as determined by reduction of fasting serum insulin (P = 0.003) and by analysis of homeostasis model assessment for insulin sensitivity (HOMA-S; P = 0.002). Pioglitazone 13-25 insulin Homo sapiens 166-173 12679450-7 2003 Therefore, pioglitazone and metformin are equally efficacious in regard to glycemic control, but they exert significantly different effects on insulin sensitivity due to differing mechanisms of action. Pioglitazone 11-23 insulin Homo sapiens 143-150 12679450-8 2003 The more pronounced improvement in indicators of insulin sensitivity by pioglitazone, as compared with metformin monotherapy in patients recently diagnosed with type 2 diabetes who are OAM-naive, may be of interest for further clinical evaluation. Pioglitazone 72-84 insulin Homo sapiens 49-56 12917943-0 2003 Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Pioglitazone 67-79 insulin Homo sapiens 0-7 12825962-6 2003 When given as monotherapy or in combination with sulphonylureas, metformin or insulin in patients with type 2 diabetes, the currently available thiazolidinediones (rosiglitazone and pioglitazone) ameliorate glycaemic control, by lowering fasting and postprandial blood glucose levels, and improve insulin sensitivity in placebo-controlled trials. Pioglitazone 182-194 insulin Homo sapiens 297-304 14668701-4 2003 The TZDs rosiglitazone and pioglitazone work mainly by reducing insulin resistance and may have the potential to alter the natural history of type 2 diabetes and reduce the cardiovascular mortality and morbidity associated with this condition. Pioglitazone 27-39 insulin Homo sapiens 64-71 12466345-5 2002 Insulin sensitivity (M-value) increased by 1.2 +/- 1.7 mg/min/kg with pioglitazone compared with 0.4 +/- 1.4 mg/min/kg (P = 0.022) with placebo. Pioglitazone 70-82 insulin Homo sapiens 0-7 12466345-7 2002 Decreases in fasting insulin and glucose were significantly (P = 0.002 and P = 0.004, respectively) greater with pioglitazone than placebo. Pioglitazone 113-125 insulin Homo sapiens 21-28 12469695-5 2002 (4) Rosiglitazone and pioglitazone (glitazones that reduce insulin resistance) have been authorized in the European Union for combination with a glucose-lowering sulphonylurea (for patients in whom metformin is ineffective or poorly tolerated) or with metformin (for obese patients). Pioglitazone 22-34 insulin Homo sapiens 59-66 12413007-4 2002 He had injected over 100 units of insulin per day, however, testosterone replacement and administration of pioglitazone improved his glycemic control, which resulted in a decrease of insulin dose to less than 50 units per day. Pioglitazone 107-119 insulin Homo sapiens 34-41 12393300-3 2002 The first of the thiazolidinedione insulin sensitizing agents, troglitazone was quickly followed by rosiglitazone and pioglitazone. Pioglitazone 118-130 insulin Homo sapiens 35-42 12413007-4 2002 He had injected over 100 units of insulin per day, however, testosterone replacement and administration of pioglitazone improved his glycemic control, which resulted in a decrease of insulin dose to less than 50 units per day. Pioglitazone 107-119 insulin Homo sapiens 183-190 12201216-0 2002 Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Pioglitazone 10-22 insulin Homo sapiens 32-42 12050251-1 2002 We examined the effect of pioglitazone on abdominal fat distribution to elucidate the mechanisms via which pioglitazone improves insulin resistance in patients with type 2 diabetes mellitus. Pioglitazone 107-119 insulin Homo sapiens 129-136 12050251-7 2002 In the postabsorptive state, hepatic insulin resistance [basal endogenous glucose production (EGP) x basal plasma insulin concentration] decreased from 41 +/- 7 to 25 +/- 3 mg/kg fat-free mass (FFM).min x microU/ml; P < 0.05) and suppression of EGP during the first insulin clamp step (1.1 +/- 0.1 to 0.6 +/- 0.2 mg/kg FFM.min; P < 0.05) improved after pioglitazone treatment. Pioglitazone 359-371 insulin Homo sapiens 37-44 12050251-14 2002 These results demonstrate that a shift of fat distribution from visceral to sc adipose depots after pioglitazone treatment is associated with improvements in hepatic and peripheral tissue sensitivity to insulin. Pioglitazone 100-112 insulin Homo sapiens 203-210 12201216-1 2002 The objective of this study was to clarify the influence of pioglitazone (Pio) on proinsulin (PI) in patients with type 2 diabetes mellitus. Pioglitazone 60-72 insulin Homo sapiens 82-92 12201216-1 2002 The objective of this study was to clarify the influence of pioglitazone (Pio) on proinsulin (PI) in patients with type 2 diabetes mellitus. Pioglitazone 74-77 insulin Homo sapiens 82-92 12074206-10 2002 Pioglitazone, when added to stable insulin regimens, significantly improved HbA1c and FPG in type 2 diabetes. Pioglitazone 0-12 insulin Homo sapiens 35-42 12137601-7 2002 CONCLUSION: Pioglitazone 30 mg/day for 12 weeks might improve the metabolic control and the insulin sensitivity in poorly controlled type 2 diabetes with previous administration of sulphonylureas and metfomin. Pioglitazone 12-24 insulin Homo sapiens 92-99 12134427-0 2002 [Prevention of arteriosclerosis with the insulin sensitizer pioglitazone. Pioglitazone 60-72 insulin Homo sapiens 41-48 11523631-3 2001 In past experiments, we used both labeled glucose uptake, lipogenesis, and stimulation of calmodulin gene expression to quantify the ability of the antidiabetic drugs (pioglitazone and metformin) to reverse tumor necrosis factor-alpha (TNF-alpha)-induced IR in these insulin-treated cells. Pioglitazone 168-180 insulin Homo sapiens 267-274 15832486-14 2002 CONCLUSIONS: Six months of pioglitazone treatment decreased insulin resistance and improved glycemic control to a significantly greater extent than acarbose treatment. Pioglitazone 27-39 insulin Homo sapiens 60-67 11874940-0 2002 Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Pioglitazone 24-36 insulin Homo sapiens 40-47 11874940-1 2002 OBJECTIVE: To investigate the dose-response effects of pioglitazone on glycemic control, insulin sensitivity, and insulin secretion in patients with type 2 diabetes. Pioglitazone 55-67 insulin Homo sapiens 89-96 11874940-6 2002 Fasting plasma insulin decreased significantly in the 45-mg/day pioglitazone group, but the mean plasma insulin during the OGTT did not change. Pioglitazone 64-76 insulin Homo sapiens 15-22 11874940-7 2002 The insulinogenic index (delta area under the curve [AUC] insulin/deltaAUC glucose) during the OGTT increased significantly in the 30- and 45-mg/day pioglitazone groups (0.13 +/- 0.03 to 0.27 +/- 0.05, P < 0.05). Pioglitazone 149-161 insulin Homo sapiens 4-11 12481203-5 2002 Pioglitazone strongly increases insulin sensitivity, improves glucose and lipid metabolism and showed no evidence of hepatotoxicity. Pioglitazone 0-12 insulin Homo sapiens 32-39 12481203-6 2002 The mechanism of the antidiabetic action of pioglitazone involves activation of insulin receptors and/or high affinity for peroxisome proliferator-activated receptor gamma (PPARgamma). Pioglitazone 44-56 insulin Homo sapiens 80-87 12481203-8 2002 The direct antioxidant effect of pioglitazone may contribute to its effect on insulin resistance. Pioglitazone 33-45 insulin Homo sapiens 78-85 11712406-4 2001 Although the exact molecular mechanism of reducing insulin resistance still remains obscure, pioglitazone normalizes abnormalities in the cellular insulin signal transduction. Pioglitazone 93-105 insulin Homo sapiens 147-154 11712406-5 2001 This effect seems to be due to the inhibitory action of pioglitazone on TNF-alpha production, which is one of the factors responsible for insulin resistance. Pioglitazone 56-68 insulin Homo sapiens 138-145 11712406-7 2001 Therefore, the agonistic activity of pioglitazone on PPAR-gamma may be involved in the mechanism for reducing insulin resistance. Pioglitazone 37-49 insulin Homo sapiens 110-117 11586492-2 2001 Pioglitazone is a newly developed antidiabetic agent that attenuates insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 69-76 11095972-1 2000 Pioglitazone, a thiazolidinedione (TZD) derivative, is an antidiabetic agent that improves hyperglycaemia and hyperlipidaemia in obese and diabetic animals via a reduction in hepatic and peripheral insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 198-205 11491207-6 2001 RESULTS: Compared with placebo, pioglitazone significantly (P= 0.0001) reduced HbA1c (-1.37% points), FPG (-3.19 mmol/l; -57.5 mg/dl), fasting C-peptide (-0.076+/-0.022 nmol/l), and fasting insulin (-11.88+/-4.70 pmol/l). Pioglitazone 32-44 insulin Homo sapiens 190-197 11491207-7 2001 Pioglitazone significantly (P < 0.001) decreased insulin resistance (HOMA-IR; -12.4+/-7.46%) and improved beta-cell function (Homeostasis Model Assessment (HOMA-BCF); +47.7+/-11.58%). Pioglitazone 0-12 insulin Homo sapiens 52-59 11491207-11 2001 CONCLUSIONS: Pioglitazone improved insulin resistance and glycemic control, as well as Tg and HDL-C - which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes. Pioglitazone 13-25 insulin Homo sapiens 35-42 11491207-11 2001 CONCLUSIONS: Pioglitazone improved insulin resistance and glycemic control, as well as Tg and HDL-C - which suggests that pioglitazone may reduce cardiovascular risk for patients with type 2 diabetes. Pioglitazone 122-134 insulin Homo sapiens 35-42 11315836-0 2001 Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Pioglitazone 100-112 insulin Homo sapiens 39-46 11315836-10 2001 CONCLUSIONS: These results suggest that pioglitazone therapy in type 2 diabetic patients decreases lasting and postprandial plasma glucose levels by improving hepatic and peripheral (muscle) tissue sensitivity to insulin. Pioglitazone 40-52 insulin Homo sapiens 213-220 11160777-7 2001 The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mechanisms of insulin resistance. Pioglitazone 42-54 insulin Homo sapiens 103-110 11160777-7 2001 The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" and exert direct effects on the mechanisms of insulin resistance. Pioglitazone 42-54 insulin Homo sapiens 170-177 11460577-8 2001 Thiazolidinediones (rosiglitazone and pioglitazone) increase the sensitivity of the tissues to insulin. Pioglitazone 38-50 insulin Homo sapiens 95-102 11965830-10 2000 Another very promising approach is the use of thiazolidinediones (rosiglitazone, pioglitazone) to improve the insulin resistance and possibly preserve the beta cells by reducing the need for increased insulin secretion. Pioglitazone 81-93 insulin Homo sapiens 110-117 11467345-8 2000 Pioglitazone is FDA approved for monotherapy as well as for use in combination therapy with metformin, insulin, or sulfonylureas. Pioglitazone 0-12 insulin Homo sapiens 103-110 11965833-8 2000 Pioglitazone, used as monotherapy or in combination with sulphonylurea, biguanide or insulin, improves glycaemic control, lowers serum triglycerides and raises high density lipoprotein (HDL)-cholesterol. Pioglitazone 0-12 insulin Homo sapiens 85-92 10983737-1 2000 Pioglitazone is an orally administered insulin sensitising thiazolidinedione agent that has been developed for the treatment of type 2 diabetes mellitus. Pioglitazone 0-12 insulin Homo sapiens 39-46 11057434-10 2000 Troglitazone and pioglitazone prevented this inhibitory effect of insulin by restoring IRS-1 and PI3-K activities. Pioglitazone 17-29 insulin Homo sapiens 66-73 10983737-5 2000 The addition of pioglitazone 30 mg/day to preexisting therapy with metformin, or of pioglitazone 15 or 30 mg/day to sulphonylurea, insulin or voglibose therapy, has been shown to decrease HbA1c and fasting blood glucose levels significantly in patients with poorly controlled type 2 diabetes mellitus. Pioglitazone 16-28 insulin Homo sapiens 131-138 10857389-2 2000 Troglitazone, rosiglitazone, and pioglitazone are a new class of oral antidiabetic agents which can ameliorate peripheral insulin resistance in type 2 diabetes. Pioglitazone 33-45 insulin Homo sapiens 122-129 10872292-7 2000 The group of insulin sensitizers includes the biguanide, metformin and the thiazolidinediones or glitazones (rosiglitazone, pioglitazone). Pioglitazone 124-136 insulin Homo sapiens 13-20 10554661-4 1999 According to existing clinical data, pioglitazone at a once daily oral dose of 15 to 45 mg, as monotherapy or in combination with sulphonylureas, metformin or exogenous insulin, has a pronounced and reproducible blood sugar-lowering effect. Pioglitazone 37-49 insulin Homo sapiens 169-176 10605995-3 1999 Acarbose, metformin, miglitol, pioglitazone, rosiglitazone and troglitazone help the patient"s own insulin control glucose levels and allow early treatment with little risk of hypoglycemia. Pioglitazone 31-43 insulin Homo sapiens 99-106 10554661-5 1999 As well as improving glucose metabolism, pioglitazone has a beneficial effect on insulin resistance and the plasma levels of free fatty acids, triglycerides and HDL-cholesterol which is clinically relevant. Pioglitazone 41-53 insulin Homo sapiens 81-88 11220287-11 1999 Recent advances in type 2 diabetes therapy have seen the development of the thiazolidinediones (troglitazone, rosiglitazone, and pioglitazone), which improve insulin resistance in patients whose diabetes is poorly controlled by diet and exercise therapy. Pioglitazone 129-141 insulin Homo sapiens 158-165 10480188-5 1999 A new therapeutic class, the thiazolidinediones (troglitazone, rosiglitazone, pioglitazone) has recently completed the family of insulin-sensitizing agents. Pioglitazone 78-90 insulin Homo sapiens 129-136 9550126-0 1997 Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Pioglitazone 0-12 insulin Homo sapiens 35-42 9768370-2 1998 To evaluate the effect of pioglitazone on insulin resistance in non-insulin-dependent diabetes mellitus (NIDDM) patients, a double-blind placebo-controlled trial was carried out with 30 NIDDM patients. Pioglitazone 26-38 insulin Homo sapiens 42-49 9768370-10 1998 In conclusion, the results indicate that pioglitazone is effective for ameliorating insulin resistance in NIDDM by enhancing SGU as well as peripheral glucose uptake. Pioglitazone 41-53 insulin Homo sapiens 84-91 9365455-0 1997 Pioglitazone-reduced insulin resistance in patient with Werner syndrome. Pioglitazone 0-12 insulin Homo sapiens 21-28 9550126-0 1997 Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Pioglitazone 14-21 insulin Homo sapiens 35-42 9550126-2 1997 We evaluated the effect of pioglitazone, a thiazolidinedione compound, on insulin-stimulated glucose disposal (Rd) and its efficacy on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus (NIDDM). Pioglitazone 27-39 insulin Homo sapiens 74-81 9550126-10 1997 The change in Rd between before and after pioglitazone administration correlated with baseline values of FPG (rho=0.633), serum insulin (rho=0.653), BMI (rho=0.456), Rd (rho 0.558) and 1,5-AG (rho=-0.522). Pioglitazone 42-54 insulin Homo sapiens 128-135 9550126-11 1997 These data indicate that pioglitazone enhances the insulin action in NIDDM patients on diet alone or SU, and thereby improves both plasma glucose level and lipid profiles. Pioglitazone 25-37 insulin Homo sapiens 51-58 9287037-5 1997 Pioglitazone markedly improves insulin action in the obese Zucker (fa/fa) rat, but doubles its weight gain after 4 weeks of treatment. Pioglitazone 0-12 insulin Homo sapiens 31-38 9288574-0 1997 Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor-alpha in liver cells. Pioglitazone 0-12 insulin Homo sapiens 35-42 8708551-1 1996 Pioglitazone hydrochloride (AD-4833), one of the thiazolidinedione analogs, is a new anti-diabetic agent which improves peripheral insulin resistance in diabetic patients. Pioglitazone 0-26 insulin Homo sapiens 131-138 8914439-6 1996 New insulin sensitizers, such as troglitazone and pioglitazone, improve insulin-mediated glucose disposal by enhancing tissue sensitivity to the actions of insulin and reversing the insulin resistance, characteristic of NIDDM. Pioglitazone 50-62 insulin Homo sapiens 4-11 8914439-6 1996 New insulin sensitizers, such as troglitazone and pioglitazone, improve insulin-mediated glucose disposal by enhancing tissue sensitivity to the actions of insulin and reversing the insulin resistance, characteristic of NIDDM. Pioglitazone 50-62 insulin Homo sapiens 72-79 8914439-6 1996 New insulin sensitizers, such as troglitazone and pioglitazone, improve insulin-mediated glucose disposal by enhancing tissue sensitivity to the actions of insulin and reversing the insulin resistance, characteristic of NIDDM. Pioglitazone 50-62 insulin Homo sapiens 72-79 8914439-6 1996 New insulin sensitizers, such as troglitazone and pioglitazone, improve insulin-mediated glucose disposal by enhancing tissue sensitivity to the actions of insulin and reversing the insulin resistance, characteristic of NIDDM. Pioglitazone 50-62 insulin Homo sapiens 72-79 8708551-1 1996 Pioglitazone hydrochloride (AD-4833), one of the thiazolidinedione analogs, is a new anti-diabetic agent which improves peripheral insulin resistance in diabetic patients. Pioglitazone 28-35 insulin Homo sapiens 131-138 8582019-3 1995 The metabolites of (+/-)-5(-)[p(-)[2-(5-ethyl-2- pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (1, pioglitazone), which is a representative insulin-sensitizing agent, were synthesized to confirm their structures and for studies of their pharmacological properties. Pioglitazone 19-93 insulin Homo sapiens 139-146 8299559-2 1994 One such analog, pioglitazone (5-(4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzyl)thiazolidine-2,4-dione hydrochloride), when fed to insulin-resistant animals such as the obese (ob/ob) mouse, reduces blood glucose and lipids and also lowers the plasma insulin level. Pioglitazone 17-29 insulin Homo sapiens 125-132 8299559-11 1994 On the other hand, the blood glucose and plasma insulin levels of the RCM-hGH treated mice fed pioglitazone were markedly reduced compared to those of the RCM-hGH-treated control-fed animals. Pioglitazone 95-107 insulin Homo sapiens 48-55 8299559-2 1994 One such analog, pioglitazone (5-(4-[2-(5-ethyl-2-pyridinyl)ethoxy]benzyl)thiazolidine-2,4-dione hydrochloride), when fed to insulin-resistant animals such as the obese (ob/ob) mouse, reduces blood glucose and lipids and also lowers the plasma insulin level. Pioglitazone 17-29 insulin Homo sapiens 244-251 8299559-12 1994 Thus, these results suggest that pioglitazone can ameliorate GH-induced insulin resistance. Pioglitazone 33-45 insulin Homo sapiens 72-79 8299559-3 1994 Because GH can produce insulin resistance in humans and animals such as the ob/ob mouse, the present study was conducted to determine whether feeding pioglitazone can 1) inhibit the ability of GH to induce enhanced insulin resistance in obese mice, 2) ameliorate or reverse GH-induced insulin resistance once it has been induced in ob/ob mice, and 3) alter the ability of GH to promote growth in hypophysectomized rats. Pioglitazone 150-162 insulin Homo sapiens 215-222 8299559-3 1994 Because GH can produce insulin resistance in humans and animals such as the ob/ob mouse, the present study was conducted to determine whether feeding pioglitazone can 1) inhibit the ability of GH to induce enhanced insulin resistance in obese mice, 2) ameliorate or reverse GH-induced insulin resistance once it has been induced in ob/ob mice, and 3) alter the ability of GH to promote growth in hypophysectomized rats. Pioglitazone 150-162 insulin Homo sapiens 215-222 8299559-7 1994 By contrast, the ability of RCM-hGH to increase blood glucose and plasma insulin levels was totally blocked in pioglitazone-fed mice. Pioglitazone 111-123 insulin Homo sapiens 73-80 8391325-5 1993 The objective of this investigation was to determine if a novel antidiabetic agent, pioglitazone, ameliorated hepatic insulin resistance in KKA(y) mice and to identify any alterations in PIP2-phospholipase C activity of liver plasma membranes that may accompany changes in insulin sensitivity. Pioglitazone 84-96 insulin Homo sapiens 118-125 34591742-5 2022 EXPERT OPINION: : Pioglitazone activates peroxisome proliferator-activated receptor-gamma which improves insulin sensitivity and helps to preserve beta-cell function with a durable improvement in glycemic control. Pioglitazone 18-30 insulin Homo sapiens 105-112 23511244-7 2013 Upon study completion, patients treated with pioglitazone had lower levels of HbA1c (6.41+-0.65 vs 6.96+-0.74%; p<0.001) and homeostasis model assessment-insulin resistance (HOMA-IR) (2.88+-1.95 vs 4.68+-3.63; p=0.013) and a reduction of the atherogenic LDL subfraction (pattern B) (-5.7%). Pioglitazone 45-57 insulin Homo sapiens 157-164 23511244-8 2013 CONCLUSIONS: The beneficial effects observed in pioglitazone-treated patients in the present study, (i.e. the increase in HDL-C and the reduction of insulin resistance and atherogenic LDL subfractions), support findings from the PROactive trial, where pioglitazone showed pleiotropic effects and reduced death, fatal myocardial infarction (MI) and non-fatal MI in T2DM patients with MS. Pioglitazone 48-60 insulin Homo sapiens 149-156 34863942-3 2022 Further study of the first generation "insulin sensitizer" pioglitazone and molecules based on its structure suggests that is possible to decouple body weight from the metabolic dysfunction that drives adverse outcomes. Pioglitazone 59-71 insulin Homo sapiens 39-46 34925073-0 2021 The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans. Pioglitazone 23-35 insulin Homo sapiens 4-11 34925073-1 2021 The insulin-sensitizer pioglitazone exerts its cardiometabolic benefits in type 2 diabetes (T2D) through a redistribution of body fat, from ectopic and visceral areas to subcutaneous adipose depots. Pioglitazone 23-35 insulin Homo sapiens 4-11 34572374-0 2021 Pioglitazone Reverses Markers of Islet Beta-Cell De-Differentiation in db/db Mice While Modulating Expression of Genes Controlling Inflammation and Browning in White Adipose Tissue from Insulin-Resistant Mice and Humans. Pioglitazone 0-12 insulin Homo sapiens 186-193 34713480-8 2022 Significant reductions in fasting insulin (FI) with pioglitazone versus placebo (SMD: -0.55; 95% CI: -1.03, -0.07; I2 = 37%; p = .02, very-low-grade evidence). Pioglitazone 52-64 insulin Homo sapiens 34-41 34718616-9 2022 Pioglitazone, an insulin-sensitizing agent, reduced both these effects of TRIB3 and the ER stressor-induced expression of TRB3. Pioglitazone 0-12 insulin Homo sapiens 17-24 34815985-3 2021 Here, we set out to ascertain the emergence of the novel mitochondrial mediator of epigenetic function acetyl-L-carnitine (LAC) in relation to previously described individual predictors of antidepressant responses to the insulin-sensitizing agent pioglitazone. Pioglitazone 247-259 insulin Homo sapiens 221-228 34311022-7 2021 Indices of insulin resistance decreased after pioglitazone, but not after sulphonylureas: -0.95+-4.57 vs. 0.37+-3.34 for HOMA-IR, p=0.032; -1.25+-4.11 vs. 1.36+-5.43 for ADIPO-IR, p=0.001; -0.53+-1.88 vs. 0.03+-2.36 for VAI, p=0.074. Pioglitazone 46-58 insulin Homo sapiens 11-18 34572374-3 2021 Herein, we used the drug pioglitazone, a thiazolidinedione with insulin-sensitizing properties, to investigate blood glucose levels, indicators of islet beta-cell health and maturity, and gene expression in adipose tissue. Pioglitazone 25-37 insulin Homo sapiens 64-71 34572374-7 2021 Moreover, pancreatic beta-cells from db/db mice treated with pioglitazone had greater expression of insulin and Nkx6.1 as well as reduced abundance of the de-differentiation marker Aldh1a3. Pioglitazone 61-73 insulin Homo sapiens 100-107 34483693-16 2021 Thereafter, pioglitazone was added to improve insulin resistance. Pioglitazone 12-24 insulin Homo sapiens 46-53 34404415-4 2021 Therefore administration of insulin-sensitizing drugs such as pioglitazone can be used for ovulation stimulation in PCO patients. Pioglitazone 62-74 insulin Homo sapiens 28-35 34311022-9 2021 CONCLUSIONS: one-year treatment with pioglitazone even at low dosage significantly improved liver steatosis and inflammation, systemic and adipose tissue insulin resistance in patients with T2D. Pioglitazone 37-49 insulin Homo sapiens 154-161 34511850-3 2021 While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Pioglitazone 155-167 insulin Homo sapiens 301-308 35434067-6 2022 CONCLUSION: Pioglitazone attenuated insulin resistance in this patient with TAIRS, and flutamide ameliorated masculinization. Pioglitazone 12-24 insulin Homo sapiens 36-43 35581905-8 2022 Unexpectedly, subjects in Group 1 had better response to combination therapy with pioglitazone plus exenatide than with insulin therapy or metformin sequentially followed by glipizide and basal insulin, while subjects in group 2 responded equally well to both therapies despite very severe insulin resistance. Pioglitazone 82-94 insulin Homo sapiens 290-297 34006325-1 2021 Since 1985, the thiazolidinedione pioglitazone has been widely used as an insulin sensitizer drug for type 2 diabetes mellitus (T2DM). Pioglitazone 34-46 insulin Homo sapiens 74-81 35014161-7 2022 In addition, insulin sensitizers such as PPARgamma (pioglitazone) and pan-PPARs agonists (lanifibranor) have shown some beneficial effects on both NASH and liver fibrosis. Pioglitazone 52-64 insulin Homo sapiens 13-20 35059243-3 2022 Thiazolidinediones (TZDs) can specifically treat insulin resistance and improve metabolic syndrome, including rosiglitazone, troglitazone and pioglitazone, which are peroxisome proliferator-activated receptor (PPAR) agonists. Pioglitazone 142-154 insulin Homo sapiens 49-56 33746449-1 2021 Of the currently available drugs tested to treat nonalcoholic fatty liver disease (NAFLD), the most efficacious drugs are pioglitazone (an insulin sensitizer) and vitamin E (an antioxidant). Pioglitazone 122-134 insulin Homo sapiens 139-146 33571166-7 2021 RESULTS: Treatment with pioglitazone or the combination of pioglitazone and mirabegron increased beige adipose tissue protein marker expression and improved insulin sensitivity and glucose homeostasis, but neither treatment induced BAT in these obese subjects. Pioglitazone 24-36 insulin Homo sapiens 157-164 33571166-7 2021 RESULTS: Treatment with pioglitazone or the combination of pioglitazone and mirabegron increased beige adipose tissue protein marker expression and improved insulin sensitivity and glucose homeostasis, but neither treatment induced BAT in these obese subjects. Pioglitazone 59-71 insulin Homo sapiens 157-164 33880995-12 2021 When failure to achieve metabolic control with metformin occurs, pioglitazone may be a safe option, lowering insulin resistance and improving both the metabolic control and lipodystrophic phenotype. Pioglitazone 65-77 insulin Homo sapiens 109-116 33746449-2 2021 By targeting insulin resistance, the key pathogenic mechanism underlying metabolic syndrome and NAFLD, pioglitazone maybe the preferred drug to treat NAFLD. Pioglitazone 103-115 insulin Homo sapiens 13-20 33638222-4 2021 Pioglitazone has shown promise in secondary stroke prevention for insulin-resistant patients; however, its use is not yet widespread. Pioglitazone 0-12 insulin Homo sapiens 66-73 32801814-10 2020 However, insulin increases the TNF-alpha expression as for pioglitazone. Pioglitazone 59-71 insulin Homo sapiens 9-16 33309864-1 2021 Pioglitazone (PGZ), a PPARgamma agonist, has been used for diabetic patients as an insulin-sensitizing agent. Pioglitazone 0-12 insulin Homo sapiens 83-90 33309864-1 2021 Pioglitazone (PGZ), a PPARgamma agonist, has been used for diabetic patients as an insulin-sensitizing agent. Pioglitazone 14-17 insulin Homo sapiens 83-90 33309864-6 2021 PGZ-administered db/db mice showed improved insulin sensitivity, and the hemorrhagic rate and infarct volume were decreased (P < 0.05). Pioglitazone 0-3 insulin Homo sapiens 44-51 32963510-1 2020 Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose effects result predominantly from its modulation of the transcriptional activity of peroxisome proliferator-activated-receptor-gamma (PPARgamma). Pioglitazone 0-12 insulin Homo sapiens 48-55 32963510-1 2020 Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose effects result predominantly from its modulation of the transcriptional activity of peroxisome proliferator-activated-receptor-gamma (PPARgamma). Pioglitazone 0-3 insulin Homo sapiens 48-55 33040780-0 2020 Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. Pioglitazone 163-175 insulin Homo sapiens 64-71 33040780-0 2020 Investigating the changes in the levels of HbA1c, blood fat and insulin sensitivity in elder patients with type II diabetes mellitus due to combined medication of pioglitazone and melbine and single-use of pioglitazone. Pioglitazone 206-218 insulin Homo sapiens 64-71 33040780-1 2020 This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients. Pioglitazone 104-116 insulin Homo sapiens 198-205 33040780-1 2020 This study was founded for the purpose investigate the differences in effects of combined medication of pioglitazone and melbine and single-use of pioglitazone on the levels of hba1c, blood fat and insulin sensitivity of elder patients with type II diabetes mellitus (T2DM), to provide clinical reference and guidance for the treatment of T2DM in elder patients. Pioglitazone 147-159 insulin Homo sapiens 198-205 33040780-8 2020 It is concluded that combined medication of pioglitazone and melbine can effectively reduce the levels of plasma glucose, blood fat and the HOMA-IR, with an elevated sensitivity to insulin, but no severe adverse reactions, manifesting a promising safety in long-term administration. Pioglitazone 44-56 insulin Homo sapiens 181-188 32252184-1 2020 PURPOSE: Pioglitazone, an antihyperglycemic drug, is widely used in diabetes mellitus patients with insulin resistance. Pioglitazone 9-21 insulin Homo sapiens 100-107 32942898-1 2020 Pioglitazone belongs to the drugs primarily reducing insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 53-60 32344313-6 2020 Our hypothesis is that drugs belonging to the family of thiazolidinediones (TZD) such as pioglitazone or rosiglitazone, approved for treating the condition of insulin resistance and the accompanying inflammation, could ameliorate the prognosis of those COVID-19 patients with diabetes, hypertension and cardiovascular disorders comorbidities. Pioglitazone 89-101 insulin Homo sapiens 159-166 32332780-6 2020 In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression. Pioglitazone 67-79 insulin Homo sapiens 47-54 32332780-6 2020 In patients with polycystic ovary syndrome and insulin resistance, pioglitazone-induced improvement of insulin action is associated with an increase in muscle ApoJ and LRP2 expression. Pioglitazone 67-79 insulin Homo sapiens 103-110 32107266-3 2020 Treatment with a low-dose combination of one antiandrogen and antimineralocorticoid drug (spironolactone) and two insulin sensitizers (pioglitazone/metformin) (SPIOMET) is particularly effective in improving these metabolic derangements. Pioglitazone 135-147 insulin Homo sapiens 114-121 31339011-6 2020 However, the pioglitazone-treated group exhibited significantly higher high density lipoprotein cholesterol levels (P<0.001) and significantly lower homeostatic model assessment of insulin resistance values (P<0.001). Pioglitazone 13-25 insulin Homo sapiens 184-191 31339011-8 2020 CONCLUSION: Among patients with T2DM inadequately controlled using metformin plus alogliptin, the addition of pioglitazone provided comparable glycemic control and various benefits (improvements in lipid profiles, insulin resistance, and hypoglycemia risk) relative to the addition of glimepiride. Pioglitazone 110-122 insulin Homo sapiens 214-221 30663560-4 2020 Regarding antidiabetic medication, metformin, gliclazide, pioglitazone, exenatide and dapagliflozin exert a beneficial effect on Endothelial Function (EF); glimepiride and glibenclamide, dipeptidyl peptidase-4 inhibitors and liraglutide have a neutral effect, while studies examining the effect of insulin analogues, empagliflozin and canagliflozin on EF are limited. Pioglitazone 58-70 insulin Homo sapiens 298-305 31827945-5 2019 Insulin was discontinued completely, and he maintained appropriate glycemic control on oral diabetic agents (metformin and pioglitazone). Pioglitazone 123-135 insulin Homo sapiens 0-7 31050706-5 2019 Accordingly, cardiovascular outcome trials with pioglitazone have demonstrated that this insulin sensitizing thiazolidinedione reduces cardiovascular events in high risk type 2 diabetic patients. Pioglitazone 48-60 insulin Homo sapiens 89-96 30738020-4 2019 Among the different classes of diabetic drugs, pioglitazone (PIO), a PPARgamma agonist classed as an insulin sensitizer, is of the highest interest for AD management. Pioglitazone 47-59 insulin Homo sapiens 101-108 31683341-14 2019 Combination of metformin and pioglitazone therapy was more effective as compared to metformin alone in reducing the levels of IL-6 and IL-8 as well as insulin resistance in PCOS. Pioglitazone 29-41 insulin Homo sapiens 151-158 31129998-1 2019 Background Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes mellitus that reduce glucose with minimal risk of hypoglycemia and potential benefits on atherosclerosis. Pioglitazone 46-58 insulin Homo sapiens 69-76 30738020-4 2019 Among the different classes of diabetic drugs, pioglitazone (PIO), a PPARgamma agonist classed as an insulin sensitizer, is of the highest interest for AD management. Pioglitazone 61-64 insulin Homo sapiens 101-108 30259621-0 2019 Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. Pioglitazone 0-12 insulin Homo sapiens 99-106 30734043-1 2019 Importance: In the Insulin Resistance Intervention After Stroke (IRIS) randomized clinical trial, pioglitazone, an insulin-sensitizing agent, reduced the risk for recurrent stroke or myocardial infarction (MI) among patients with insulin resistance. Pioglitazone 98-110 insulin Homo sapiens 19-26 30734043-1 2019 Importance: In the Insulin Resistance Intervention After Stroke (IRIS) randomized clinical trial, pioglitazone, an insulin-sensitizing agent, reduced the risk for recurrent stroke or myocardial infarction (MI) among patients with insulin resistance. Pioglitazone 98-110 insulin Homo sapiens 115-122 30734043-1 2019 Importance: In the Insulin Resistance Intervention After Stroke (IRIS) randomized clinical trial, pioglitazone, an insulin-sensitizing agent, reduced the risk for recurrent stroke or myocardial infarction (MI) among patients with insulin resistance. Pioglitazone 98-110 insulin Homo sapiens 230-237 30259621-5 2019 In the present study, we examined the effect of the addition of dapagliflozin plus pioglitazone on plasma ketone concentration in insulin-treated T2DM patients and compared the results to the effect of dapagliflozin alone. Pioglitazone 83-95 insulin Homo sapiens 130-137 30259621-7 2019 Dapagliflozin plus pioglitazone produced a robust decrease in HbA1c (-1.4%) and resulted in a 50% reduction in daily insulin dose, from 133 to 66 units, while dapagliflozin alone caused a 0.8% reduction in HbA1c. Pioglitazone 19-31 insulin Homo sapiens 117-124 31117067-3 2019 We also performed glucose uptake assays to explore the action of insulin and the effects of pioglitazone, an insulin sensitizer, on glucose transport in the OC. Pioglitazone 92-104 insulin Homo sapiens 109-116 30706731-4 2019 Pioglitazone is a potent insulin sensitizer, preserves beta-cell function, causes durable reduction in HbA1c, corrects multiple components of metabolic syndrome and improves nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Pioglitazone 0-12 insulin Homo sapiens 25-32 30729133-0 2019 High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone. Pioglitazone 152-164 insulin Homo sapiens 18-25 30729133-4 2019 The cells derived from human bladder epithelial cells (HBlEpCs) were treated with metformin or pioglitazone with high glucose and insulin. Pioglitazone 95-107 insulin Homo sapiens 130-137 30729133-6 2019 Metformin or pioglitazone suppressed cell viability concentration and time dependently, which was reversed by exposure to high glucose with or without insulin. Pioglitazone 13-25 insulin Homo sapiens 151-158 30729133-7 2019 Prolonged exposure to high glucose and insulin enhanced cyclin D, cyclin-dependent kinase 4 (Cdk4), and Cdk2 expression and suppressed cyclin-dependent kinase inhibitors p21 and p15/16 in HBlEpC cotreated with pioglitazone and metformin. Pioglitazone 210-222 insulin Homo sapiens 39-46 30729133-8 2019 Levels of tumor suppressor proteins p53 and cav-1 were downregulated while those of the oncogenic protein as c-Myc were upregulated under high glucose and insulin supplementation in HBlEpC cotreated with pioglitazone and metformin. Pioglitazone 204-216 insulin Homo sapiens 155-162 31117067-9 2019 Pioglitazone conferred a small but nonsignificant potentiation of glucose uptake at the highest concentration of insulin. Pioglitazone 0-12 insulin Homo sapiens 113-120 31117067-11 2019 Pioglitazone significantly upregulated IR and GLUT1 mRNA expression, which was further increased by insulin. Pioglitazone 0-12 insulin Homo sapiens 100-107 29934374-0 2018 Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Pioglitazone 134-146 insulin Homo sapiens 68-75 30337873-1 2018 For almost two decades, pioglitazone has been prescribed primarily to prevent and treat insulin resistance in some type 2 diabetic patients. Pioglitazone 24-36 insulin Homo sapiens 88-95 29934374-1 2018 BACKGROUND: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. Pioglitazone 92-104 insulin Homo sapiens 28-35 29934374-1 2018 BACKGROUND: The IRIS trial (Insulin Resistance Intervention After Stroke) demonstrated that pioglitazone reduced the risk for both cardiovascular events and diabetes mellitus in insulin-resistant patients. Pioglitazone 92-104 insulin Homo sapiens 178-185 29934374-17 2018 CONCLUSIONS: In IRIS, with surveillance and dose adjustments, pioglitazone did not increase the risk of HF and conferred net cardiovascular benefit in patients with insulin resistance and cerebrovascular disease. Pioglitazone 62-74 insulin Homo sapiens 165-172 30104075-1 2018 BACKGROUND: Insulin sensitizers like metformin and pioglitazone are clinically used since last decades for the treatment of PCOS, but their efficacy and possible role in PCOS patients remains questionable. Pioglitazone 51-63 insulin Homo sapiens 12-19 30008760-5 2018 Considering the efficacy and safety of combination therapy of insulin with older hypoglycemic agents, in general metformin and pioglitazone have the best and worst profiles, respectively. Pioglitazone 127-139 insulin Homo sapiens 62-69 30008760-10 2018 Conclusions: Considering the quality and longevity of evidence, compared to insulin monotherapy, insulin combined with metformin and pioglitazone has the best and worst profiles, respectively. Pioglitazone 133-145 insulin Homo sapiens 97-104 29223443-12 2018 Pioglitazone was associated with a significantly greater insulin sensitivity in adipose tissue of patients with diabetes vs without diabetes (P < .001), but nonsignificant differences in responses in hepatic (P = .49) and skeletal muscle (P = .32) insulin sensitivity. Pioglitazone 0-12 insulin Homo sapiens 57-64 29223443-12 2018 Pioglitazone was associated with a significantly greater insulin sensitivity in adipose tissue of patients with diabetes vs without diabetes (P < .001), but nonsignificant differences in responses in hepatic (P = .49) and skeletal muscle (P = .32) insulin sensitivity. Pioglitazone 0-12 insulin Homo sapiens 248-255 29223443-14 2018 However, pioglitazone reduced liver fibrosis and increased adipose tissue insulin sensitivity at significantly greater levels in patients with type 2 diabetes than in patients with prediabetes. Pioglitazone 9-21 insulin Homo sapiens 74-81 29227578-0 2018 Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. Pioglitazone 71-83 insulin Homo sapiens 0-7 29580285-0 2018 Pioglitazone is effective for multiple phenotyepes of the Zucker fa/fa rat with polycystc ovary morphology and insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 111-118 29227578-3 2018 Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c <= 7.0%) with pioglitazone plus exenatide. Pioglitazone 166-178 insulin Homo sapiens 0-7 29227578-3 2018 Insulin secretion measured with plasma C-peptide concentration during the OGTT was the strongest predictor of response to combination therapy (HbA1c <= 7.0%) with pioglitazone plus exenatide. Pioglitazone 166-178 insulin Homo sapiens 39-48 29536426-0 2018 Pioglitazone Improved Insulin Sensitivity and First Phase Insulin Secretion Among Obese and Lean People with Diabetes: A Multicenter Clamp Study. Pioglitazone 0-12 insulin Homo sapiens 22-29 29536426-1 2018 INTRODUCTION: To investigate the effects of pioglitazone (PIO) on insulin resistance and first phase insulin secretion among obese and lean Chinese people with type 2 diabetes mellitus (T2DM). Pioglitazone 44-56 insulin Homo sapiens 66-73 29580285-4 2018 Pioglitazone, an insulin sensitizer, is administered to PCOS patients with insulin resistance to induce ovulation but the mechanisms by which this occurs have not been elucidated. Pioglitazone 0-12 insulin Homo sapiens 17-24 29580285-4 2018 Pioglitazone, an insulin sensitizer, is administered to PCOS patients with insulin resistance to induce ovulation but the mechanisms by which this occurs have not been elucidated. Pioglitazone 0-12 insulin Homo sapiens 75-82 29580285-20 2018 This proves that pioglitazone treatment improves healthy follicle growth in these PCO model rats with insulin resistance. Pioglitazone 17-29 insulin Homo sapiens 102-109 29138876-6 2018 RESULTS: Individuals aged >=65 years on metformin + pioglitazone had a significantly lower risk of dementia compared with those on metformin + sulfonylurea (HR 0.56; 95% CI 0.34, 0.93), and a lower, but insignificant, risk of dementia compared with those on other metformin-based dual regimens (i.e. metformin + acarbose, metformin + meglitinide, metformin + insulin or metformin + dipeptidyl peptidase 4 inhibitors). Pioglitazone 55-67 insulin Homo sapiens 362-369 28918389-6 2018 Although pioglitazone is emerging as the treatment of choice for NASH in patients with insulin-resistance, or those with T2DM, many other options are being tested. Pioglitazone 9-21 insulin Homo sapiens 87-94 29084736-0 2018 Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). Pioglitazone 0-12 insulin Homo sapiens 149-156 29084736-1 2018 BACKGROUND: The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. Pioglitazone 92-104 insulin Homo sapiens 28-35 29084736-1 2018 BACKGROUND: The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone reduced the risk for a composite outcome of stroke or myocardial infarction among nondiabetic patients with insulin resistance and a recent stroke or transient ischemic attack. Pioglitazone 92-104 insulin Homo sapiens 213-220 29084736-9 2018 CONCLUSIONS: Pioglitazone was effective for secondary prevention of ischemic stroke in nondiabetic patients with insulin resistance. Pioglitazone 13-25 insulin Homo sapiens 113-120 29256528-0 2017 Comparison of metformin and pioglitazone in achieving sustained virological response in chronic hepatitis C patients with insulin resistance: A quasi-experimental study. Pioglitazone 28-40 insulin Homo sapiens 122-129 29040733-2 2018 Considering the increased prevalence of gout in the diabetic population, this study evaluated the effects of pioglitazone, an insulin resistance inhibitor, on the incidence of gout in the diabetic population. Pioglitazone 109-121 insulin Homo sapiens 126-133 29786570-2 2018 The aim: The purpose of the paper is to determine the dynamics of the insulin resistance indices in patients with type 2 diabetes mellitus concomitant with coronary heart disease in the combination therapy with metformin and pioglitazone during 3 and 6 months. Pioglitazone 225-237 insulin Homo sapiens 70-77 29786570-5 2018 RESULTS: Results: The resulting data proved the statistically significant lowering of the markers and level of the insulin resistance under the effect of combination treatment with metformin and pioglitazone. Pioglitazone 195-207 insulin Homo sapiens 115-122 29183107-0 2017 Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Pioglitazone 53-65 insulin Homo sapiens 0-7 29163673-3 2017 Pioglitazone, a member of the thiazolidinedione class, with a proven antihyperglycemic effect, is known to positively influence insulin sensitivity and beta-cell function and to have the potential to alter the lipid profile. Pioglitazone 0-12 insulin Homo sapiens 128-135 28847910-5 2017 RESULTS: Pioglitazone reduced HbA1c by 0.9%; decreased systolic and diastolic blood pressure by 7 +- 2 and 7 +- 2 mmHg, respectively (P < 0.05); and increased whole-body insulin-stimulated glucose uptake by 71% (3.4 +- 1.3 to 5.8 +- 2.1 mg/kg min; P < 0.01) in subjects with T2D. Pioglitazone 9-21 insulin Homo sapiens 173-180 29038211-0 2017 Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". Pioglitazone 122-134 insulin Homo sapiens 152-159 28323503-0 2017 Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved beta-cell function and insulin sensitivity in metformin treated PCOS. Pioglitazone 63-75 insulin Homo sapiens 108-115 28975238-0 2017 Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone Hydrochloride? Pioglitazone 76-102 insulin Homo sapiens 40-47 29038212-0 2017 Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". Pioglitazone 131-143 insulin Homo sapiens 161-168 29038213-0 2017 Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". Pioglitazone 135-147 insulin Homo sapiens 165-172 28337819-8 2017 Moreover, insulin-sensitizing drugs (metformin, pioglitazone, and rosiglitazone) suppress LPS-induced TGF-beta and TNF-alpha mRNA expression in PFMC. Pioglitazone 48-60 insulin Homo sapiens 10-17 28912917-1 2017 Pioglitazone is one of thiazolidinedione derivatives, which stimulates nuclear peroxisome proliferator-activated receptor gamma and improves glucose and lipid metabolism and insulin sensitivity. Pioglitazone 0-12 insulin Homo sapiens 174-181 28912917-6 2017 The low-dose pioglitazone therapy may show the same degree of improvements in glucose and lipid metabolism, fatty liver, insulin resistance, and adiponectin as the standard- and high-dose pioglitazone therapy. Pioglitazone 13-25 insulin Homo sapiens 121-128 29362600-0 2017 Palmitate-induced insulin resistance is attenuated by Pioglitazone and EGCG through reducing the gluconeogenic key enzymes expression in HepG2 cells. Pioglitazone 54-66 insulin Homo sapiens 18-25 29362600-11 2017 Combined treatment of insulin-resistant cells with EGCG and pioglitazone significantly decreased the mRNA level of PEPCK and G6Pase by 73 and 80%, respectively. Pioglitazone 60-72 insulin Homo sapiens 22-29 29362600-13 2017 When the insulin resistant HepG2 cells were treated alone with EGCG and pioglitazone, the glucose production reduced by 50 and 55%, respectively. Pioglitazone 72-84 insulin Homo sapiens 9-16 29362600-15 2017 CONCLUSIONS: These data suggest the additive inhibitory effect of co-treatment with pioglitazone and EGCG on the gluconeogenesis pathway in palmitate-induced insulin resistance HepG2 cells. Pioglitazone 84-96 insulin Homo sapiens 158-165 29087390-5 2017 Pioglitazone, which improved insulin sensitivity, plasma lipids and inflammation, increased the mitochondrial copy number, and led to a redistribution of mitochondria from a punctate to a more reticular pattern as observed in NGT. Pioglitazone 0-12 insulin Homo sapiens 29-36 29145540-9 2017 Three-month treatment with metformin and pioglitazone significantly improved insulin sensitivity and increased orexin concentrations by 26% (p = 0.025) and 14% (p = 0.076), respectively. Pioglitazone 41-53 insulin Homo sapiens 77-84 29145540-12 2017 Three-month anti-hyperglycemic treatment with proportionate doses of metformin or pioglitazone increased orexin concentrations via amelioration of insulin resistance and improvement of glycemic control. Pioglitazone 82-94 insulin Homo sapiens 147-154 28219664-2 2017 Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA. Pioglitazone 123-135 insulin Homo sapiens 8-15 28246237-0 2017 Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. Pioglitazone 80-92 insulin Homo sapiens 110-117 28246237-2 2017 The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or nonfatal stroke and MI in patients with insulin resistance without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack. Pioglitazone 80-92 insulin Homo sapiens 16-23 28246237-2 2017 The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or nonfatal stroke and MI in patients with insulin resistance without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack. Pioglitazone 80-92 insulin Homo sapiens 175-182 28246237-14 2017 CONCLUSIONS: Among patients with insulin resistance without diabetes mellitus, pioglitazone reduced the risk for acute coronary syndromes after a recent cerebrovascular event. Pioglitazone 79-91 insulin Homo sapiens 33-40 28219664-2 2017 Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA. Pioglitazone 123-135 insulin Homo sapiens 165-172 28219664-2 2017 Because insulin resistance is an independent predictor of cardiovascular disease (CVD), this study was initiated to see if pioglitazone administration would improve insulin sensitivity and thereby decrease risk of CVD in overweight/obese, nondiabetic, insulin-resistant patients with untreated OSA. Pioglitazone 123-135 insulin Homo sapiens 165-172 28219664-4 2017 Insulin sensitivity increased 31% (p <0.001) among pioglitazone-treated subjects, associated with a decrease in C-reactive protein concentration (p <=0.001), a decrease in plasma triglyceride, and increase in high-density lipoprotein cholesterol concentrations (p <=0.001), accompanied by significant changes in apolipoprotein A1 and B concentrations and lipoprotein subclasses known to decrease CVD risk. Pioglitazone 54-66 insulin Homo sapiens 0-7 29203734-0 2017 Effect of pioglitazone on insulin resistance, progression of atherosclerosis and clinical course of coronary heart disease. Pioglitazone 10-22 insulin Homo sapiens 26-33 28340963-0 2017 Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. Pioglitazone 0-12 insulin Homo sapiens 30-37 28606576-9 2017 The insulin sensitizers, metformin and pioglitazone, improved insulin resistance and the concentration of circulating GLP-1, increased the relative number of intestinal L cells to a certain degree. Pioglitazone 39-51 insulin Homo sapiens 4-11 28606576-9 2017 The insulin sensitizers, metformin and pioglitazone, improved insulin resistance and the concentration of circulating GLP-1, increased the relative number of intestinal L cells to a certain degree. Pioglitazone 39-51 insulin Homo sapiens 62-69 28325803-1 2017 Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Pioglitazone 0-12 insulin Homo sapiens 48-55 28325804-1 2017 Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Pioglitazone 0-12 insulin Homo sapiens 48-55 28099407-0 2017 Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. Pioglitazone 116-128 insulin Homo sapiens 97-104 28099407-1 2017 BACKGROUND AND OBJECTIVES: Pioglitazone is a thiazolidinedione antihyperglycemic drug with insulin-sensitizing properties. Pioglitazone 27-39 insulin Homo sapiens 91-98 27999139-8 2017 Use of pioglitazone in stroke patients with insulin resistance, prediabetes, and diabetes mellitus was associated with lower risk of recurrent stroke (hazard ratio 0.68; 95% confidence interval, 0.50-0.92; P=0.01) and future major vascular events (hazard ratio 0.75; 95% confidence interval, 0.64-0.87; P=0.0001). Pioglitazone 7-19 insulin Homo sapiens 44-51 27999139-11 2017 CONCLUSIONS: Pioglitazone reduces recurrent stroke and major vascular events in ischemic stroke patients with insulin resistance, prediabetes, and diabetes mellitus. Pioglitazone 13-25 insulin Homo sapiens 110-117 28057658-0 2017 Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. Pioglitazone 0-12 insulin Homo sapiens 58-65 28057658-1 2017 OBJECTIVES: To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes. Pioglitazone 38-50 insulin Homo sapiens 66-73 28057658-6 2017 Pioglitazone therapy was associated with a lower risk of MACE in patients with pre-diabetes or insulin resistance (RR 0.77, 95% CI 0.64 to 0.93), and diabetes (RR 0.83, 95% CI 0.72 to 0.97). Pioglitazone 0-12 insulin Homo sapiens 95-102 28057658-8 2017 CONCLUSIONS: Pioglitazone was associated with reduced risk of MACE in people with insulin resistance, pre-diabetes and diabetes mellitus. Pioglitazone 13-25 insulin Homo sapiens 82-89 28566590-10 2017 In the pioglitazone group, the changes in fasting insulin levels correlated significantly with increased bone resorption, independent of age and gender. Pioglitazone 7-19 insulin Homo sapiens 50-57 29203734-3 2017 THE AIM: Our aim was to study the effect of pioglitazone on insulin resistance, the clinical course of atherosclerosis and coronary heart disease (CHD). Pioglitazone 44-56 insulin Homo sapiens 60-67 29203734-9 2017 CONCLUSION: Long-term treatment with pioglitazone at low doses against the background of standard therapy contributes to functional and clinical condition of patients, promotes the prevention of atherosclerosis and reduction of insulin resistance, thereby improving the clinical manifestations of coronary heart disease. Pioglitazone 37-49 insulin Homo sapiens 228-235 27118251-4 2016 Notably, cellular steroidogenesis models have facilitated the understanding of the mechanistic effects of pharmacotherapies, including insulin sensitizers (e.g., pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production. Pioglitazone 162-174 insulin Homo sapiens 135-142 28331909-6 2016 RESULTS: Metformin and pioglitazone and combination therapy induced favorable changes in fasting serum insulin, HOMA-IR index, QUICKI, fasting glucose to insulin ratio in women with PCOS. Pioglitazone 23-35 insulin Homo sapiens 103-110 28331909-6 2016 RESULTS: Metformin and pioglitazone and combination therapy induced favorable changes in fasting serum insulin, HOMA-IR index, QUICKI, fasting glucose to insulin ratio in women with PCOS. Pioglitazone 23-35 insulin Homo sapiens 154-161 27914514-8 2016 These findings suggest that fish oil and/or pioglitazone prevents beta-cell dysfunction by improving the insulin resistance and decreasing the ER stress. Pioglitazone 44-56 insulin Homo sapiens 105-112 27118251-4 2016 Notably, cellular steroidogenesis models have facilitated the understanding of the mechanistic effects of pharmacotherapies, including insulin sensitizers (e.g., pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production. Pioglitazone 162-174 insulin Homo sapiens 216-223 27613867-5 2016 Pioglitazone-treated mice showed identical weight gain, body fat distribution, and insulin sensitivity compared with controls. Pioglitazone 0-12 insulin Homo sapiens 83-90 27620069-3 2016 Although Thiazolidinediones (TZDs) such as rosiglitazone and pioglitazone are outstanding insulin sensitizers and are in clinical use since 1990s, however, their serious side effects such as heart attack and bladder cancer have limited their utilization. Pioglitazone 61-73 insulin Homo sapiens 90-97 27405860-2 2016 The international IRIS trial assessed whether pioglitazone, a glucose-lowering insulin-sensitizing drug, would reduce recurrent vascular events in patients with ischaemic stroke or transient ischaemic attack. Pioglitazone 46-58 insulin Homo sapiens 79-86 27465265-0 2016 Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Pioglitazone 0-12 insulin Homo sapiens 48-55 27465265-1 2016 OBJECTIVE: The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). Pioglitazone 93-105 insulin Homo sapiens 15-22 27465265-1 2016 OBJECTIVE: The Insulin Resistance Intervention after Stroke (IRIS) trial recently found that pioglitazone reduced risk for stroke and myocardial infarction in patients with insulin resistance but without diabetes who had had a recent ischemic stroke or transient ischemic attack (TIA). Pioglitazone 93-105 insulin Homo sapiens 173-180 27465265-9 2016 CONCLUSIONS: Among patients with insulin resistance but without diabetes who had had a recent ischemic stroke or TIA, pioglitazone decreased the risk of diabetes while also reducing the risk of subsequent ischemic events. Pioglitazone 118-130 insulin Homo sapiens 33-40 27222525-0 2016 Insulin Resistance Intervention After Stroke Trial of Pioglitazone: Is This Perhaps the End of the Beginning? Pioglitazone 54-66 insulin Homo sapiens 0-7 27028341-0 2016 Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. Pioglitazone 0-12 insulin Homo sapiens 31-38 27028341-3 2016 Pioglitazone improves insulin sensitivity in women with PCOS, but it is unknown whether this may be contributed by enhanced insulin-stimulated release of the DCI-IPG second messenger. Pioglitazone 0-12 insulin Homo sapiens 22-29 27028341-4 2016 The study aimed to determine if pioglitazone increases release of biologically active DCI-IPG per unit insulin released during an oral glucose tolerance test (OGTT). Pioglitazone 32-44 insulin Homo sapiens 103-110 27028341-8 2016 RESULTS: After treatment with pioglitazone, AUCinsulin during the OGTT decreased and whole body insulin sensitivity, as determined by the Matsuda index, increased significantly only in the pioglitazone group. Pioglitazone 30-42 insulin Homo sapiens 47-54 27028341-11 2016 CONCLUSION: In women with PCOS, pioglitazone increased insulin-stimulated release of the DCI-IPG second messenger of insulin action, which may contribute to its insulin-sensitizing effect in these women. Pioglitazone 32-44 insulin Homo sapiens 55-62 27028341-11 2016 CONCLUSION: In women with PCOS, pioglitazone increased insulin-stimulated release of the DCI-IPG second messenger of insulin action, which may contribute to its insulin-sensitizing effect in these women. Pioglitazone 32-44 insulin Homo sapiens 117-124 27028341-11 2016 CONCLUSION: In women with PCOS, pioglitazone increased insulin-stimulated release of the DCI-IPG second messenger of insulin action, which may contribute to its insulin-sensitizing effect in these women. Pioglitazone 32-44 insulin Homo sapiens 117-124 27546965-9 2016 Pioglitazone users had higher hypertension, obesity, DM-2 family history (all p < 0.003), and use of insulin and oral hypoglycemics (all p < 0.0001) in comparison to non-users. Pioglitazone 0-12 insulin Homo sapiens 104-111 27531132-0 2016 Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). Pioglitazone 71-83 insulin Homo sapiens 36-43 27531132-3 2016 Study objective is to evaluate the efficacy and safety of Insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (MS). Pioglitazone 93-105 insulin Homo sapiens 58-65 27544837-6 2016 Although insulin sensitivity increased 31% among pioglitazone-treated compared with no change among individuals receiving placebo (p <0.001 for between-group difference), no improvement in quantitative or qualitative sleep measurements was observed. Pioglitazone 49-61 insulin Homo sapiens 9-16 27210264-11 2016 The recent IRIS (Insulin Resistance Intervention after Stroke) study documented a significant reduction in stroke and MI when pioglitazone instead of placebo was given to nondiabetic patients presenting with both stroke/transient ischemic attack and insulin resistance, confirming results from the PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) study in patients with T2DM. Pioglitazone 126-138 insulin Homo sapiens 17-24 27210264-11 2016 The recent IRIS (Insulin Resistance Intervention after Stroke) study documented a significant reduction in stroke and MI when pioglitazone instead of placebo was given to nondiabetic patients presenting with both stroke/transient ischemic attack and insulin resistance, confirming results from the PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) study in patients with T2DM. Pioglitazone 126-138 insulin Homo sapiens 250-257 27210264-11 2016 The recent IRIS (Insulin Resistance Intervention after Stroke) study documented a significant reduction in stroke and MI when pioglitazone instead of placebo was given to nondiabetic patients presenting with both stroke/transient ischemic attack and insulin resistance, confirming results from the PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events) study in patients with T2DM. Pioglitazone 321-333 insulin Homo sapiens 17-24 27544837-7 2016 CONCLUSIONS: Pioglitazone administration increased insulin sensitivity in otherwise untreated individuals with OSA, without any change in polysomnographic sleep measures over an eight-week period. Pioglitazone 13-25 insulin Homo sapiens 51-58 26886418-2 2016 The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease. Pioglitazone 123-135 insulin Homo sapiens 22-29 26886418-2 2016 The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease. Pioglitazone 123-135 insulin Homo sapiens 152-159 26886418-10 2016 CONCLUSIONS: In this trial involving patients without diabetes who had insulin resistance along with a recent history of ischemic stroke or TIA, the risk of stroke or myocardial infarction was lower among patients who received pioglitazone than among those who received placebo. Pioglitazone 227-239 insulin Homo sapiens 71-78 27034186-15 2016 Treatment with pioglitazone supported that increased insulin sensitivity in PCOS is associated with improved inflammatory and cardiovascular risk markers. Pioglitazone 15-27 insulin Homo sapiens 53-60 26710090-2 2016 Pioglitazone (Pio) is a PPARgamma agonist used clinically as an anti-diabetic agent for improving insulin sensitivity in patients with diabetes. Pioglitazone 0-12 insulin Homo sapiens 98-105 26575297-6 2016 Treatment of T2DM yields preservation of brain gray matter and insulin sensitizers, such as pioglitazone, improve symptoms of depression in unipolar or bipolar disorders. Pioglitazone 92-104 insulin Homo sapiens 63-70 26887289-7 2016 Treatment of subjects with T2DM with pioglitazone increased NPRR in adipose tissue (P <= 0.01) in conjunction with improvements in insulin sensitivity and increases of the thermogenic markers PPARgamma coactivator-1alpha and uncoupling protein 1 (P <= 0.01). Pioglitazone 37-49 insulin Homo sapiens 134-141 26822630-9 2016 Insulin sensitivity increased significantly from baseline to week 8 in the pioglitazone group (+88%, p=0.02) but not in the placebo group (+15%, p=0.14). Pioglitazone 75-87 insulin Homo sapiens 0-7 26822630-10 2016 Change in HMW adiponectin was significantly correlated with the change in insulin sensitivity in the pioglitazone group (r = 0.784, p=0.003). Pioglitazone 101-113 insulin Homo sapiens 74-81 26822630-13 2016 CONCLUSION: Low-dose pioglitazone favorably modulates plasma HMW adiponectin, which was associated with an improvement in insulin sensitivity, in patients with the metabolic syndrome without diabetes. Pioglitazone 21-33 insulin Homo sapiens 122-129 27127397-2 2016 Pioglitazone has been very popular as it is an insulin sensitizer and insulin resistance is prevalent among Indians. Pioglitazone 0-12 insulin Homo sapiens 47-54 27127397-2 2016 Pioglitazone has been very popular as it is an insulin sensitizer and insulin resistance is prevalent among Indians. Pioglitazone 0-12 insulin Homo sapiens 70-77 26710090-2 2016 Pioglitazone (Pio) is a PPARgamma agonist used clinically as an anti-diabetic agent for improving insulin sensitivity in patients with diabetes. Pioglitazone 0-3 insulin Homo sapiens 98-105 26215435-0 2015 Continuation or discontinuation of pioglitazone when starting bedtime insulin in patients with poorly controlled type 2 diabetes in an inner-city population. Pioglitazone 35-47 insulin Homo sapiens 70-77 29900709-14 2015 Pioglitazone is an extremely useful agent in the treatment of type 2 diabetes mellitus (DM) through its actions on alleviating insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 127-134 26254513-0 2015 Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial. Pioglitazone 19-31 insulin Homo sapiens 56-63 25959529-11 2015 CONCLUSIONS: Pioglitazone in individuals with MetS induces a potent decrease in plasma ceramides, and some of the changes correlate with changes in insulin resistance and adiponectin levels. Pioglitazone 13-25 insulin Homo sapiens 148-155 25440598-5 2015 Non-diabetic patients with HTN who used the insulinsensitizing drug pioglitazone had improved FMD with a reduction in insulin resistance. Pioglitazone 68-80 insulin Homo sapiens 44-51 26288659-3 2015 Pioglitazone is recommended as a second-line therapy because of its strong antihyperglycemic effect and its ability to reduce insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 126-133 25954816-6 2015 Next, dysmetabolic NHPs were treated for 28 days with pioglitazone (3 mg/kg) and again had their insulin sensitivity assessed, illustrating a significant improvement in hepatic and peripheral insulin sensitivity. Pioglitazone 54-66 insulin Homo sapiens 192-199 25954816-9 2015 We have also demonstrated that insulin-resistant, dysmetabolic NHPs respond to the established insulin sensitizer, pioglitazone, thus confirming their use as an ideal pre-clinical translational model to assess insulin sensitizing compounds. Pioglitazone 115-127 insulin Homo sapiens 31-38 25954816-9 2015 We have also demonstrated that insulin-resistant, dysmetabolic NHPs respond to the established insulin sensitizer, pioglitazone, thus confirming their use as an ideal pre-clinical translational model to assess insulin sensitizing compounds. Pioglitazone 115-127 insulin Homo sapiens 95-102 25425451-7 2015 CONCLUSION: The results of this exploratory study show that combination therapy with metformin/pioglitazone/exenatide in patients with newly diagnosed T2DM is more effective and results in fewer hypoglycaemic events than sequential add-on therapy with metformin, sulfonylurea and then basal insulin. Pioglitazone 95-107 insulin Homo sapiens 291-298 26543510-5 2015 OBJECTIVE: The goal of our study was to test whether the thiazolidinedione pioglitazone has prominent early metabolic effects that can be detected in an obese, nondiabetic, insulin-resistant population. Pioglitazone 75-87 insulin Homo sapiens 173-180 26543510-12 2015 CONCLUSIONS: Significant changes in insulin action across multiple insulin-sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with nondiabetic insulin resistance. Pioglitazone 174-186 insulin Homo sapiens 36-43 26543510-12 2015 CONCLUSIONS: Significant changes in insulin action across multiple insulin-sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with nondiabetic insulin resistance. Pioglitazone 174-186 insulin Homo sapiens 67-74 26543510-12 2015 CONCLUSIONS: Significant changes in insulin action across multiple insulin-sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with nondiabetic insulin resistance. Pioglitazone 174-186 insulin Homo sapiens 67-74 25954816-9 2015 We have also demonstrated that insulin-resistant, dysmetabolic NHPs respond to the established insulin sensitizer, pioglitazone, thus confirming their use as an ideal pre-clinical translational model to assess insulin sensitizing compounds. Pioglitazone 115-127 insulin Homo sapiens 95-102 25603459-1 2015 OBJECTIVE: The objective was to test the clinical utility of Quantose M(Q) to monitor changes in insulin sensitivity after pioglitazone therapy in prediabetic subjects. Pioglitazone 123-135 insulin Homo sapiens 97-104 25603459-9 2015 CONCLUSIONS: In IGT subjects, Quantose M(Q) parallels changes in insulin sensitivity and glucose tolerance with pioglitazone therapy. Pioglitazone 112-124 insulin Homo sapiens 65-72 25852732-5 2015 Compared to control, insulin resistance improved in the pioglitazone group (p = 0.002) but not in the exercise group (p = 0.25). Pioglitazone 56-68 insulin Homo sapiens 21-28 25852732-7 2015 CONCLUSION: In this pilot study, pioglitazone improved insulin resistance but not cognitive performance in older adults with MCI and insulin resistance. Pioglitazone 33-45 insulin Homo sapiens 55-62 25469280-1 2015 Pioglitazone is an insulin sensitizer used for the treatment of diabetes mellitus (DM). Pioglitazone 0-12 insulin Homo sapiens 19-26 25469280-11 2015 In addition, significantly decreased homeostasis model assessment for insulin resistance values (P=0.002) and significantly increased serum high-molecular-weight adiponectin levels (P<0.001) were observed following pioglitazone treatment. Pioglitazone 218-230 insulin Homo sapiens 70-77 25469280-13 2015 Moreover, pioglitazone improved insulin resistance and adipocytokine levels. Pioglitazone 10-22 insulin Homo sapiens 32-39 25525174-1 2014 PURPOSE: Previously, we reported that pioglitazone prevented insulin resistance and cell death in type 2 diabetic retina by reducing TNFalpha and suppressor of cytokine signaling 3 (SOCS3) levels. Pioglitazone 38-50 insulin Homo sapiens 61-68 25738311-10 2015 Interestingly, the ER stress and chemotherapy resistance observed in HepG2/IR cells could be reversed by treatment with the insulin sensitizer pioglitazone. Pioglitazone 143-155 insulin Homo sapiens 124-131 25525174-10 2014 Insulin growth factor binding protein-3 activity was increased and apoptosis decreased by pioglitazone, which was eliminated when serine site 156 of IGFBP-3 was mutated suggesting a key role of this phosphorylation site in pioglitazone actions. Pioglitazone 90-102 insulin Homo sapiens 0-7 25525174-10 2014 Insulin growth factor binding protein-3 activity was increased and apoptosis decreased by pioglitazone, which was eliminated when serine site 156 of IGFBP-3 was mutated suggesting a key role of this phosphorylation site in pioglitazone actions. Pioglitazone 223-235 insulin Homo sapiens 0-7 24769306-1 2014 OBJECTIVES: This study tested the hypothesis that pioglitazone reduces endothelin-1 activity in the forearm vasculature in non-diabetic patients with hypertension or hypercholesterolemia and variable degrees of insulin resistance. Pioglitazone 50-62 insulin Homo sapiens 211-218 25138792-1 2014 UNLABELLED: Differential activation/deactivation of insulin signaling, PI-3K and MAP-K pathways by high glucose and palmitate, with/out the insulin sensitizer pioglitazone (PIO), have been previously shown in vascular smooth muscle cells (VSMCs). Pioglitazone 159-171 insulin Homo sapiens 52-59 25138792-1 2014 UNLABELLED: Differential activation/deactivation of insulin signaling, PI-3K and MAP-K pathways by high glucose and palmitate, with/out the insulin sensitizer pioglitazone (PIO), have been previously shown in vascular smooth muscle cells (VSMCs). Pioglitazone 159-171 insulin Homo sapiens 140-147 25695301-1 2014 INTRODUCTION: The thiazolidinediones (pioglitazone) increases the action of insulin and produces the glycemic control in the patients with type 2 diabetes mellitus. Pioglitazone 38-50 insulin Homo sapiens 76-83 25458644-0 2014 Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Pioglitazone 0-12 insulin Homo sapiens 119-126 25458644-3 2014 Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA. Pioglitazone 50-62 insulin Homo sapiens 67-74 25458644-3 2014 Specifically, IRIS will test the effectiveness of pioglitazone, an insulin-sensitizing drug of the thiazolidinedione class, for reducing the risk for stroke and myocardial infarction (MI) among insulin resistant, nondiabetic patients with a recent ischemic stroke or TIA. Pioglitazone 50-62 insulin Homo sapiens 194-201 25458644-10 2014 SUMMARY: The IRIS Trial will determine whether treatment with pioglitazone improves cardiovascular outcomes of nondiabetic, insulin-resistant patients with stroke or TIA. Pioglitazone 62-74 insulin Homo sapiens 124-131 25330088-2 2014 The aim of this study was to test whether pioglitazone, a powerful insulin sensitizer, alters body fat distribution and adipokine secretion in these subjects and whether it is associated with improved insulin sensitivity. Pioglitazone 42-54 insulin Homo sapiens 67-74 24937535-11 2014 These findings demonstrate a physiologic control mechanism wherein the increase in ISR ensures adequate insulin delivery into the portal circulation to suppress hepatic glucose production while delivering a reduced but sufficient amount of insulin to peripheral tissues to maintain the pioglitazone-mediated improvement in insulin sensitivity without excessive hyperinsulinemia. Pioglitazone 286-298 insulin Homo sapiens 240-247 24937535-11 2014 These findings demonstrate a physiologic control mechanism wherein the increase in ISR ensures adequate insulin delivery into the portal circulation to suppress hepatic glucose production while delivering a reduced but sufficient amount of insulin to peripheral tissues to maintain the pioglitazone-mediated improvement in insulin sensitivity without excessive hyperinsulinemia. Pioglitazone 286-298 insulin Homo sapiens 240-247 25086044-0 2014 Pioglitazone normalizes insulin signaling in the diabetic rat retina through reduction in tumor necrosis factor alpha and suppressor of cytokine signaling 3. Pioglitazone 0-12 insulin Homo sapiens 24-31 25086044-8 2014 These changes occurred in both REC and Muller cells treated with pioglitazone, suggesting that these two cell types are key to insulin resistance in the retina. Pioglitazone 65-77 insulin Homo sapiens 127-134 24722248-4 2014 We also show that Foxa2 and miR-29 are significantly upregulated in the livers of Zucker diabetic fatty (fa/fa) rats and that the levels of both returned to normal upon treatment with the insulin-sensitizing agent pioglitazone. Pioglitazone 214-226 insulin Homo sapiens 188-195 26171320-4 2014 Pioglitazone is classified as an insulin-sensitizing, anti-hyperglycemic agent. Pioglitazone 0-12 insulin Homo sapiens 33-40 25010722-2 2014 This study examined adipose pathology of insulin resistant subjects who were treated with pioglitazone or fish oil. Pioglitazone 90-102 insulin Homo sapiens 41-48 24769306-5 2014 RESULTS: Pioglitazone lowered plasma insulin (P < 0.001), improved insulin sensitivity (P < 0.001), increased HDL (P < 0.001), and reduced triglycerides (P = 0.003), free fatty acids (P = 0.005), and C-reactive protein (P = 0.001). Pioglitazone 9-21 insulin Homo sapiens 37-44 24769306-5 2014 RESULTS: Pioglitazone lowered plasma insulin (P < 0.001), improved insulin sensitivity (P < 0.001), increased HDL (P < 0.001), and reduced triglycerides (P = 0.003), free fatty acids (P = 0.005), and C-reactive protein (P = 0.001). Pioglitazone 9-21 insulin Homo sapiens 70-77 24769306-8 2014 CONCLUSIONS: In non-diabetic patients with hypertension or hypercholesterolemia, pioglitazone improves insulin sensitivity, lipid profile, and inflammation but does not affect endothelin activity. Pioglitazone 81-93 insulin Homo sapiens 103-110 24715548-6 2014 RESULTS: Supporting an association between insulin sensitization and depression severity, pioglitazone treatment was associated with a decrease in the total Inventory of Depressive Symptomatology (IDS-C30) score from 38.7 +- 8.2 at baseline to 21.2 +- 9.2 at week 8 (p < 0.001). Pioglitazone 90-102 insulin Homo sapiens 43-50 24551137-9 2014 These findings suggest that pioglitazone may partially ameliorate insulin resistance through its direct inhibitory effects on fetuin-A expression in the liver. Pioglitazone 28-40 insulin Homo sapiens 66-73 24705615-2 2014 We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (SI) and glucose tolerance status. Pioglitazone 68-80 insulin Homo sapiens 166-173 24705615-10 2014 The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin. Pioglitazone 55-67 insulin Homo sapiens 184-191 24940437-8 2014 Therefore, the administration of metformin and pioglitazone in patients with T2DM may improve insulin function, reduce the role of IR and improve endothelial function. Pioglitazone 47-59 insulin Homo sapiens 94-101 23389468-0 2014 Gender differences in non-glycemic responses to improved insulin sensitivity by pioglitazone treatment in patients with type 2 diabetes. Pioglitazone 80-92 insulin Homo sapiens 57-64 23389468-2 2014 To study whether the insulin sensitizer pioglitazone affects basal cortisol levels and the GH-IGF-I axis in patients with T2D. Pioglitazone 40-52 insulin Homo sapiens 21-28 23389468-5 2014 Pioglitazone decreased proinsulin/insulin ratio and HbA(1c) decreased (HbA(1c) from 7.8 +- 0.2 to 6.6 +- 0.2% in men and from 7.6 +- 0.2 to 6.1 +- 0.2% in women, p < 0.001 in both). Pioglitazone 0-12 insulin Homo sapiens 23-33 23389468-5 2014 Pioglitazone decreased proinsulin/insulin ratio and HbA(1c) decreased (HbA(1c) from 7.8 +- 0.2 to 6.6 +- 0.2% in men and from 7.6 +- 0.2 to 6.1 +- 0.2% in women, p < 0.001 in both). Pioglitazone 0-12 insulin Homo sapiens 26-33 23389468-15 2014 There seems to be gender differences in treatment responses to pioglitazone on lipid metabolism and basal cortisol, perhaps correcting different mechanisms of insulin resistance between genders. Pioglitazone 63-75 insulin Homo sapiens 159-166 24592408-1 2014 BACKGROUND: Pioglitazone is a thiazolidinedione (TZD) insulin sensitizer approved for use in human type 2 diabetes mellitus. Pioglitazone 12-24 insulin Homo sapiens 54-61 24815457-11 2014 By contrast, HepG2/IR cells exhibited decreased adhesion and invasion after treatment with the insulin sensitizer pioglitazone hydrochloride. Pioglitazone 114-140 insulin Homo sapiens 95-102 24701440-1 2014 Pioglitazone improves glycemic control by acting as an insulin sensitizer and is used in the management of Type 2 diabetes mellitus. Pioglitazone 0-12 insulin Homo sapiens 55-62 24701440-7 2014 We avoid using pioglitazone with insulin. Pioglitazone 15-27 insulin Homo sapiens 33-40 25134381-0 2014 The endothelial protective effects of pioglitazone on insulin resistance in endothelial cells. Pioglitazone 38-50 insulin Homo sapiens 54-61 25134381-2 2014 Pioglitazone is an insulin-sensitizing agent and can reduce insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 19-26 25134381-2 2014 Pioglitazone is an insulin-sensitizing agent and can reduce insulin resistance. Pioglitazone 0-12 insulin Homo sapiens 60-67 25134381-3 2014 METHODS: In this study, the cellular model of insulin resistance was used to investigate the mechanisms involved in the endothelial protective effects of pioglitazone in a vascular endothelial cell damage model. Pioglitazone 154-166 insulin Homo sapiens 46-53 25134381-4 2014 RESULTS: The results showed that pioglitazone could effectively increase the survival rate of human umbilical vein endothelial cells (ECV), reduce apoptosis, and relieve insulin resistance damage. Pioglitazone 33-45 insulin Homo sapiens 170-177 25134381-6 2014 CONCLUSIONS: These results suggested that pioglitazone could have endothelial protective effects in a vascular endothelial cell damage model of insulin resistance and used to prevent beforehand and treat a vascular endothelial cell damage of insulin resistance. Pioglitazone 42-54 insulin Homo sapiens 144-151 25134381-6 2014 CONCLUSIONS: These results suggested that pioglitazone could have endothelial protective effects in a vascular endothelial cell damage model of insulin resistance and used to prevent beforehand and treat a vascular endothelial cell damage of insulin resistance. Pioglitazone 42-54 insulin Homo sapiens 242-249 23770533-2 2013 In addition to exerting anti-inflammatory and neuroprotective effects, PPAR-gamma agonists, such as the insulin-sensitizing drug pioglitazone, promote the differentiation of oligodendrocytes (OLs), the myelin-forming cells of the central nervous system (CNS). Pioglitazone 129-141 insulin Homo sapiens 104-111 23782502-5 2013 The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. Pioglitazone 114-126 insulin Homo sapiens 8-15 23782502-5 2013 The 5-h insulin total AUC increased with sitagliptin versus all other treatments and increased with sitagliptin + pioglitazone versus pioglitazone. Pioglitazone 134-146 insulin Homo sapiens 8-15 23782502-8 2013 The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. Pioglitazone 93-105 insulin Homo sapiens 4-11 23782502-8 2013 The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. Pioglitazone 93-105 insulin Homo sapiens 58-65 23782502-8 2013 The insulin sensitivity index (ISI), a composite index of insulin sensitivity, improved with pioglitazone and sitagliptin + pioglitazone versus placebo. Pioglitazone 124-136 insulin Homo sapiens 4-11 24141239-5 2013 RESULTS: Obese subjects demonstrated significant decreases in insulin resistance and many adipose inflammatory parameters with pioglitazone relative to placebo. Pioglitazone 127-139 insulin Homo sapiens 62-69 24141239-8 2013 CONCLUSIONS: These findings support the efficacy of pioglitazone to improve insulin resistance and reduce adipose tissue inflammation in obese patients with T2DM. Pioglitazone 52-64 insulin Homo sapiens 76-83 24290093-2 2013 The newest controversy revolves around Pioglitazone, a thiozolidindione, which improves insulin sensitivity and is reputed to have cardioprotective actions, but is riddled with several controversies related to weight gain, distal fractures of long bones, recent reports of bladder cancer and others. Pioglitazone 39-51 insulin Homo sapiens 88-95 23216460-11 2013 CONCLUSIONS: These results indicate that (1) while similar glycemic effects were observed, distinct regulations of UA and other diabetic parameters were observed with pioglitazone depending on the baseline UA levels; (2) pioglitazone downregulated hyperuricemia by possibly relieving insulin resistance; and (3) the level of UA together with other parameters might provide some diabetic characteristics of the subjects. Pioglitazone 167-179 insulin Homo sapiens 284-291 23524525-5 2013 Pioglitazone reduced fasting plasma insulin, whereas glibenclamide increased it. Pioglitazone 0-12 insulin Homo sapiens 36-43 24121378-3 2013 In addition, pioglitazone is an insulin sensitizer used in diabetes mellitus type 2 (T2DM), improving insulin resistance (IR) in adipose tissue and muscles. Pioglitazone 13-25 insulin Homo sapiens 32-39 24121378-3 2013 In addition, pioglitazone is an insulin sensitizer used in diabetes mellitus type 2 (T2DM), improving insulin resistance (IR) in adipose tissue and muscles. Pioglitazone 13-25 insulin Homo sapiens 102-109